Counteracting resistance to chemo-radiotherapy and to targeted therapy in solid tumors by Sabbatino, Francesco
Doctorate Program in Molecular 
Oncology and Endocrinology 
Doctorate School in Molecular 
Medicine 
 
XXV cycle - 2009–2012 
Coordinator: Prof. Massimo Santoro 
 
 
 
 
”Counteracting resistance to chemo-
radiotherapy and to targeted therapy in  
solid tumors” 
 
 
Francesco Sabbatino 
 
 
 
 
Università degli Studi di Napoli Federico II 
Dipartimento di Medicina Molecolare e Biotecnologie Mediche 
Administrative Location 
 
Università degli Studi di Napoli Federico II 
Dipartimento di Medicina Molecolare e Biotecnologie Mediche 
 
Partner Institutions 
 
Italian Institutions 
Università degli Studi di Napoli “Federico II”, Naples, Italy 
Istituto di Endocrinologia ed Oncologia Sperimentale “G. Salvatore”, CNR, Naples, Italy 
Seconda Università di Napoli, Naples, Italy 
Università degli Studi di Napoli “Parthenope”, Naples, Italy 
Università degli Studi del Sannio, Benevento, Italy 
Università degli Studi di Genova, Genova, Italy 
Università degli Studi di Padova, Padova, Italy 
Università degli Studi “Magna Graecia”, Catanzaro, Italy 
Università degli Studi di Udine, Udine, Italy 
 
Foreign Institutions 
Université Libre de Bruxelles, Bruxelles, Belgium 
Universidade Federal de Sao Paulo, Brazil 
University of Turku, Turku, Finland 
Université Paris Sud XI, Paris, France 
University of Madras, Chennai, India  
University Pavol Jozef Šafàrik, Kosice, Slovakia 
Universidad Autonoma de Madrid, Centro de Investigaciones Oncologicas (CNIO), Spain  
Johns Hopkins School of Medicine, Baltimore, MD, USA 
Johns Hopkins Krieger School of Arts and Sciences, Baltimore, MD, USA 
National Institutes of Health, Bethesda, MD, USA 
Ohio State University, Columbus, OH, USA 
Albert Einstein College of Medicine of Yeshiwa University, N.Y., USA 
 
Supporting Institutions 
Dipartimento di Biologia e Patologia Cellulare e Molecolare “L. Califano”, Università degli Studi di 
Napoli “Federico II”, Naples, Italy 
Istituto di Endocrinologia ed Oncologia Sperimentale “G. Salvatore”, CNR, Naples, Italy 
Istituto Superiore di Oncologia, Italy 
Italian Faculty 
 
 
 
Salvatore Maria Aloj 
Francesco Saverio Ambesi Impiombato 
Francesco Beguinot 
Maria Teresa Berlingieri 
Bernadette Biondi 
Francesca Carlomagno 
Gabriella Castoria 
Maria Domenica Castellone 
Angela Celetti 
Lorenzo Chiariotti 
Annamaria Cirafici  
Annamaria Colao 
Sabino De Placido 
Gabriella De Vita 
Monica Fedele  
Pietro Formisano 
Alfredo Fusco 
Domenico Grieco 
Michele Grieco 
Maddalena Illario 
Paolo Laccetti 
Antonio Leonardi 
Paolo Emidio Macchia 
Barbara Majello 
Rosa Marina Melillo 
Claudia Miele 
Nunzia Montuori 
Roberto Pacelli 
Giuseppe Palumbo 
Maria Giovanna Pierantoni 
Rosario Pivonello 
Giuseppe Portella 
Maria Fiammetta Romano  
Giuliana Salvatore 
Massimo Santoro 
Giampaolo Tortora 
Donatella Tramontano 
Giancarlo Troncone 
Giancarlo Vecchio,  
Giuseppe Viglietto 
Mario Vitale 
 
 
 
 
 
 
 
 
 
 
 
  
 
“Counteracting resistance to 
chemo-radiotherapy and to 
targeted therapy in  
solid tumors” 
 
1 
 
TABLE OF CONTENTS 
         Page 
LIST OF PUBLICATIONS      3 
 
LIST OF ABBREVIATIONS      4 
 
INTRODUCTION        5 
 
ABSTRACT         7  
 
1. BACKGROUND        8 
 
1.1. Melanoma         8 
 
1.2. Biology of mutated BRAF and its role in melanoma  
development and progression      9 
 
1.3. Inhibition of BRAFV600E       13 
 
1.4. Limitations of BRAF-I        18 
 
1.4.1. Intrinsic resistance to BRAF-I      19 
 
1.4.2. Acquired resistance to BRAF-I     23 
 
1.5. Strategies to overcome BRAF-I resistance    25 
 
2. AIMS OF THE STUDY       28 
 
3. MATERIALS AND METHODS     29 
 
3.1. Cell cultures        29 
 
3.2. Chemical reagents, antibodies and shRNAs    29 
 
3.3. Cell proliferation and MTT assay     30 
 
3.4. Western blot analysis       30 
 
3.5. Transduction of melanoma cells with Lentiviral vectors  
encoding  shRNA         31 
2 
 
 
3.6. Flow Cytometry        32 
 
3.7. In vivo studies        32 
 
3.8. Patient Samples        33 
 
3.9. Immunohistochemistry       33 
 
3.10. Statistical analysis       34 
 
4. RESULTS AND DISCUSSION      35 
 
4.1. ERK reactivation, AKT activation and PDGFRα  
upregulation in Colo38R, M21R and TPF-10-741  
melanoma cell lines with acquired vemurafenib resistant    35 
 
4.2. PDGFRα mediates acquired vemurafenib resistance  
of Colo38R, M21R, and TPF-10-741 melanoma cells by  
reactivation of the RAS/RAF/ERK pathway and activation  
of the PI3K/AKT pathway       40 
 
4.3. Association of PDGFRα upregulation in melanoma 
 patient derived biopsies with vemurafenib resistance   42 
 
4.4. Inhibition of PDGFRα increases the anti-tumor activity  
of vemurafenib in BRAF-I sensitive and resistant melanoma  
cell lines         44 
 
4.5. BRAF and PDGFRα inhibition leads to ERK and AKT  
kinase signaling pathway inhibition      48 
 
4.6. Effective melanoma xenograft growth inhibition by  
the combination of vemurafenib and a PDGFRα inhibitor   49 
 
5. CONCLUSIONS        58 
 
6. REFERENCES        61 
 
7.0. TABLE         73 
    
 
3 
 
 
   LIST OF PUBLICATIONS 
 
This dissertation is based upon the following publications:  
 
1) Multidisciplinary Approach to Patient with Malignant Melanoma. Scarpati GD, 
Fusciello C, Sabbatino F, Ferrone S, Caponigro F, Perri F, Carlomagno C, Pepe S. 
Anticancer Agents Med Chem. 2012 Dec 14. In press. 
 
2) Can the "Right" EGFR-Specific mAb Dramatically Improve EGFR-Targeted 
Therapy? Sabbatino F, Ferrone S. Clin Cancer Res. 2013;19:958-60. 
 
3) p53 modulates the enhanced cytotoxicity induced by Poly(ADP-Ribose) 
Polymerase-1 inhibition to Topoisomerase-I inhibitor and radiotherapy in human 
glioblastoma cell lines. Sabbatino F, Fusciello C, Leonardi A, Pacelli R,  Poudel 
R, Pepin D, Ferrone S, Carlomagno C, Pepe S. To be submitted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
LIST OF ABBREVIATIONS 
 
AE   Adverse events  
ATP   Adenosine triphosphate   
BAD    Bcl-2-associated death promote  
Bcl    B-cell lymphoma 
BMF    Bcl-2-modifying factor  
BRAF   v-raf murine sarcoma viral oncogene homolog B1 
BRAF-I   BRAF inhibitors  
CDK    Cyclin-dependent protein kinases  
EGFR   Epidermal growth factor receptor  
FDA    Food and Drug Administration 
FDG-PET  Fluorodeoxyglucose- positron emission tomography 
GIST    Gastrointestinal Stromal Tumors  
HDAC   Histone deacetylase  
HGF   Hepatocyte growth factor  
HLA   Human leukocyte antigen 
HSP90   Heat shock protein 90  
IL   Interleukin  
IGF-1R  Insuline growth factor-1 receptor  
KAs    keratoacanthomas 
MCL    Myeloid cell Leukemia  
Mcl-1   Myeloid cell leukemia sequence 1  
MAPK   Mitogen-activated protein kinase  
NSCLC   Non Small Cell Lung Cancer  
OS   Overall survival  
PARP1  Poly (ADP-ribose) polymerase 1 
PCNA   Proliferating cell nuclear antigen  
PDGFR   Platelet-derived growth factor receptor  
PDL1   Programmed cell death ligand 1 
PTEN   Tumor suppressor phosphatase and tensin homolog 
RAF    Rapidly growing Fibrosarcoma 
Rb    Retinoblastoma  
RTK   Receptor tyrosine kinases  
SCC    Cutaneous squamous cell carcinomas  
SH2   Sequence homology 2  
SOS    Son of sevenless  
TA   Tumor antigen  
TGFβ    Transforming growth factor beta 
T reg    T cell regulators  
VEGFR  Vascular endothelial growth factor receptor 
5 
 
 
INTRODUCTION 
The resistance to anticancer drugs (cytotoxic compounds and molecular targeted 
agents) and radiotherapy is the main obstacle for an effective treatment of human 
cancers. In this study are presented several results regarding: 
a)  The molecular basis of resistance to treatment   with novel inhibitor of the 
tyrosine-kinase encoded by the mutated form of the gene BRAF in 
melanoma carrying the mutant  BRAF V600E and potential therapeutic 
strategies to counteract this resistance.  
b) The role of specific inhibition of PARP1 enzyme to potentiate the 
cytotoxicity of chemo-radiotherapy in human glioblastoma cells. 
The frequency of BRAF mutations varies in human cancers. In over 50% of 
metastatic melanoma patients melanoma cells harbor the BRAF V600E point 
mutation (T1799A). Clinical trials have demonstrated that the BRAF inhibitor 
PLX4032, now known as vemurafenib, and other inhibitors in its class 
(GSK2118436 or dabrafenib) can induce tumor regression in > 50% of patients 
with metastatic melanoma harboring the BRAF V600E mutation and increase the 
overall survival of metastatic melanoma patients as compared to dacarbazine. 
However in spite of the drug's high efficacy, melanomas  develop resistance to the 
treatment with BRAF-I and there is the need to identify the molecular mechanisms 
underlying this resistance.  
Another line of research is devoted to the study of the inhibition of the activity of a 
specific DNA-repair pathway mediated by the poly (ADP-ribose) polymerase 1 
(PARP1) as a therapeutic strategy capable of significantly increasing the activity 
of conventional cytotoxic and radiation treatment in solid tumors. PARP-1 also 
known as NAD
+
 ADP-ribosyltransferase 1 or poly[ADP-ribose] synthase 1  has a 
role in repair of single-stranded DNA breaks. Knocking down intracellular PARP1 
levels with siRNA or inhibiting PARP1 activity with small molecules reduces 
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repair of DNA breaks. As  PARP1 enzyme activity is stopped, when these breaks 
are encountered during DNA replication, the replication fork stalls, and double-
strand DNA breaks accumulate. These double strand DNA breaks are repaired via 
homologous recombination repair. Inhibition of PARP1 activity is found highly 
toxic for cells that are deficient in BRCA1 or BRCA2 since their gene products are 
involved in homologous recombination repair. To date, PARP1 inhibitors are 
studied as specific treatment for BRCA deficient cancers (i.e. BRCA 1 -/- breast 
and ovarian cancer). However several forms of cancer seem to be more dependent 
on PARP1 than regular cells. These findings makes PARP1 as an attractive target 
for cancer therapy to be used as single agents or in combination with conventional 
strategies such as chemotherapeutic agents  or radiotherapy  causing DNA 
damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
ABSTRACT 
Control of mutant BRAF (V600E) metastatic melanomas by the selective BRAF 
inhibitor (BRAF-I), vemurafenib, is limited by the the lack of complete response 
due to intrinsic resistance and the often rapid development of acquired resistance . 
By utilizing melanoma cell lines with acquired BRAF-I resistance, we demonstrate 
for the first time an association between BRAF-I resistance and PDGFRα 
upregulation in vitro and in vivo. PDGFRα inhibition by PDGFRα-specific shRNA 
restores melanoma cells’ sensitivity to BRAF-I in vitro. These effects are mediated 
by inhibition of ERK and AKT activation, which is associated with BRAF-I 
resistance. Combining vemurafenib with a PDGFRα inhibitor (sunitinib or 
imatinib) in vitro and in vivo demonstrate a significantly greater anti-proliferative 
and pro-apoptotic effect than either agent individually. These effects reflect the 
inhibition of ERK and AKT activation, which inhibits the proliferation and 
induces apoptosis. We corroborated this finding by demonstrating PDGFRα 
upregulation in melanomas harvested from patients who demonstrated disease 
progression following treatment with BRAF-I. Furthermore, analysis of matched 
biopsies of BRAF-I treated melanoma patients before treatment, after 1-2 weeks of 
treatment and at the time of disease progression demonstrated that PDGFRα 
upregulation correlated with  less tumor regression (based on RECIST criteria) and 
a shorter time to disease progression. Our results demonstrate that PDGFRα 
inhibitors (sunitinib or imatinib) in combination with vemurafenib can overcome 
BRAF-I resistance mediated by PDGFRα. Although we could not associate 
baseline PDGFRα with clinical outcome, our data suggest that monitoring patients 
for early up regulation of PDGFRα may identify those for whom combination 
therapy would be most appropriate. 
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1. BACKGROUND 
1.1. Melanoma. 
Melanoma is an aggressive form of skin cancer arising from malignantly 
transformed melanocytes
1
. The incidence and mortality from melanoma are 
currently rising, placing significant demands on healthcare provision and 
representing a major public health issue
2
. The reasons for the higher incidence of 
melanoma remain unclear but increased exposures to sun or ultraviolet radiation 
are some of the major risk factors. Family history of melanoma, genetic 
susceptibility, environmental factors, and age-related immunosuppressions are also 
some of the contributing factors that could influence the incidence rates
3, 4
. 
In many cases melanoma begins with the transformation of a benign nevus that 
develops into a dysplastic lesion before progressing into a radial and vertical-
growth phase that can invade into the dermis, regional lymph nodes, and from 
there disseminates to distant organs, leading to metastatic melanoma
4
. However, 
not all melanomas arise from nevus and many arise through direct transformation 
of normal skin cells
3
. 
While surgical excision is still the standard of care for the treatment of primary 
melanomas, until 2011 only chemotherapy with dacarbazine and immunotherapy 
with high dose of IL-2 were approved by U.S. Food and Drug Administration 
(FDA) for metastatic melanoma treatment although both of these did not 
demonstrate to increase the overall survival (OS) of metastatic melanoma 
patients
5-7
. However in the last 10 years significant advances have been facilitated 
by an improved understanding of the driving genetic aberrations of melanoma. 
Molecular profiling and genome sequencing have shown that melanomas are a 
heterogeneous and complex group of malignancies whose progression is driven by 
distinct patterns of oncogenic mutation
8-12
.  
The discovery of activating mutations in the serine/threonine kinase BRAF (v-raf 
murine sarcoma viral oncogene homolog B1) in approximately 50% of all 
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melanomas
8
 has led to the development of novel targeted therapy which, in less 
than 10 years, has led to the U.S. FDA approval of the BRAF inhibitors (BRAF-
I)
13-15
. These agents have provided a strong improvement in objective responses 
and in overall survival of melanoma patients carrying mutant BRAF. However like 
other oncogene directed therapies, such as imatinib in Myeloid cell Leukemia 
(MCL) and Gastrointestinal Stromal Tumors (GIST)
16, 17
 or erlotinib in Non Small 
Cell Lung Cancer (NSCLC)
17
, treatment with BRAF-I is effective for a limiting 
time and complete responses are infrequently seen due to onset of resistance. 
Therefore identification and characterization of the mechanisms mediating BRAF-
I resistance is now need and essential for the rational design of novel targeted 
strategies to improve melanoma patient responses and survival. 
 
1.2. Biology of mutated BRAF and its role in melanoma development and 
progression. 
BRAF is a member of the RAF (Rapidly growing Fibrosarcoma) family of 
serine/threonine kinases. The RAF family includes three members: ARAF, BRAF, 
and CRAF. All RAF proteins are part of the RAS/RAF/MEK/ERK mitogen-
activated protein kinase (MAPK) signaling pathway (Fig. 1) which is constitute by 
all serine/threonine-specific protein kinases
18
. This signaling cascade promotes 
proliferation, survival, and invasion by linking cell surface growth factor receptors 
(such a receptor tyrosine kinases [RTKs]) to the transcription of genes involved in 
cell cycle progression and anti apoptotic activity
19
. Canonical activation of the 
MAPK pathways occurs when growth factors bind the corresponding growth 
factor receptors which lead to the activation of a RAS family member, any of the 
three isoform H/N/or KRAS. Subsequent to RAS activation, RAF isoforms are 
activated by the interaction of RAS with the RAS binding domain on RAF
20-22
.  
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Figure 1. MAPK pathway. The MAPKs are part of the phospho-relay system that 
translate a plethora of extracellular signals into diverse cellular responses. A 
simplified MAPK signalling module is illustrated here with the RAS–RAF–MEK–
ERK pathway. After binding of ligands, such as growth factors, to their respective 
RTK, receptor dimerization triggers the intrinsic tyrosine-kinase activity. This is 
followed by autophosphorylation of specific tyrosine residues on the intracellular 
portion of the receptor. These phosphorylated tyrosine residues then bind the 
sequence homology 2 (SH2) domains of adaptor proteins such as GRB2. Such a 
complex formation recruits SOS (son of sevenless), a cytosolic protein, into close 
proximity to RAS on the plasma membrane. Like other G proteins, RAS (HRAS, 
NRAS and KRAS) cycles between the GDP-bound inactive form and the GTP-
bound active form. In the quiescent state, RAS exists in the GDP-bound form. The 
binding of SOS to RAS causes a change in the RAS conformation and leads to the 
dissociation of GDP and binding of GTP. GTP-bound RAS is the activator of this 
signaling module. It initiates the signal cascade by phosphorylating a RAF (CRAF, 
ARAF and BRAF). RAF, in turn, phosphorylates the MEK (MEK1 and MEK2), 
which then phosphorylates the ERK (extracellular signal regulated kinases, ERK1 
and ERK2). Activated ERKs then translocate into the nucleus where they 
phosphorylate specific substrates that are involved in the regulation of cellular 
responses 
23
. 
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In cells without mutations in BRAF, RAF activation occurs only after the 
formation of homo- or hetero-dimers (between ARAF, BRAF or CRAF)- RAF 
activation leads to the phosphorylation of MEK which activates ERK through its 
phospshorylation
24, 25
.  
In melanoma activation of MAPK signaling by oncogenic mutations is found in up 
to 90% of cases. BRAF is the most common oncogene to be mutated in the MAPK 
signaling in melanoma with approximately 60% of all melanomas harbor 
activating mutations in BRAF. Although over 50 distinct mutations in BRAF gene 
have been identified, more than 80% of mutations in BRAF result in the 
substitution of valine to glutamic acid at amino acid 600 (BRAF V600E 
mutation)
8, 9, 26, 27
. Other point common mutations identified at same level include 
substitution of valine to an aspartic acid (V600D) or a lysine (V600K) or an 
arginine (V600R). The BRAF V600D, V600K and V600R mutations account for 
16% and 3% of the BRAF mutations
28
. Mutations of BRAF cause the 
destabilization of the inactive conformation of the BRAF kinase which shifts the 
equilibrium to the active state
29
. Activated BRAF in turn activates the downstream 
components of the MAPK pathway such as MEK and ERK (Fig. 2).  
Figure 2. MAPK pathway in BRAF V600E 
mutant melanoma. A preponderance of 
melanomas are driven by MAPK signaling. 
Under wild-type conditions (left panel), RAF 
isoforms dimerize upon upstream stimulation 
of receptor tyrosine kinases and signaling 
through RAS to RAF. RAF dimers signal 
through MEK and ERK, eventually leading 
to downstream growth, proliferation, and 
survival. In BRAF V600E mutant melanoma 
(right panel), signaling between RAS and 
RAF is disconnected because of the 
constitutive, oncogenic signaling by mutant 
BRAF
30
. 
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Several mechanisms mediated by MEK and ERK activation have been 
demonstrated to drive cellular proliferation and oncogenic activity in melanoma.   
1) Signaling through the MAPK pathway determines up-regulation of Cyclin D1 
expression and down-regulation of the cell cycle inhibitor p27
31
. These alterations 
cause deregulation of Cyclin/ cyclin-dependent protein kinases (CDK) complex 
which promotes tumor progression through the G1-S phase of the cell cycle.  
2) MAPK activation by BRAF increases melanoma cell survival by regulating the 
expression and function of a number of pro apoptotic and anti apoptotic proteins 
such as BIM, Bcl-2-modifying factor (BMF), Bcl-2-associated death promote 
(BAD), and myeloid cell leukemia sequence 1 (Mcl-1)
32-35
. Phosphorylation of 
BIM at Ser69 by ERK activity leads to proteasomal degradation of BIM and 
inhibition of its activity binding to pro survival proteins of the B-cell lymphoma 2 
(Bcl-2) family such as Bcl-2, Bcl-w, Bcl-XL, and Mcl-1
36, 37
. MAPK activation 
also regulate anti apoptotic signals by controlling the stability and inhibiting the 
degradation of Mcl-1 expression by its phosphorilation on Thr163 residue
33
.  
3) Constitutive activity in the BRAF/MEK/ERK pathway in melanoma drives the 
invasive and motile behavior of melanoma cells through the reorganization of the 
cytoskeleton, activation of the cells’ migratory machinery and up-regulation of 
matrix metalloproteinase expression
38, 39
. Mechanistically, mutated BRAF down-
regulates the expression of the cyclic GMP phosphodiesterase PDE5A, which 
facilitates melanoma cell invasion by increasing intracellular levels of cGMP. 
These alterations lead to the release of cytosolic calcium and the phosphorylation 
of myosin light chain 2 which favorite the motility and invasiveness of melanoma 
cells
40
. 
4) BRAF oncogene and MAPK activation regulates the interaction of melanoma 
cells with the host microenvironment by alteration of human leukocyte antigen 
(HLA) Class I antigens, programmed cell death ligand 1 (PDL1) and melanoma 
tumor antigen (TA) expression. These alterations lead to the lack of recognition of 
13 
 
tumor cells by the immune cells and inhibition of cytotoxic T cell activation
41-44
. 
Furthermore BRAF oncogene by ERK activation increases the production of 
immunosuppressive cytokines such as Interleukin 10 (IL-10) and transforming 
growth factor beta (TGFβ) by melanoma cells. Increased secretion of IL-10 and 
TGFβ leads to increase number of T cell regulators (T reg) in the tumor 
microenviroment which in turn inhibits cytotoxic T cell activation
45
.  
These evidences demonstrate that mutant BRAF is oncogenic and drives tumor 
cell proliferation, anti apoptotic signals and tumor escape mechanisms. However it 
is noteworthy that presence of BRAF V600E is not sufficient to develop 
spontaneous melanoma. In vivo studies demonstrated that transgenic mice carrying 
BRAF V600E develop spontaneous melanomas only in presence of concomitant 
inactivation of the tumor suppressor phosphatase and tensin homolog (PTEN). The 
latter is a tumor suppressor gene which regulates the activation of AKT also 
known as Protein Kinase B, a component of the major prosurvival signaling 
pathway. Thus, although mutated BRAF may be an initiating factor in 
melanomagenesis, its alteration is not sufficient to lead to malignancy and other 
co-operating events are also required for melanoma development.  
 
1.3. Inhibition of BRAF V600E. 
Because of the relatively high frequency of mutations (approximately 50%) as 
well as its oncogenic potential, BRAF has represented a prime therapeutic target. 
Sorafenib is the first drug to have been investigated in inhibiting BRAF and the 
melanoma growth
46
. Besides RAF including BRAF wild type and BRAF mutated, 
sorafenib inhibits tyrosine kinases such as the vascular endothelial growth factor 
receptor 2 (VEGFR2), VEGFR3, platelet-derived growth factor receptor 
(PDGFR), p38 MAPK, FLT, cKIT, FMA, and RET
47
. In vitro studies 
demonstrated that sorafenib abrogated the MAPK signaling and inhibited the 
growth of melanoma cells. However early clinical trials failed to show any activity 
14 
 
of sorafenib as monotherapy or in combination with standard chemotherapy in 
patients with metastatic melanoma even when patients were selected for their 
BRAF mutational status
47
. It is supposed that sorafenib failure reflects the lack in 
targeting selectively mutant BRAF. This effect caused intolerable off-target side 
effects through inhibition of wild type BRAF and other target proteins.  
Although sorafenib has failed in the treatment of BRAF mutant melanoma, during 
the last few years novel agents have been proven to be effective in targeting BRAF 
V600E melanoma. The latest generation of BRAF-I has offered a significant 
improvement over sorafenib in potency against mutant BRAF and far fewer off-
target effects. Compounds that have been evaluated pre-clinically include AZ628, 
XL281, GDC-0879, SB590885, GSK2118436, PLX4032 and its analog PLX4720 
48, 49
. So far, PLX4032 (vemurafenib) and GSK2118436 (dabrafenib) are the most 
extensively studied BRAF-I both preclinically and clinically.  
Vemurafenib is an orally available adenosine triphosphate (ATP)-competitive 
RAF inhibitor that potent inhibits BRAF V600E [drug concentration required for 
50% inhibition of BRAF V600E kinase activity (IC50), 31 nM; CRAF IC50, 48 
nM; wild type BRAF IC50, 100 nM]. Biochemical assays showed that 
vemurafenib exhibits selectivity against a broad range of kinases but the vast 
majority of them is inhibited by doses of vemurafenib much higher than the 
clinically achievable drug concentrations
49
. In in vitro and in vivo studies treatment 
with vemurafenib demonstrated to inhibit the growth of melanoma cell lines 
harboring not only BRAF V600E mutations
50
 but also BRAF V600D, V600R and 
V600K mutations
51
. Analysis of signaling pathways showed that the growth 
inhibitory effects induced by vemurafenib are mediated by the inactivation of the 
RAF-MEK-ERK pathway
52
, the induction of G1-phase cell cycle arrest and the 
increase of the fraction of apoptotic cells correlated with increased BIM 
expression
50, 53
. When tested in melanoma patients vemurafenib has demonstrated 
to be an effective treatment for metastatic melanoma patients carrying mutant 
15 
 
BRAF. In a phase I study, treatment with vemurafenib demonstrated substantial 
tumor regression in 81% of patients with metastatic melanoma who had a BRAF 
V600E mutation
54
. In all cases objective responses were associated with a strong 
inhibition of proliferation as demonstrated by the inhibition of intra-tumoral ERK 
activation, reduction of Ki-67 positivity, and inhibition of glucose uptake as 
measured by FDG-PET. In a phase III randomized control trial (BRIM3) BRAF 
V600E melanoma patients were randomized to receive vemurafenib or 
dacarbazine. Analysis of the clinical data demonstrated that treatment with 
vemurafenib improved response rate (48% versus 5%), progression free survival 
(5.3 versus 1.6 months), and increased the percent of patients alive at six months 
(84% versus 64%) with a reported 75% of reduction in risk of death
13
.  
Dabrafenib as well as vemurafenib is an orally available ATP-competitive 
inhibitor that selectively inhibits the BRAF V600E kinase
14
. The drug 
concentration required for 50% inhibition of BRAF V600E kinase activity (IC50) 
is five times lower than that for BRAF wild type or CRAF
49
. Preclinical data 
demonstrated that dabrafenib inhibits the MAPK pathway in BRAF V600E 
melanoma cells, leading to decreased proliferation and regression in xenograft 
mouse models. Although more clinical data are available for vemurafenib than 
dabrafenib, the latter demonstrates a comparable activity to vemurafenib in 
melanoma patients. In phase I study the response rates in patients treated with 
dabrafenib was comparable to that achieve using vemurafenib
55
. Initial results of 
phase III trial (BREAK3) demonstrated that treatment with dabrafenib compared 
to dacarbazine in melanoma patients carrying BRAF V600E improved response 
rates (50% versus 6%) and progression free survival (6.7 versus 2.9 months). 
However OS data of this trial are not yet mature
14
. 
Vemurafenib and dabrafenib are characterized not only for their high clinical 
efficacy in BRAF V600E melanoma patients but also for their uncommon toxicity. 
The most frequent adverse events (AEs) with selective BRAF-I include arthralgia, 
16 
 
rash, nausea, photosensitivity, fatigue, pruritus and palmar-plantar dysesthesia. 
However the most important toxicity related to BRAF-I is accelerated growth of 
cutaneous squamous cell carcinomas (SCC) and keratoacanthomas (KAs)
13, 47
. The 
development of these skin lesions has been attributed to a differential effect of 
BRAF-I on the MAPK pathway in cells carrying BRAF wild type. This 
phenomenon has been coined “paradoxical activation” of MAPK signaling. In 
vitro studies have shown that a paradoxical activation of MAPK signaling arose in 
cells carrying both BRAF wild-type and oncogenic RAS mutations or upstream 
constitutive RTK activity (such as in HER2) after treatment with BRAF-I
56-59
. This 
paradoxical activation of MAPK signaling seems to be caused by the differential 
ability of BRAF-I to inhibit BRAF and CRAF. The high inhibition of wild type 
BRAF compared to the low inhibition of CRAF by BRAF-I causes MERK and 
ERK activation via CRAF which can be activated by upstream components of 
MAPK signaling such as oncogenic RAS mutations or activated RTK (Fig. 3)
56
.  
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Figure 3. Signal transduction through the MAPK pathway and the effect of 
BRAF inhibitors. a) Signal transduction downstream of oncogenic BRAF in the 
setting of activating mutations, b) inhibition of ERK/MAPK signaling with class 
BRAF inhibitors. c) Paradoxical CRAF activation by BRAF. Upstream signaling 
from oncogenic RTK or RAS results in preferential recruitment of CRAF to the 
plasma inner membrane, which transduces oncogenic RAS signaling through the 
MAPK pathway. In this case, wild type BRAF remains cytosolic in an inactive 
conformation. In the presence of BRAF-I, the inhibited wild-type BRAF is 
recruited to the plasma membrane by RAS, where it serves as a scaffold to 
enhance CRAF heterodimer activity and consequently increase MAPK pathway 
signaling output. This would not happen with RAF inhibitors with similar activity 
against CRAF and BRAF, where inhibition of both isoforms would inhibit MAPK 
signaling 
60
. 
 
It is noteworthy that HRAS mutations are commonly found in SCC and in KAs. 
Analysis of a large cohort of KAs from melanoma patients treated with BRAF-I 
demonstrated their significant enrichment for RAS mutations
61
. The pre-existence 
of keratinocytes harboring HRAS mutations as upstream activator of CRAF 
provides the perfect context for a growth stimulatory effect to produce the SCC 
with KA features which are observed in patients treated with selective BRAF-I. 
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1.4. Limitations of BRAF-I.  
BRAF-I such as vemurafenib and dabrafenib have been demonstrated to be 
effective in the treatment of BRAF mutant melanoma patients. However like many 
other oncogene directed therapies, such as imatinib in MCL and GIST or erlotinib 
in NSCLC, treatment with BRAF-I is limited in time (5.3 months) and complete 
responses are infrequently seen (only 5%) due to onset of resistance.  
Resistance to targeted agent might be caused by clonal selection of pre existing 
cells (tumor heterogeneity) which carrying different genetic and biologic properties. 
These cells which do not respond to the treatment support tumor growth, invasion, and 
metastasis and determine lack of complete response to target therapy. On the other 
hand resistance to targeted agent might be caused by the presence of additional 
alterations in tumor cells which also can drive tumor growth but coexist with the 
targeted alterations. These additional alterations are present before starting the 
treatment and determine a decreased sensitivity to the targeted agent (intrinsic 
resistance). Lastly, new alterations in oncogene or oncosuppressor genes, which 
will coexist with targeted alteration, might occur when the treatment is already 
started. These new alterations drive new proliferative and antiapoptotic signals and 
determine the lack of sensitivity to the targeted agent (acquired resistance).  
Conflicting data have been published about the tumor heterogeneity of BRAF 
V600E melanoma. Both intra- and inter-tumor heterogeneity in BRAF V600E 
expression in melanoma cells isolated from different regions of the primary lesions 
have been described
62
. BRAF V600E positive melanoma cells have been described 
to coexist in primary lesions with tumor cells harboring wild type BRAF. 
Furthermore, although clinical data demonstrated that BRAF V600E and NRAS 
mutations are mutually exclusive
63
, BRAF V600E melanoma cells and NRAS 
mutated melanoma cells have been also described to coexist in primary and in 
metastatic melanoma 
62, 64, 65
. 
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On the other hand many alterations have been identified to drive intrinsic and 
acquired BRAF-I resistance. In both cases BRAF-I resistance is likely to be caused 
by MAPK-dependent and/or -independent pathway activation (Fig. 4).  
 
Figure 4. Mechanisms of BRAF-I resistance in BRAF-mutated melanomas. 
Several mechanisms (shown in yellow balloons) have been identified to drive 
BRAF-I resistance in BRAF-mutated melanomas. They include PDGFRβ and 
IGF1R receptor tyrosine kinase signaling, secondary NRAS mutations, BRAF 
V600E amplification, BRAF V600E p61 splice variant, RAF isoform signal 
switching, MEK1
C121S
 mutation, COT amplification, increased AKT activity, loss 
of PTEN, PRKD3, amplified cyclin D1, and RB1 inactivation. The central theme 
of BRAF-I escape is the reactivation of MAP kinase and/or increased 
PI3K/AKT/mTOR signaling (skeleton pathways shown in blue boxes), which 
leads to melanoma growth and survival. As a further complication to the 
incredibly diverse resistance landscape, it has been demonstrated that multiple 
mutations, and possibly others that have yet to be identified, can occur within the 
same melanoma tumor or cell line, resulting in intratumor heterogeneity
66
.  
 
1.4.1. Intrinsic resistance to BRAF-I. 
An intrinsic resistance to BRAF-I has been reported in both preclinical and clinical 
studies. In vitro experiment demonstrated that a significant proportion of BRAF 
V600E mutated melanoma cell lines had different sensitivity to the growth 
inhibitory effect of BRAF-I with a wide range of IC50 values for vemurafenib and 
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other BRAF-I 
35, 67, 68
. It is known that melanomas carry a mutational profiles with 
multiple alterations in many genes including MITF, AKT3, COT, Cyclin D1, 
CDK2, CDK4, and retinoblastoma (Rb). However is still unclear how some of 
these alterations can modulate the biological behavior of melanoma cells and the 
response to BRAF-I.  
Alteration of Cyclin D1 have been shown to decrease the cytotoxic sensitivity to 
BRAF-I
69
. Cyclin D1 is a protein that in humans is encoded by the CCND1 gene. 
The protein encoded by this gene belongs to the highly conserved cyclin family, 
whose members are characterized by a dramatic periodicity in protein abundance 
throughout the cell cycle. Different cyclins exhibit distinct expression and 
degradation patterns which contribute to the temporal coordination of each mitotic 
event. Specifically cyclins are positive regulators of CDK which represent the 
catalytic subunit of the Cyclin/CDK complex. Negative regulators of Cyclin/CDK 
complex are represented by serine/threonine kinases such as p21 and p16. In case 
of Cyclin D1, this protein forms a complex with and functions as a regulatory 
subunit of CDK4 or CDK6, whose activity are required for cell cycle G1/S 
transition. Cyclin D1/CDK4 complex induces G1/S transition by phosphorylation 
of tumor suppressor Rb gene product which plays a major role in preventing the 
cell from replicating damaged DNA during G1 into S phase transition. Rb binds 
and inhibits transcription factors of the E2F family, which are composed of dimers 
of an E2F protein and a DP protein. The latter complex when is activated by Rb 
release, by transcripting the DNA, pushes a cell into S phase. Furthermore when 
E2F is free it activates factors like cyclins (e.g. Cyclin E and A), which push the 
cell through the S phase of cell cycle by activating CDK, and a molecule called 
proliferating cell nuclear antigen, or PCNA, which speeds DNA replication and 
repair by helping to attach polymerase to DNA and become active. As long as 
E2F-DP is inactivated, the cell remains stalled in the G1 phase. When Rb is bound 
to E2F, the complex acts as a growth suppressor and prevents progression through 
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the cell cycle. The Rb-E2F/DP complex also attracts a histone deacetylase 
(HDAC) protein to the chromatin, reducing transcription of S phase promoting 
factors, further suppressing DNA synthesis. Cyclin D1/CDK4 complex by 
phosphorylation of Rb allows E2F-DP to dissociate from Rb. In several tumors 
mutations, amplification and overexpression of Cyclin D1 have been observed. 
Cyclin D1 amplification has been described in clinical samples and in melanoma 
cell lines simultaneously with BRAF V600E mutation
69
. As previously described, 
in mutant BRAF V600E melanoma cells tumor growth is associated with 
uncontrolled cell cycle progression mediated by MAPK activation. MAPK 
activation leads to increasing Cyclin D1 expression. The inhibition of BRAF 
signaling by BRAF-I leads to the attenuation of the MAPK signaling, attenuation 
of Cyclin D1 expression, and arrest of cell cycle in the G1-phase. Therefore, an 
independent Cyclin D1 overexpression leads to intrinsic resistance to BRAF-I by 
facilitating cell cycle entry even when BRAF is inhibited. Similar alterations in the 
Cyclin/CDK complex such as aberrations in CDK4 or alterations in its negative 
regulators such as p16 or p53 have been also described
70
 as well as alterations in 
Rb
71
.  
An intrinsic resistance to BRAF-I, have been also described to be mediated by 
alterations of PTEN gene
35, 71
. PTEN alterations have been reported in more than 
30% and 50% of BRAF V600E melanomas and patients with PTEN alterations 
have been shown to display a decreased response rate to BRAF-I. PTEN is a tumor 
suppressor gene which acts through its phosphatase protein product in regulating 
cell cycle and survival. Unlike most of the protein tyrosine phosphatases, this 
protein preferentially dephosphorylates phosphoinositide substrates. Specifically, 
PTEN negatively regulates intracellular levels of phosphatidylinositol-3,4,5-
trisphosphate in cells and functions as a tumor suppressor by negatively regulating 
the PI3K/AKT signaling pathway. In absence of PTEN activity the PI3K/AKT 
pathway is iperactivated and leads to increased survival of tumor cells. This effect 
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is mediated by suppression of the pro-apoptotic protein BAD which is 
phosphorilated and subsequently inactivated by AKT at Ser99. Phosphorilation of 
BAD prevents its binding to Bax, a proapoptotic proteins, and relieves the 
antagonism of Bax on Bcl-2 and Bcl-XL which act as anti-apoptotic proteins
34
. In 
addition increased AKT signaling suppresses the expression of oncosuppressor 
gene product, BIM. Its phosphorylation by AKT determines the nuclear export of 
the transcription factor FOXO3a which regulates several oncosuppressor genes
35
. 
Therefore the decreased sensitivity to BRAF-I, when inactivating mutations of 
PTEN are present, is mediated by an increased AKT mediated survival of 
melanoma cells. In BRAF V600E melanoma similar findings have been also 
described for upregulation of the insuline growth factor-1 receptor (IGF-1R)
72
, a 
RTK. Its activation leads to an increased AKT activation by activation of its 
upstream components PI3K which as well as PTEN alteration determine an 
intrinsic BRAF-I resistance. 
Lastly, in BRAF V600E melanoma an intrinsic resistance to BRAF-I have been 
described to be mediated by alteration of tumor microenvironment
73
. In this case a 
decreased sensitivity to BRAF-I is not caused by tumor cell-intrinsic mechanisms 
but by alteration of the interaction between melanoma cells and tumor 
microenvironment. By definition, tumor microenvironment or “tumor stroma” 
includes all those components that are not cancer cells such as endothelial cells, 
fibroblasts, and infiltrating leukocytes, as well as extracellular matrix proteins in 
the cancer microenvironment. It has been demonstrated that BRAF-I resistance 
results to be mediated by fibroblast production of growth factors such as the 
hepatocyte growth factor (HGF)
73
. In presence of BRAF-I, HGF increased 
production by activating its natural ligand c-Met (HGF receptor with tyrosine-
kinase activity) caused reactivation of MAPK pathway (MAPK dependent) or 
activation of AKT pathway (MAPK independent) which leads to BRAF-I intrinsic 
resistance.  
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1.4.2. Acquired resistance to BRAF-I. 
Several mechanisms of acquire resistance have been described in vitro and have 
been validated in BRAF V600E melanoma specimens. Unlike the acquired 
resistance mechanisms to targeted therapy found in other malignancies, large-scale 
sequencing analysis of melanoma specimens demonstrated that acquired resistance 
to BRAF-I is not caused by the development of secondary mutations (so-called 
gatekeeper) in BRAF oncogene
65, 74
. Generation of acquired resistance, by 
continuous exposition of BRAF V600E melanoma cell lines to BRAF-I in vitro, 
has demonstrated that different mechanism are involved in the acquired BRAF-I 
resistance.  
So far, the mechanisms described of acquired BRAF-I resistance include 
activation of constitutive signaling in receptor tyrosine kinases (IGF-1R and 
PDGFRβ)65, 75, increased expression of the MAPK family member COT 
(MAP3K8, TPL-2)
76
, BRAF V600E amplification
77
, aberrantly spliced BRAF 
V600E
78
, elevated CRAF activity
79
 and acquisition of mutation in NRAS
65
 and 
MEK1
80
. For all these mechanisms it has been shown that BRAF-I resistance is 
mediated by reactivation of ERK (MAPK dependent) or activation of alternative 
pathways such as PI3K/AKT (MAPK independent).  
In the context of BRAF V600E inhibition, ERK reactivation can be caused by 
activation of up-stream components or down- stream components in MAPK 
pathway of BRAF as well as for the incapacity of BRAF-I in inhibiting BRAF 
V600E. Thus an ERK reactivation by up-stream components of BRAF V600E is 
mediated by activation of CRAF or ARAF which bypasses the BRAF inhibition 
(paradoxical MAPK activation, see before). CRAF or ARAF activation can be 
caused by upstream activation of RTK such as IGFR-1 or PDGFRβ, activating 
mutations in NRAS or by amplification of ARAF or CRAF. On the other hand, an 
ERK reactivation by the lack of ability of BRAF-I in inhibiting BRAF V600E is 
mediated by truncated BRAF V600E spliced isoforms. In this case although BRAF 
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maintains the mutation at the 600 position (i.e. V600E), it loses the binding site for 
BRAF-I and dimerises readily in the presence of a BRAF inhibitor, thereby hyper 
activating the MAPK pathway. Similar mechanisms have been also described for 
amplification of BRAF V600E. In this case BRAF monodimer inhibition by 
BRAF-I has been shown to be not sufficient to inhibit BRAF dimerization which 
in turn leads to ERK reactivation. An ERK reactivation by BRAF down-stream 
components can be mediated by a BRAF independent-MEK or ERK activation. 
Thus an increased expression of the MAPK family member COT or activating 
mutations of MEK leads to ERK reactivation by a direct phosphorilation of ERK.  
MAPK play a major role in melanoma growth. However in the context of BRAF 
V600E and subsequently MAPK inhibition, activation of alternative pathways can 
restore tumor growth. Several signaling pathways have been shown to induce an 
increase proliferation, prosurvival signals, antiapoptotic signals as well as 
proangiogenetic signals. Thus an increased prosurvival signaling mediated by 
activation of PI3K/AKT has been demonstrated in BRAF V600E melanoma 
resistant to BRAF-I. It can be mediated by upregulation of RTK such as IGF-1R, 
PDGFRβ and epidermal growth factor receptor (EGFR), by activating mutations 
of PI3K or AKT, and by acquired mutations of PTEN as previously described for 
the intrinsic resistance of BRAF-I.  
All together these findings demonstrate that several mechanisms can drive a 
BRAF-I intrinsic or acquired resistance. However it is still unknown whether 
therapeutic escape arises as the result of an evolutionary process within the 
melanoma or from the selection of pre-existing ‘‘resistant’’ clones that are already 
present prior to the initiation of therapy. In addition, to date, the resistance 
mechanisms described account for less than 50% of patients whose disease 
relapses while being treated with a BRAF-I and the remaining alterations need to 
be defined. Lastly many of the described mechanisms of BRAF-I resistant which 
have been demonstrated in vitro still required to be validated in clinical samples 
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and for most of them the molecular event induced by BRAF-I still need to be 
determined. 
 
1.5. Strategies to overcome BRAF-I resistance 
Development of BRAF-I resistance in melanoma patients as well as drug 
resistance to treatment with targeted agents in other malignancies demonstrated 
that tumor growth is driven by several alterations. Therefore to achieve a 
sustainable therapeutic response an effective strategy has to target multiple 
alterations. In melanoma the characterization of the molecular mechanisms 
underlies resistance in BRAF V600E melanoma has lead a rational designed of 
targeted combinatorial therapies. Most of the proposed combinatorial strategies to 
overcome BRAF-I resistance have been demonstrated in vitro, some of them are in 
clinical development but to date few of them have been already validated in 
clinical setting. 
Although different mechanisms have been described for BRAF-I resistance most 
of them have demonstrated to lead the reactivation of the MAPK pathways or 
activation of the PI3K/AKT pathways. Several novel inhibitors are in clinical 
development to target almost all components of these two pathways. The 
simultaneous inhibition of the activation of different components of the MAPK 
and PI3K/AKT pathways has led to the develop of combinatorial strategies such as 
the combination of BRAF-I and MEK- inhibitor (MEK-I), BRAF-I/MEK-I and 
mTOR/PI3K/AKT inhibitor, BRAF-I and IGF-1R inhibitor, and BRAF and 
PDGFRβ inhibitor75, 81-83.  
In the context of the MAPK pathway reactivation, the combination of BRAF-I and 
MEK-I has demonstrated in several in vitro studies to be effective in delaying and 
overcoming the BRAF-I resistance
49
. Since MEK is a down-stream component of 
the MAPK pathway its inhibition has been shown in vitro to lead ERK inhibition 
in presence of BRAF-I resistance mediated by RTK, NRAS, BRAF, CRAF, 
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ARAF, COT and MEK alterations. The combination of BRAF-I and MEK-I has 
been also tested in clinical setting. A phase I trial in patients who disease 
progressed after BRAF-I treatment did not demonstrate a clinical responses to 
MEK-I in the treated patients
84
. Another phase I-II trail in patients who disease 
progressed after BRAF-I combined BRAF-I and MEK-I demonstrated short 
survival and low number of response rate. However a recent phase II trial 
evaluating the combination of BRAF-I and MEK-I in naïve melanoma patients 
carrying BRAF V600E or V600K demonstrated an increase in progression free 
survival in the combinatorial treatment compared to administration of BRAF-I 
alone (9.2 months in dabrafenib 150 mg/die and trametenib 1mg/die arm, 9.4 
months in dabrafenib 150 mg/die and trametenib 2mg arm, 5.8 in dabrafenib 
150mg/die arm as single agent, p<0.001)
85
. The rate of complete or partial 
responses with combination 150 mg /2 mg of BRAF-I/MEK-I therapy was 76%, as 
compared with 54% with BRAF-I monotherapy (P=0.03). Furthermore a 
decreased incidence of KA and SCC in BRAF-I/MEK-I combination was found 
compared to BRAF-I. These data validate the role of rebound BRAF inhibitor 
mediated MEK/ERK signaling (paradoxical MAPK activation) in the development 
of these types of tumors
85
.  
In case of resistance mediated by increased IGF-1R signaling it has been shown in 
vitro that dual MEK and PI3K inhibition or BRAF-I and IGFR-1 inhibition might 
be an effective strategy. Interesting in vitro resistance mediated through increased 
PDGFRβ signaling has been shown to be not overcome by PDGFR inhibitors 
sunitinib and imatinib but by the combination of the mTOR/PI3K/AKT inhibitor 
and MEK/BRAF inhibitor
86
. Clinical trials have been initiated to examine the 
PI3K/mTOR inhibitor BEZ235 in combination with the MEK-I MEK162 
(NCT01337765). This trial is currently enrolling patients who have BRAF 
mutations and those who have NRAS mutations.  
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In case of resistance mediated by increased fibroblast secretion of HGF the 
combination of BRAF-I and c-Met inhibitor have been shown in vitro to sensitize 
resistant melanoma cells to BRAF-I
73
. 
Another approach used to delay and overcome BRAF-I resistance have been also 
proposed. Simultaneous administration of BRAF-I and an inhibitor of the heat 
shock protein 90 (HSP90) have been demonstrated in vitro to overcome an 
acquired resistance to BRAF-I mediated by NRAS mutation, PDGFRβ 
upregulation and COT overexpression
87
. HSP90 is a cellular chaperone required 
for the refolding of denatured proteins, cellular survival under stress conditions, 
and the maturation of a subset of proteins. Therefore it has been shown that 
inhibition of HSP90 induces instability and degradation of client proteins such as 
MEK, BRAF and AKT overcoming resistance to BRAF-I
87
.  
These evidences demonstrate that several strategies can be effective to overcome 
and delay the lack of sensitivity of BRAF V600E melanoma cells to BRAF-I. 
However several open questions remain to be determined. First, there is still the 
need to identify molecular biomarkers which allow the selection of melanoma 
patients and predict the most effective therapeutic strategy. Second, most of the 
proposed strategies need to be validated in vivo (i.e.,  mTOR-/PI3K-/AKT-I and 
MEK-/BRAF-I or HSP90 inhibitor and BRAF-I) and their reliability in terms of 
toxicity still need to be determined. It is noteworthy that targeting downstream 
components of signaling pathways as well as targeting a broad range of client 
proteins with HSP90 inhibitor is expected to be associated with an increased 
toxicity. Third, some of mechanisms and the strategies described to overcome the 
BRAF-I resistance still remain not convincing as well as the PDGFRβ mediated 
resistance and the lack of efficacy of PDGFRβ inhibitor in overcoming this 
resistance. Lastly mechanisms in the MAPK pathways need to be better elucidated 
such as the lower ability of MEK-I as compared to BRAF-I in inhibiting 
melanoma growth when it is driven by MAPK pathway.   
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2. AIMS OF THE STUDY 
The discovery of BRAF mutation and the development of targeted agents to 
inhibits mutant BRAF has changed the approach to the treatment of melanoma 
patients. However the existence of many potential resistance mechanisms to 
BRAF-I has demonstrated the plasticity of melanoma in intrinsic and acquired 
resistance. These observations have led to the development of novel combinatorial 
strategies which have demonstrated the importance of targeting multiple signaling 
pathways to achieve a sustainable therapeutic response. Nevertheless more effort 
is need to discover the unknown mechanisms of intrinsic and acquired resistance 
to develop strategies which are effective in counteracting the mechanisms of 
BRAF-I resistance of melanoma cells. It is likely that the existence of so many 
potential resistance mechanisms will require patient-specific approaches to the 
management of therapeutic escape and the further personalization of melanoma 
therapy.  
Therefore the aims of this study were to identify novel potential mechanisms of 
BRAF-I resistance and to validate novel combinatorial strategies for overcoming 
BRAF-I resistance. We have identified PDGFRα upregulation as a new 
mechanism involved in the intrinsic and acquired BRAF-I resistance in BRAF 
V600E melanoma. Melanoma cell lines with acquired BRAF-I resistance provided 
a model to study melanoma patients who develop BRAF-I resistance. To validate 
our cell line results demonstrating PDGFRα upregulation, we tested melanoma 
lesions harvested from patients who developed BRAF-I resistance. Lastly we 
demonstrate that both in vitro and in vivo the PDGFRα mediated BRAF-I 
resistance can be overcome by combining a BRAF-I, vemurafenib, with a 
PDGFRα inhibitors such as sunitinib or imatinib. 
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3. MATERIALS AND METHODS 
3.1. Cell cultures.  
The parental BRAF V600E melanoma cell lines Colo38 and M21 were cultured in 
RPMI 1640 medium (Mediatech, Inc. Herndon, VA) supplemented with 2 mmol/L 
L-glutamine (Mediatech) and 10% fetal calf serum (FCS; Atlanta Biologicals, 
Lawrenceville, GA). The BRAF V600E melanoma cell line TPF-10-741 was 
cultured in DMEM (Mediatech) supplemented with 2 mmol/L L-glutamine and 
10% FCS. This cell line was started from a cutaneous metastasis of the melanoma 
patient TPF-10-741 who had developed BRAF-I resistance following treatment 
with vemurafenib. Melanoma cell lines with acquired vemurafenib resistance 
(Colo38R and M21R) were generated by propagating parental Colo38 and M21 
cells in increasing concentrations of BRAF-I (up to 2 µM) to achieve chronic 
selection. Colo38R and M21R were cultured in RPMI 1640 medium supplemented 
with 2 mmol/L L-glutamine, 10% FCS and 500 nM vemurafenib. All cells were 
cultured at 37°C in a 5% CO2 atmosphere. 
 
3.2. Chemical reagents, antibodies and shRNAs. 
Vemurafenib (PLX4032), was purchased from ChemieTek (Indianapolis, IN). 
Sunitinib and imatinib were purchased from Selleck Chemicals LLC (Houston, 
TX). 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) was 
purchased from Sigma (St. Louis, MO). Phospho (p)-AKT (Ser473)-, AKT-, p-
PI3K p85 (γ458)-, p-CRAF (S289/296/301)-, p-MEK 1/2 (S217/221)-,  p-ERK 1/2 
(Thr202/Tyr204)-, ERK1/2-, PTEN-, PDFGRβ-, p-PDGFRα-, PDGFRα-, 
VEGFR2-, Cleaved Caspase-3 (Asp175)-, p-Histone H3 (Ser10)- and β-actin-
specific monoclonal antibodies (mAbs) were purchased from Cell Signaling 
Technology (Danvers, MA). The calnexin-specific mAb TO-5 was developed and 
characterized as described 
88. PDGFRα-specific short hairpin RNA (shRNA) and 
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GFP-shRNA were provided by the- Vector Core Facility of the University of 
Pittsburgh Cancer Institute (Pittsburgh, PA). 
 
3.3. Cell proliferation and MTT assay. 
Cells were plated in triplicate in 96-well microtiter plates at the density of 2.5 x 
10
3
 per well in 100ul in RPMI 1640 or DMEM medium supplemented with 2% 
FCS and treated with vemurafenib and/or PDGFRα inhibitor (sunitinib or 
imatinib). DMSO (vehicle of the drugs) concentration was maintained at 0.02% in 
all wells. Cell proliferation was evaluated by MTT assay at indicated time points. 
Briefly, 10 uL of MTT was added into each well, and the mixture incubated for 
approximately 3–4 h at 37°C. Metabolically active, viable cells convert MTT into 
a purple-colored formazan product that can be measured using a 
spectrophotometric microplate reader (MTX Lab System, Inc, Vienna, VA) at 540 
nm following solubilization. Data were expressed as percent of inhibition or 
percent of proliferation of treated cells compared with the untreated control cells. 
All experiments were performed three independent times in triplicates. 
 
3.4. Western blot analysis.  
For samples preparation from cell lines, cells were seeded at the density of 1 x 10
5
 
per well in a 6-well plate in medium supplemented with 2% FCS and treated with 
vemurafenib (1 µM), sunitinib (3 µM), imatinib (20 µM) and vemurafenib plus 
sunitinib or imatinib at 37 °C in a 5% CO2 atmosphere for the indicated time 
points. The DMSO (vehicle of the drugs) concentration was maintained at 0.02% 
in all wells. Untreated cells were used as a control. Cells were collected and lysed 
in lysis buffer [10 mM Tris–HCl (pH 8.2), 1% NP40, 1 mM EDTA, 0.1% BSA, 
150 mM NaCl) containing 1/50 (vol/vol) of protease inhibitor cocktail 
(Calbiochem, La Jolla, CA). For sample preparation from tumor xenografts, 
tumors were extracted at the time of killing, harvested and stored at -80°C. 
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Proteins were extracted by homogenization in the presence of 2 to 5 ml lysis 
buffer. After incubation on ice for 20 to 30 minutes, the lysates were centrifuged at 
10,000 rpm for 30 minutes. The protein concentration of the lysate was 
determined. Equal amounts of proteins (80 µg per well) for cell lysates and for 
tumor lysates were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS–PAGE) and transferred onto polyvinylidene fluoride 
(PVDF) membranes (0.45 lm pore size) (Millipore, Bedford, MA). Membranes 
were blocked with 5% nonfat dry milk plus 2% BSA at room temperature for 2 h 
and then incubated overnight at 4°C with the indicated mAbs. Corresponding 
peroxidase-conjugated secondary mAbs (Cell signaling technology) were then 
added to respective blots and incubations continued at room temperature for an 
additional 1 h. Blots were washed 5 times for 5 min with 0.01 M tris-buffered 
saline (pH 7.2), 0.05% tween-20 (TBST) between all steps. Blots were developed 
using the ECL Plus Western Blotting Detection System (GE Healthcare, 
Buckinghamshire, UK) and bands visualized using the FOTO/Analyst Investigator 
Eclipse System (Fotodyne Incorporate, Hartland, WI). β-actin or Calnexin were 
used as the protein loading control.  
 
3.5. Transduction of melanoma cells with Lentiviral vectors encoding shRNA.  
Colo38R, M21R and TPF-10-741 cells were seeded at the density of 6 x10
4
 per 
well in a 6-well plate and incubated in culture medium for 24 h at 37ºC in a 5% 
CO2 atmosphere prior to viral infection. Cells were transduced with PDGFRα-
specific shRNAs [Target sequence: CCAGCCTCATATAAGAAGAAA (#1), 
CCAGCTTTCATTACCCTCTAT (#2), CGGTGAAAGACAGTGGAGAT (#3), 
CCCAACTTTCTTATCCAACTT (#4), CAATGGACTTACCCTGGAGAA (#5)] 
or GFP-shRNA, used as a control, lentiviral particles (1 x 10
6
 per well) in presence 
of polybrene (2 μg/ml) as described elsewhere 89. Following an 18 h incubation at 
37ºC, culture medium was removed and replaced with fresh culture medium. 
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Following an additional incubation for up to 72 h at 37ºC, cells were analyzed for 
GFP expression under the microscope, split, enriched for infected cells by 
selection with puromycin (2.5 ug/ml) and collected for further analysis. 
 
3.6. Flow Cytometry. 
Cells were seeded in 6-well plates in triplicate at the density of 1 x 10
5
 per well 
and treated with vemurafenib and/or sunitinib. Following a 24 h treatment 
apoptotic cells were identified by staining with Annexin -V and PI (BD 
Bioscience, San Jose, CA) for 15 min at room temperature. Flow cytometry data 
were analyzed using Summit v4.3 software (DAKO, Carpinteria, CA). 
 
3.7. In vivo studies. 
C.B-17 severe combined immunodeficient (SCID) female mice (8–10 week old) 
were purchased from Taconic Farms, Inc. (Hudson, NY). Parental and BRAF-I 
resistant cell lines M21 and M21R (1 x 10
6
 cells/mouse) were implanted 
subcutaneously in the right lateral flank of mice. A total of 20 SCID mice was 
challenged with each cell line. Body weight and tumor volume were measured 
twice per week. Tumor volume was measured by vernier caliper. Treatment was 
initiated 10 days after cell inoculation when the tumor developed and had a 
diameter of around 0.4 cm. Mice were randomly divided into 4 groups of 5 mice 
each. Mice in Group 1 were treated with vemurafenib (12.5 or 25 mg/kg/twice per 
day)
50
, those in Group 2 with sunitinib (20mg/kg/day)
90
 or imatinib 
(100mg/kg/twice)
91
 and those in Group 3 with vemurafenib (12.5 or 25mg 
/kg/twice per day) plus sunitinib (20mg/kg/day) or imatinib (100mg/kg/twice). 
Mice in Group 4 were left untreated as a reference for the natural course of the 
disease. Drugs were administered by oral gavage. When tumor diameter from 
untreated mice reached 2.0 cm all mice were sacrificed. Primary tumors and 
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organs were collected for further analysis. Animal studies have been approved by 
the Institutional Animal Care and Use Committee.  
 
3.8. Patient Samples. 
Patients with metastatic melanoma harboring the BRAF V600E mutation 
(confirmed by genotyping) were enrolled in clinical trials with the BRAF-I 
(vemurafenib) or with BRAF-I (dabrafenib) and MEK inhibitor (MEK-I) 
(trametinib). Patients were consented for tissue acquisition per IRB-approved 
protocol. Tumor biopsies were performed pre-treatment (day 0), at 10-14 days on 
treatment, and/or at the time of disease progression [as defined by Response 
Evaluation Criteria In Solid Tumors (RECIST)] if applicable. Formalin-fixed 
tissue was analyzed to confirm that viable tumor was present via hematoxylin and 
eosin (H&E) staining.  
 
3.9. Immunohistochemistry. 
Patient biopsies and tumors generated in mice were formalin fixed and paraffin 
embedded and then used as substrates in immunohistochemical reactions. Five-um 
thick xenograft tissue sections were fixed on silane-coated glass slides, 
deparaffinized, and subjected to antigen retrieval (Target retrieval solution, 
DAKO). Following blocking, slides from mice were incubated with Cleaved 
Caspase-3 (Asp175) and p-Histone H3 (Ser10) –specific mAbs overnight. Eight-
um thick sections from patient-derived samples were incubated with PDGFRα-
specific mAb (sc-338, Santa Cruz) (1:400) overnight. Sections were then washed 
with PBS, and the primary antibody was amplified using the VECTASTAIN ABC 
Kit (Peroxidase rabbit IgG, Vector Laboratories, PK-4001). The detection of this 
antibody was performed with the DAB Peroxidase Substrate Kit from DAKO and 
the sections were counterstained with H&E. PDGFRα expression, as measured by 
its staining intensity, in tumors harvested from BRAF-I treated patients either on 
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treatment or at the time of disease progression was compared to that the staining in 
pretreatment tumors. Scores were recorded semiquantitatively as 1+, 2+, 3+ and 
4+, when , 1–25%, 26–50%, 51-75% and >75% of nuclei were stained, 
respectively. Mitotic and apoptotic tumor cells in the sections of primary tumors 
harvested from mice were detected by staining p-Histone H3 (Ser10) and Cleaved 
Caspase-3 proteins, respectively, and quantified by counting 5 random fields per 
section (magnification ×200). Data were expressed as the mean number of mitotic 
or apoptotic tumor cells in each group. The number of mitotic or apoptotic tumor 
cells was counted by an investigator who was blinded to the type of treatment 
received by the mice from which tumors had been harvested.  
 
3.10. Statistical analysis.  
Averages, standard deviations, and unpaired t-test were calculated using MS-
Excel. Data showed the mean ± SD of the results obtained in at least three 
independent experiments. Time of disease progression (time to progression) of 
BRAF-I treated patients was calculated using the Kaplan-Meier methods. 
Differences between groups were considered significant when the P value was < 
0.05. The asterisk (*) indicates P < 0.05. 
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4. RESULTS AND DISCUSSION 
4.1. ERK reactivation, AKT activation and PDGFRα upregulation in 
Colo38R, M21R and TPF-10-741 melanoma cell lines with acquired 
vemurafenib resistance. 
Colo38 and M21 melanoma cell lines which are driven by mutant BRAF V600E 
are exquisitely sensitive to the anti-proliferative activity of vemurafenib. To select 
cells with acquired BRAF-I resistance, Colo38 and M21 cells were grown in the 
presence of serially increasing concentrations of vemurafenib up to a dose of 2 
µM. At the end of 3 months, resistant cells were isolated from each of the two cell 
lines. These cell lines were named Colo38R and M21R. Additionally a novel cell 
line TPF-10-741 was developed from a cutaneous metastasis from a melanoma 
patient who had developed BRAF-I resistance following treatment with 
vemurafenib, and that harbors the BRAF V600E mutation. MTT assays 
demonstrated that Colo38R and M21R cells had acquired resistance to the growth 
inhibitory effects of vemurafenib, while the TPF-10-741 cell line displayed an 
intermediate sensitivity to vemurafenib (Fig. 5).  
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Figure 5. BRAF V600E melanoma cell lines, autologous cells made resistant 
to BRAF-I by continuous exposure to increasing doses of vemurafenib and a 
melanoma cell line isolated from a patient who acquired BRAF-I resistance. 
M21, M21R and TPF-10-741 cells were treated with the indicated concentrations 
of vemurafenib. Cell growth inhibition was determined by MTT assay following a 
five day incubation at 37°C.  Percentage of cell growth inhibition was calculated 
as the ratio of treated to untreated cells at each vemurafenib dose. Data are 
expressed as the mean ± SD of the results obtained in three independent 
experiments. 
 
 
This acquired resistance model was then used to investigate the molecular 
mechanisms underlying disease progression after an initial response to 
vemurafenib.  
Growth inhibitory effects of vemurafenib are mediated by inhibiting the 
RAF/MEK/ERK pathway 
92
. Since acquired vemurafenib resistance can be 
mediated by reactivation of the RAF/MEK/ERK pathway or activation of 
alternative pathways like PI3K/AKT, signaling through these pathways were 
evaluated in both parental and resistant cell lines (Fig. 6). Western blot analysis 
demonstrated that following a 1, 24 and 48 h incubation with vemurafenib p-ERK 
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levels were reduced in both Colo38 and M21 cells, but there was no detectable 
effect on p-ERK levels in Colo38R and M21R cells, and a limited effect on TPF-
10-741 cells. p-AKT levels were increased in vemurafenib-resistant cells 
(Colo38R and M21R) compared to vemurafenib-sensitive cells (Colo38 and M21),  
and in TPF-10-741 cells  as well as in the M21 sensitive cells after treatment with 
BRAF-I. Thus the decreased sensitivity to the inhibition of the RAF/MEK/ERK 
pathway by BRAF-I was associated with the reactivation of the RAF/MEK/ERK 
pathway and with activation of AKT.  
 
 
 
 
 
 
 
 
 
 
Figure 6. Association of 
vemurafenib resistance with 
ERK reactivation and AKT 
activation in BRAF V600E 
melanoma cells. Colo38, 
Colo38R, M21, M21R and TPF-
10-741 cells were treated with 
vemurafenib (1 µM). Following 
an incubation at indicated time 
points at 37°C cells were 
harvested and lysed. Cell lysates 
were analyzed by western blot 
with the indicated mAbs. β-actin- 
was used as a loading control.  
. 
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Acquired vemurafenib resistance through activation of the PI3K/AKT pathway 
can be mediated by the upregulation of PDGFRβ or other growth factor receptors 
like IGFR 
65
. Therefore, to investigate the role of growth factor receptors in 
acquired vemurafenib resistance, we evaluated the expression levels of PDGFRα, 
PDGFRβ and VEGFR2 in Colo38, Colo38R, M21, M21R, and TPF-10-741 cell 
lines after treatment with vemurafenib. Western blot analysis demonstrated that 
treatment with vemurafenib enhanced PDGFRα expression and activation in the 
two resistant cell lines as compared to  the BRAF-I sensitive cell lines. PDGFRα 
was also expressed and activated in the partially BRAF-I resistant TPF-10-741 cell 
line both under basal conditions and following treatment with vemurafenib (Fig. 
7).  
 
 
 
 
 
 
 
 
Figure 7. Association of vemurafenib resistance with PDGFRα upregulation 
in BRAF V600E melanoma cells. Colo38, Colo38R, M21, M21R and TPF-10-
741 cells were treated with vemurafenib (1 µM). Following a 48 h incubation at 
37°C cells were harvested and lysed. Cell lysates were analyzed by western blot 
with the indicated mAbs. Calnexin was used as a loading control. The results 
presented are representative of the results obtained in three independent 
experiments. 
 
 
PDGFRβ was found to be upregulated on TPF-10-741 cells after treatment with 
vemurafenib, but not in Colo38, Colo38R, M21 and M21R cells. VEGFR2 
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expression was not detected in any of the cell lines (Colo38, Colo38R, M21, 
M21R and TPF-10-741) before or after treatment with vemurafenib. Further 
analysis of components of the RAF/MEK/ERK pathway and PI3K/AKT pathway 
demonstrated that PDGFRα upregulation was associated with PI3K, CRAF and 
MEK activation in Colo38R, M21R, and TPF-10-741 cells. Lasltly PTEN 
mutation was demonstared in TPF-10-741 cells but not in Colo38, Colo38R, M21 
and M21R. Based on these observations, we investigated whether PDGFRα 
upregulation was causally related to vemurafenib resistance (Fig. 8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Analysis of RTK, MAPK and PI3K/AKT pathway components in 
BRAF V600E melanoma cells. Colo38, Colo38R, M21, M21R and TPF-10-741 
cells were treated with vemurafenib (1 µM). Following a 48 h incubation at 37°C 
cells were harvested and lysed. Cell lysates were analyzed by western blot with the 
indicated mAbs. Β-actin was used as a loading control. The results presented are 
representative of the results obtained in three independent experiments. 
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4.2. PDGFRα mediates acquired vemurafenib resistance of Colo38R, M21R, 
and TPF-10-741 melanoma cells by reactivation of the RAS/RAF/ERK 
pathway and activation of the PI3K/AKT pathway. 
To test whether increased PDGFRα expression caused the vemurafenib resistance 
of Colo38R, M21R and TPF-10-741, PDGFRα was knocked down in the three cell 
lines using 5 PDGFRα-specific shRNAs. As shown in Fig. 9, lentiviral 
transduction of M21R cells with a PDGFRα-specific shRNA (#4) construct 
knocked down PDGFRα protein expression. PDGFRα downregulation was 
associated with decreased p-ERK and p-AKT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additionally, the M21R and TPF-10-741 cells transduced with the PDGFRα-
specific shRNA (#4) displayed a significantly increased sensitivity to vemurafenib, 
as compared to the autologous cells transduced with a GFP-shRNA (P<0.01) (Fig. 
10). Lastly, western blot analysis demonstrated that the PDGFRα downregulation 
caused by the PDGFRα-specific shRNA (#4) in combination with vemurafenib 
Figure 9. Restoration by PDGFRα 
downregulation of vemurafenib 
signaling pathway inhibtion of 
BRAF V600E melanoma cells with 
acquired BRAF-I resistance. M21R 
and TPF-10-741 cells were transduced 
with PDGFRα-specific shRNA (#4) or 
with GFP-shRNA, used as a control, 
lentiviral particles. Transduced cells 
were treated with vemurafenib (1µM). 
Following a three day incubation at 
37°C cells were harvested and lysed. 
Cell lysates were analyzed by western 
blot with the indicated mAbs. β-actin 
was used as a loading control. The 
results presented are representative of 
the results obtained in three 
independent experiments. 
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treatment dramatically decreased the levels of p-ERK and p-AKT in M21R cells 
(Fig. 9). These findings demonstrate that PDGFRα mainly induces both ERK and 
AKT activation in the cells that are completely or partially resistant to 
vemurafenib, and suggests that PDGFRα inhibition could overcome this acquired 
resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Restoration by PDGFRα downregulation of vemurafenib cell 
growth inhibtion of BRAF V600E melanoma cells with acquired BRAF-I 
resistance. PDGFRα-specific shRNA (#4) transduced M21R and TPF-10-741 
cells were treated with the indicated vemurafenib concentrations. GFP-shRNA 
transduced M21R and TPF-10-741 cells were used as controls. Cell proliferation 
was determined by MTT assay following a three day incubation at 37°C. 
Percentage of cell proliferation was calculated as the ratio of treated cells to 
untreated GFP-shRNA transduced cells. Data are expressed as mean ± SD of the 
results obtained in three independent experiments. *** indicates P < 0.01. 
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4.3. Association of PDGFRα upregulation in melanoma patient derived 
biopsies with vemurafenib resistance. 
To validate our in vitro findings we compared PDGFRα expression in biopsies 
obtained from 9 melanoma patients treated with  BRAF-I or with BRAF-I and 
MEK-I (Table 1). Tumor biopsies were performed before treatment, on treatment, 
and at the time of disease progression. IHC staining demonstrated PDGFRα 
upregulation in 5 out of 9 patients following treatment with vemurafenib or with 
dabrafenib and trametinib (Fig. 11A). Interestingly, in 3 of the 5 patients a 
significant increase in PDGFRα expression (>1) was observed after treatment.  
Patients with a significant (>1) increase in PDGFRα expression after treatment 
with BRAF-I +/- MEK-I had less tumor regression based on RECIST criteria (Fig. 
11B) and a shorter time to disease progression (Fig. 11C) when compared to 
patients who had no change or a small change in expression (≤1). These results 
demonstrate an association between PDGFRα overexpression and vemurafenib 
resistance in patients with melanoma. 
 
A. 
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B. 
 
 
 
 
 
 
 
C. 
 
 
 
 
 
 
 
Figure 11. PDGFRα expression in melanoma tumors obtained from patients 
who acquired BRAF-I resistance.  Tumor biopsies of melanoma removed from 
patients were performed pre-treatment (day 0), at 10-14 days on treatment, and/or 
at the time of disease progression following treatment with BRAF-I or with 
BRAF-I and MEK-I. Frozen sections were fixed with 4% PFA and stained with 
H&E and PDGFRα-specific rabbit antibody. Patients were divided in two groups 
based on change of PDGFRα expression at IHC after treatment: those whose 
PDGFRα staining score had no or 1 point increase after treatment (≤1) and those 
for whose PDGFRα staining score increased 2 or more points after treatment (>1). 
A. Representative IHC staining of PDGFRα expression in melanoma patients 
before treatment, on treatment  and at the time of disease progression in 5 out of 9 
tumor biopsies. Magnification is indicated. B. Two groups of patients were 
graphed based upon RECIST criteria and compared as a percent of the total 
population of the PDGFRα stain score group. C. Two groups of patients were 
graphed based upon the time to disesase progression utilizing Kaplan–Meier 
methods.  
 
44 
 
4.4. Inhibition of PDGFRα increases the anti-tumor activity of vemurafenib in 
BRAF-I sensitive and resistant melanoma cell lines. 
To investigate whether the anti-tumor activity of BRAF-I could be enhanced by 
PDGFRα inhibition in both BRAF-I sensitive and resistant melanoma cell lines, 
the BRAF-I sensitive Colo38 and M21 cell lines and the BRAF-I resistant 
Colo38R, M21R and TPF-10-741 cell lines were treated with vemurafenib and/or 
PDGFRα inhibitors sunitinib90 and imatinib 91. Both multitargeted tyrosine kinase 
inhibitors (TKIs) markedly inhibit both PDGFRα and PDGFRβ. Sunitinib also 
inhibits VEGFR2 and c-Kit receptor kinases. A dose titration experiment 
established the dose of PDGFR inhibitors sunitinib and imatinib to be combined 
with vemurafenib in the 5 cell lines. The IC50 dose of sunitinib and imanitinib 
were found to be 2 and 15 µM, respectively (Fig. 12).  
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Dose dependent effect of sunitinib on the in vitro proliferation of 
BRAF-I sensitive and resistant melanoma cells harboring BRAF V600E. 
Colo38, Colo38R, M21and M21R cells were treated with the indicated 
concentrations of sunitinib. Cell growth inhibition was determined by MTT assay 
following a five day incubation at 37°C. Percentage of cell growth inhibition was 
calculated as the ratio of treated to untreated cells at each sunitinib dose. Data are 
expressed as mean ± SD of the results obtained in three independent experiments. 
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The dose of 1.5 µM and 3 µM for sunitinib and the dose of 10 µM and 20 µM for 
imatinib were chosen to be tested in combination with vemurafenib for their effect 
on cell growth and survival. Cell growth inhibition of Colo38 and M21 by the 
MTT assay demonstrated that following a three and five day treatment of 
vemurafenib in combination with PDGFRα inhibitors sunitinib or imatinib 
significantly inhibited proliferation (p<0.05)  when compared to each agent alone 
(Fig. 13). Furthermore, both sunitinib and imatinib synergized (p<0.05) with 
vemurafenib to overcome BRAF-I resistance, increasing the growth inhibition of 
BRAF-I resistant Colo38R and M21R cells, and the partially BRAF-I resistant 
TPF-10-741 cells.  
 
A. 
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Figure 13. Enhancement by PDGFRα inhibition of the in vitro anti-
proliferative activity of vemurafenib in BRAF-I sensitive and resistant 
melanoma cells harboring BRAF V600E. Colo38, Colo38R, M21, M21R and 
TPF-10-741 cells were treated with the indicated concentrations of vemurafenib 
and/or sunitinib or imatinib. Cell growth inhibition was determined by MTT assay 
following a three days (A) and five (B) of treatment. Percentage of cell growth 
inhibition was calculated as ratio of treated to untreated cells at each treatment. 
Data are expressed as mean ± SD of the results obtained in three independent 
experiments. The asterisk (*) indicates P < 0.05. 
 
Analysis of apoptosis by the Annexin-V expression assay (Fig. 14) demonstrated 
that following a 24 h treatment of vemurafenib and sunitinib induced apoptosis in 
a significantly (p<0.05) higher percentage of cells than each agent alone in both 
BRAF-I sensitive and resistant cell lines. When tested individually, vemurafenib  
induced apoptosis in a smaller number of BRAF-I sensitive and resistant cells than 
sunitinib (p<0.05). 
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Figure 14. Enhancement by PDGFRα inhibition of apoptosis induction by 
vemurafenib in melanoma cells harboring BRAF V600E. M21 and M21R cells 
(A), Colo38 and Colo38R cells (B), and TPF-10-741 cells (C) were treated with 
vemurafenib (500 nM) and/or sunitinib (3 µM). Following a 24 h incubation at 
37°C cells were harvested and stained with Annexin V and PI. The data presented 
are representative of the staining obtained in three independent experiments (left 
panel). The levels of apoptosis are plotted and expressed as mean fraction of 
apoptotic cells ± SD of the results obtained in three independent experiments 
(right panel). The asterisk (*) indicates P < 0.05. 
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4.5. BRAF and PDGFRα inhibition leads to ERK and AKT kinase signaling 
pathway inhibition. 
The extent of PDGFRα depletion by specific shRNA in BRAF-I resistant cell lines 
was correlated with the degree of inhibition of ERK reactivation and AKT 
activation. Thus, additional experiments tested whether vemurafenib in 
combination with the PDGFRα inhibitors sunitinib or imatinib could inhibit the 
ERK and AKT kinase signaling pathways in BRAF-I sensitive and resistant cells. 
Western blot analysis (Fig. 15) demonstrated that following a 1, 24, and 72 h 
incubation p-ERK levels were decreased when BRAF-I sensitive Colo38 and M21 
cells were treated with vemurafenib and to a lesser extent with sunitinib.  In 
addition, p-AKT levels were increased when M21 cells were treated with 
vemurafenib and reduced when Colo38 and M21 cells were treated with sunitinib. 
However, vemurafenib in combination with sunitinib strongly inhibited the levels 
of both p-ERK and p-AKT in both BRAF-I sensitive cell lines. On the other hand, 
p-ERK levels were not inhibited by the treatment with vemurafenib in BRAF-I 
resistant Colo38R and M21R cells or the partially resistant TPF-10-741 cells. 
Treatment with sunitinib minimally inhibited p-ERK levels in Colo38R, M21R 
and TPF-10-741 cells, but reduced p-AKT levels in Colo38R, M21R and TPF-10-
741 cells. However, vemurafenib in combination with sunitinib inhibited both p-
ERK and p-AKT levels to a greater extent than each single agent in the all BRAF-I 
resistant cell lines. Similar results were obtained with vemurafenib in combination 
with imatinib. These data demonstrate that vemurafenib in combination with a 
PDGFRα inhibitor is an effective strategy to inhibit ERK reactivation and AKT 
activation caused by PDGFRα mediated BRAF-I resistance. Furthermore, this 
provides the mechanism for the anti-proliferative and pro-apoptotic effects seen in 
the BRAF-I sensitive and resistant cell lines treated with vemurafenib in 
combination with a PDGFRα inhibitor. 
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Figure 15. Enhancement by PDGFRα inhibition of the signaling pathway 
inhibition by vemurafenib in melanoma cells harboring BRAF V600E. 
Colo38, Colo38R, M21, M21R and TPF-10-741 cells were treated with 
vemurafenib (1 µM) and/or sunitinib (3 µM) and/or imatinib (20 µM). Following 
an incubation at indicated time points at 37°C cells were harvested and lysed. Cell 
lysates were analyzed by western blot with the indicated mAbs. β-actin was used 
as a loading control. The results presented are representative of the results 
obtained in three independent experiments. 
 
 
4.6. Effective melanoma xenograft growth inhibition by the combination of 
vemurafenib and a PDGFRα inhibitor.  
To assess the in vivo relevance of the described in vitro results, the combination of 
vemurafenib and the PDGFRα inhibitors sunitinib and imatinib were tested for its 
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ability to inhibit the growth of BRAF-I sensitive M21 cells and BRAF-I resistant 
M21R cells in SCID mice. The oral administration of the drugs was well tolerated 
and caused no side effects (data not shown). In the mice grafted with the BRAF-I 
sensitive human melanoma cells M21 (Fig. 16) treatment with vemurafenib or 
sunitinib significantly (p<0.001) inhibited tumor growth as compared to untreated 
mice. However, vemurafenib in combination with sunitinib inhibited tumor growth 
to a significantly (p<0.001) greater extent than each single agent. The mean tumor 
volume at day 38 was 241.33, 674.37 and 539.28 cm3 in the group of mice treated 
with vemurafenib and sunitinib, with vemurafenib alone or sunitinib alone, 
respectively. The tumor volume in the group of untreated mice was 3544.95 cm
3
.  
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Enhancement by PDGFRα inhibition of the growth inhibition by 
vemurafenib of BRAF V600E melanoma M21 cells grafted in 
immunodeficient mice. M21 cells were implanted subcutaneously in 20 SCID 
mice. When tumors became palpable, mice were randomly divided into 4 groups 
(5 mice/group). One group was treated with vemurafenib (12.5 mg/kg, twice 
daily), one with sunitinib (20 mg/kg, once each day) and one with the vemurafenib 
(12.5 mg/kg, twice daily) in combination with sunitinib (20 mg/kg, once each 
day). One group of mice was left untreated as a reference for the natural course of 
the disease. Efficacy data are plotted as mean tumor volume (in mm
3
) ± SD. The 
asterisk (***) indicates P < 0.001 
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Similar results were obtained combining vemurafenib (25 mg/kg twice daily) with 
imatinib (100 mg/kg each day) (Fig. 17).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Enhancement by PDGFRα inhibition of the growth inhibition by 
vemurafenib of BRAF V600E melanoma M21 cells grafted in 
immunodeficient mice. M21 cells were implanted subcutaneously in 20 SCID 
mice. When tumors became palpable, mice were randomly divided into 4 groups 
(5 mice/group). One group was treated with vemurafenib (25 mg/kg, twice daily), 
one with imatinib (100 mg/kg, once each day) and one with the vemurafenib (25 
mg/kg, twice daily) in combination with imatinib (100 mg/kg, once each day). One 
group of mice was left untreated as a reference for the natural course of the 
disease. Efficacy data are plotted as mean tumor volume (in mm
3
) ± SD. The 
asterisk (***) indicates P < 0.001. 
 
 
Western blot analysis of the tumors lysates removed from treated and untreated 
mice (Fig. 17) demonstrated that vemurafenib decreased p-ERK levels but 
increased p-AKT levels, while sunitinib decreased p-ERK and p-AKT levels. This 
effect was more marked in tumors from mice treated with vemurafenib in 
combination with sunitinib.  
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Figure 17. Enhancement by PDGFRα inhibition of signaling pathway 
inhibition by vemurafenib of BRAF V600E melanoma M21 cells grafted in 
immunodeficient mice. Tumors harvested from untreated and treated mice (three 
for each group) were lysed and analyzed for expression and activation of the 
indicated signaling pathways components.  β-actin was used as a loading control. 
 
 
Primary tumors were also evaluated by IHC for the rate of tumor cell proliferation 
and for induction of apoptosis using the surrogate markers p-Histone H3 and 
Cleaved Caspase-3. Both vemurafenib and sunitinib significantly decreased the 
number of mitotic cells in tumors as compared to tumors from untreated mice. 
Vemurafenib in combination with sunitinib (Fig. 18A) reduced the number of 
mitotic cells in tumors by 80% and 50%, respectively, when compared to tumors 
from untreated mice (p< 0.001) or  mice treated with the single agents (p<0.001). 
The number of apoptotic cells (Fig 18B) in tumors from mice treated with 
vemurafenib in and sunitinib was approximately 40%, 29% and 26% higher than 
in tumors from untreated mice or from mice treated with vemurafenib or sunitinib 
individually (p<0.001). Sunitinib, but not vemurafenib resulted in a significantly 
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higher number of apoptotic cells in the tumors when compared to untreated mice 
(p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Enhancement by PDGFRα inhibition of the mitotic cell inhibtion 
and induction of the apoptotic cells by vemurafenib of BRAF V600E 
melanoma M21 cells grafted in immunodeficient mice. Tumor tissue sections 
were analyzed for the content of mitotic cells by staining with p-Histone H3 
(Ser10) protein-specific antibodies. Mitotic tumor cells were quantified by 
counting 5 randomly selected high-power fields per section (magnification ×200) 
(A). Tumor tissue sections were analyzed for the content of apoptotic cells by 
staining with Cleaved Caspase-3 (Asp175)-specific antibodies. Apoptotic tumor 
cells were quantified by counting 5 randomly selected high-power fields per 
section (magnification ×200) (B). Data are presented as means ± SD. *** indicates 
P < 0.001. 
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Mice engrafted with the BRAF-I resistant human melanoma cells M21R (Fig. 19) 
had no significant inhibition of tumor growth when treated with vemurafenib as 
compared to untreated mice. In contrast, treatment with sunitinib caused a 
statistically significant inhibition of tumor growth compared to untreated mice 
(p<0.001). However vemurafenib in combination with sunitinib inhibited tumor 
growth to a significantly (P<0.001) greater extent than sunitinib alone.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Enhancement by PDGFRα inhibition of the growth inhibition by 
vemurafenib of BRAF V600E melanoma M21R cells grafted in 
immunodeficient mice. M21R cells were implanted subcutaneously in 20 SCID 
mice. When tumors became palpable, mice were randomly divided into 4 groups 
(5 mice/group). One group was treated with vemurafenib (12.5 mg/kg, twice 
daily), one with sunitinib (20 mg/kg, once each day) and one with the vemurafenib 
(12.5 mg/kg, twice daily) in combination with sunitinib (20 mg/kg, once each 
day). One group of mice was left untreated as a reference for the natural course of 
the disease. Efficacy data are plotted as mean tumor volume (in mm
3
) ± SD. The 
asterisk (***) indicates P < 0.001 
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Western blot analysis of tumor lysates (Fig. 20) demonstrated that sunitinib 
inhibited p-AKT and p-ERK levels. This effect was more marked in tumors from 
mice treated with vemurafenib in combination with sunitinib. As expected the 
levels of p-ERK and p-AKT were not affected by treatment with vemurafenib as a 
single agent.  
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Enhancement by PDGFRα inhibition of signaling pathway 
inhibition by vemurafenib of BRAF V600E melanoma M21R cells grafted in 
immunodeficient mice. Tumors harvested from untreated and treated mice (three 
for each group) were lysed and analyzed for expression and activation of the 
indicated signaling pathways components.  β-actin was used as a loading control 
 
 
IHC staining (Fig. 21A) revealed that treatment with sunitinib decreased the 
number of mitotic cells in tumors by 46% and 43% as compared to that in tumors 
from vemurafenib or untreated mice (p<0.001). In addition, treatment with 
sunitinib caused a strong increase in the number of apoptotic cells in tumors as 
compared to tumors from vemurafenib treated or untreated mice (Fig. 21B). 
However treatment with vemurafenib in combination with sunitinib decreased the 
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number of mitotic cells and increased the number of apoptotic cells to a 
significantly (p<0.001) greater extent than treatment with sunitinib alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Enhancement by PDGFRα inhibition of the mitotic cell inhibtion 
and induction of the apoptotic cells by vemurafenib of BRAF V600E 
melanoma M21R cells grafted in immunodeficient mice. Tumor tissue sections 
were analyzed for the content of mitotic cells by staining with p-Histone H3 
(Ser10) protein-specific antibodies. Mitotic tumor cells were quantified by 
counting 5 randomly selected high-power fields per section (magnification ×200) 
(A). Tumor tissue sections were analyzed for the content of apoptotic cells by 
staining with Cleaved Caspase-3 (Asp175)-specific antibodies. Apoptotic tumor 
cells were quantified by counting 5 randomly selected high-power fields per 
section (magnification ×200) (B). Data are presented as means ± SD. *** indicates 
P < 0.001. 
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These findings corroborate the in vitro results and demonstrate that the oral 
administration of vemurafenib in combination with a PDGFRα inhibitor is more 
effective than either agent alone in inhibiting the growth of BRAF-I sensitive and 
resistant melanoma cells if PDGFRα is mediating the BRAF-I resistance. 
Furthermore, they demonstrate that this growth inhibitory effect in both BRAF-I 
sensitive and resistant melanoma cell lines is mediated by a marked decrease of p-
ERK and p-AKT levels. Lastly, they demonstrate that the oral administration of 
vemurafenib and PDGFRα inhibitors (sunitinib or imatinib) is well tolerated, 
supporting their further investigation in a clinical setting. 
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5. CONCLUSIONS 
PDGFRα is overexpressed in sarcoma and glioma. It is thought to be involved in 
tumor growth, metastasis and neoangiogenesis in the tumor microenvironment, as 
well as in the development of resistance to cytotoxic therapy 
93
. These functional 
properties of PDGFRα are likely to reflect its ability to engage signaling pathways, 
such as RAS/RAF/MEK/ERK, PI3K/AKT and PLC-γ which play a role in tumor 
cell proliferation and aggressive tumor phenotypes. The present study 
demonstrates that PDGFRα is expressed by human melanoma cells both in vitro 
and in vivo, and has identified an additional potential clinically relevant property 
of this growth factor receptor.  Specifically, PDGFRα upregulation in human 
melanoma cells harboring the BRAF V600E mutation has been shown for the first 
time to be associated with the loss of their sensitivity to the anti-proliferative and 
pro-apoptotic activity of the BRAF-I vemurafenib both in vitro and in vivo. The 
association between PDGFRα upregulation and vemurafenib resistance reflects a 
cause-effect relationship, since sensitivity to vemurafenib is restored in melanoma 
cells which downregulate PDGFRα expression following transduction with a 
PDGFRα-specific shRNA. Association between PDGFRα and BRAF V600E 
mutation is also observed in wide type PDGFRα gastrointestinal stromal tumors 
(GIST) which acquire the BRAF (V600E) mutation when they develop resistance 
to PDGFRα inhibitors 94-97.  
Vemurafenib resistance of melanoma cells harboring a BRAF mutation is likely to 
reflect ERK and AKT activation induced by PDGFRα upregulation, since 
inhibition of its synthesis by PDGFRα-specific shRNA causes a reduction of ERK 
and AKT activation and restores sensitivity to BRAF-I. This conclusion is 
corroborated by the in vitro and in vivo results obtained by inhibiting the function 
of PDGFRα with the tyrosine kinase inhibitor sunitinib or imatinib. Vemurafenib 
in combination with a PDGFRα inhibitor inhibits in vitro proliferation and induces 
apoptosis of melanoma cells with a PDGFRα upregulation mediated BRAF-I 
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resistance. These results are paralleled by our in vivo findings. Vemurafenib in 
combination with the PDGFRα inhibitor sunitinib inhibited the growth and 
induced apoptosis in human melanoma cells with PDGFRα upregulation mediated 
BRAF-I resistance engrafted in immunodeficient mice. These effects are mediated 
by the inhibition of the RAF/MEK/ERK  and PI3K/AKT signaling pathways since 
the levels of p-ERK and p-AKT were markedly reduced in melanoma cells with 
PDGFRα upregulation mediated BRAF-I resistance following in vitro or in vivo 
treatment with vemurafenib in combination with a PDGFRα inhibitor. It is 
noteworthy that vemurafenib in combination with a PDGFRα inhibitor (sinitinib or 
imatinib) has a significantly greater anti-proliferative and pro-apoptotic effect than 
either agent alone both in vitro and in vivo also with BRAF-I sensitive human 
melanoma cells which expresses PDGFRα. These effects are mediated by a more 
marked inhibition of ERK and AKT activation by vemurafenib in combination 
with a PDGFRα inhibitor than by the individual agents. Therefore our results 
suggest that the combinatorial strategy we have developed may overcome not only 
the acquired, but also the intrinsic BRAF-I resistance if PDGFRα is expressed. 
Furthermore they confirm that simultaneous inhibition of both the AKT and ERK 
signaling pathways is more effectively in suppressing  tumor cell proliferation and  
in inducing apoptosis in both BRAF-I sensitive and resistant melanoma cells  
75, 98-
104
. 
PDGFRα is not the only growth factor receptor which plays a role in BRAF-I 
resistance. IGFR 
75
 and PDGFRβ 65, 86 are involved in the acquired BRAF-I 
resistance of melanoma cell lines chronically exposed to increasing doses of 
BRAF-I and are upregulated in melanoma cells isolated from patients who 
developed BRAF-I resistance following treatment. BRAF-I resistance mediated by 
IGFR and PDGFRβ, similar to PDGFRα, is mediated by ERK and AKT 
activation. However as reported by Shi et al 
80
 and as found by us (data not 
shown) the PDGFRα / PDGFRβ inhibitors sunitinib and imatinib are not able to 
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overcome BRAF-I resistance mediated by PDGFRβ upregulation. The inability of 
sunitinib to overcome PDGFRβ mediated BRAF-I resistance reflects the lack of 
inhibition of ERK activation in spite of the inhibition of AKT activation since the 
inhibition of these two downstream components of the RAF/MEK/ERK and 
PI3K/AKT signaling pathways by a PDGFRβ specific shRNA restored sensitivity 
of melanoma cells to vemurafenib.  
The potential clinical relevance of our results is suggested by two lines of 
evidence. First, PDGFRα expression was upregulated in  5 out of the 9 melanoma 
lesions with a BRAF V600E mutation surgically removed from patients who had 
developed BRAF-I resistance. Second, the extent of PDGFRα increase in 
melanoma lesions, as indicated by the IHC staining intensity, was associated with 
the clinical course of the disease. Specifically a marked increase in PDGFRα was 
found to be associated with a significantly shorter time to progression and worse 
objective response based on RECIST criteria. Notably, baseline expression of 
PDGFRα did not correlate with response or time to progression. In order to utilize 
the phenomenon we had observed as a method for patient selection, one would 
need to monitor up regulation of PDGFRα in tumor biopsy specimens in a similar 
early time point as we observed or develop noninvasive or surrogate methods to 
detect its up regulation. 
These findings provide a strong rationale to translate to a clinical setting the 
combinatorial strategy which we have shown to be effective in counteracting the 
BRAF-I PDGFRα-mediated resistance of melanoma cells both in vitro and in vivo. 
The translation of this approach is facilitated by the fact that the agents we 
investigated are already approved for cancer treatment. Whether the side effects 
caused by the combined use of a BRAF-I and a PDGFRα inhibitor will represent a 
major obstacle to their clinical use remains to be determined. 
 
 
61 
 
6. REFERENCES 
1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd 
DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty 
KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Jr., Morton 
DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 ajcc melanoma 
staging and classification. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 2009;27:6199-6206 
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer 
journal for clinicians. 2010;60:277-300 
3. de Souza CF, Morais AS, Jasiulionis MG. Biomarkers as key contributors 
in treating malignant melanoma metastases. Dermatology research and 
practice. 2012;2012:156068 
4. Miller AJ, Mihm MC, Jr. Melanoma. The New England journal of 
medicine. 2006;355:51-65 
5. Hill GJ, 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole 
carboxamide and combination therapy for melanoma. Iv. Late results after 
complete response to chemotherapy (central oncology group protocols 
7130, 7131, and 7131a). Cancer. 1984;53:1299-1305 
6. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, 
Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, 
Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients 
with metastatic melanoma: Analysis of 270 patients treated between 1985 
and 1993. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 1999;17:2105-2116 
7. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors 
associated with response to high-dose interleukin-2 in patients with 
metastatic melanoma. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2001;19:3477-3482 
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, 
Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, 
Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, 
Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, 
Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, 
Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, 
Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber 
BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster 
R, Stratton MR, Futreal PA. Mutations of the braf gene in human cancer. 
Nature. 2002;417:949-954 
9. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho 
KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of 
62 
 
genetic alterations in melanoma. The New England journal of medicine. 
2005;353:2135-2147 
10. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of kit in 
distinct subtypes of melanoma. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 2006;24:4340-4346 
11. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, 
Town A, Harlow A, Cruz F, 3rd, Azar S, Rubin BP, Muller S, West R, 
Heinrich MC, Corless CL. Kit gene mutations and copy number in 
melanoma subtypes. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2008;14:6821-6828 
12. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between 
nras and braf mutations and pten/mmac1 inactivation in melanoma. The 
Journal of investigative dermatology. 2004;122:337-341 
13. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, 
Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, 
Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, 
Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, 
Flaherty KT, McArthur GA, Group B-S. Improved survival with 
vemurafenib in melanoma with braf v600e mutation. The New England 
journal of medicine. 2011;364:2507-2516 
14. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, 
Rutkowski P, Blank CU, Miller WH, Jr., Kaempgen E, Martin-Algarra S, 
Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney 
P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in 
braf-mutated metastatic melanoma: A multicentre, open-label, phase 3 
randomised controlled trial. Lancet. 2012;380:358-365 
15. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, 
McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, 
Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, 
Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. 
Survival in braf v600-mutant advanced melanoma treated with 
vemurafenib. The New England journal of medicine. 2012;366:707-714 
16. Bauer S, Duensing A, Demetri GD, Fletcher JA. Kit oncogenic signaling 
mechanisms in imatinib-resistant gastrointestinal stromal tumor: Pi3-
kinase/akt is a crucial survival pathway. Oncogene. 2007;26:7560-7568 
17. Sawyers C. Targeted cancer therapy. Nature. 2004;432:294-297 
18. Beeram M, Patnaik A, Rowinsky EK. Raf: A strategic target for 
therapeutic development against cancer. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology. 
2005;23:6771-6790 
63 
 
19. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH, 
Shaw PE. Erk phosphorylation potentiates elk-1-mediated ternary complex 
formation and transactivation. The EMBO journal. 1995;14:951-962 
20. Daub M, Jockel J, Quack T, Weber CK, Schmitz F, Rapp UR, Wittinghofer 
A, Block C. The rafc1 cysteine-rich domain contains multiple distinct 
regulatory epitopes which control ras-dependent raf activation. Molecular 
and cellular biology. 1998;18:6698-6710 
21. Fischer A, Hekman M, Kuhlmann J, Rubio I, Wiese S, Rapp UR. B- and c-
raf display essential differences in their binding to ras: The isotype-specific 
n terminus of b-raf facilitates ras binding. The Journal of biological 
chemistry. 2007;282:26503-26516 
22. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. Complexes of 
ras.Gtp with raf-1 and mitogen-activated protein kinase kinase. Science. 
1993;260:1658-1661 
23. Chin L. The genetics of malignant melanoma: Lessons from mouse and 
man. Nature reviews. Cancer. 2003;3:559-570 
24. Terai K, Matsuda M. The amino-terminal b-raf-specific region mediates 
calcium-dependent homo- and hetero-dimerization of raf. The EMBO 
journal. 2006;25:3556-3564 
25. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and 
mutant b-raf activate c-raf through distinct mechanisms involving 
heterodimerization. Molecular cell. 2005;20:963-969 
26. Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, 
Guo J. Prevalence of braf v600e mutation in chinese melanoma patients: 
Large scale analysis of braf and nras mutations in a 432-case cohort. 
European journal of cancer. 2012;48:94-100 
27. Jakob JA, Bassett RL, Jr., Ng CS, Curry JL, Joseph RW, Alvarado GC, 
Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, 
Davies MA. Nras mutation status is an independent prognostic factor in 
metastatic melanoma. Cancer. 2012;118:4014-4023 
28. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, 
Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Prognostic and 
clinicopathologic associations of oncogenic braf in metastatic melanoma. 
Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2011;29:1239-1246 
29. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, 
Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, Cancer 
Genome P. Mechanism of activation of the raf-erk signaling pathway by 
oncogenic mutations of b-raf. Cell. 2004;116:855-867 
64 
 
30. Luke JJ, Hodi FS. Vemurafenib and braf inhibition: A new class of 
treatment for metastatic melanoma. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 2012;18:9-14 
31. Smalley KS. Understanding melanoma signaling networks as the basis for 
molecular targeted therapy. The Journal of investigative dermatology. 
2010;130:28-37 
32. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in b-raf-targeted 
melanoma cells. Cancer research. 2010;70:6670-6681 
33. Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE. Mcl-1 is required 
for melanoma cell resistance to anoikis. Molecular cancer research : MCR. 
2009;7:549-556 
34. Boisvert-Adamo K, Aplin AE. Mutant b-raf mediates resistance to anoikis 
via bad and bim. Oncogene. 2008;27:3301-3312 
35. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, 
Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, 
Nathanson KL, Koomen JM, Messina JL, Smalley KS. Pten loss confers 
braf inhibitor resistance to melanoma cells through the suppression of bim 
expression. Cancer research. 2011;71:2750-2760 
36. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, 
McMahon M. Oncogenic braf(v600e) inhibits bim expression to promote 
melanoma cell survival. Pigment cell & melanoma research. 2008;21:534-
544 
37. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the 
erk1/2 signaling pathway promotes phosphorylation and proteasome-
dependent degradation of the bh3-only protein, bim. The Journal of 
biological chemistry. 2003;278:18811-18816 
38. Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, 
Bray PF, Saylor VL, McMahon M. Induction of beta3-integrin gene 
expression by sustained activation of the ras-regulated raf-mek-
extracellular signal-regulated kinase signaling pathway. Molecular and 
cellular biology. 2001;21:3192-3205 
39. Pritchard CA, Hayes L, Wojnowski L, Zimmer A, Marais RM, Norman JC. 
B-raf acts via the rockii/limk/cofilin pathway to maintain actin stress fibers 
in fibroblasts. Molecular and cellular biology. 2004;24:5937-5952 
40. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward 
R, Viros A, Sahai E, Marais R. Oncogenic braf induces melanoma cell 
invasion by downregulating the cgmp-specific phosphodiesterase pde5a. 
Cancer cell. 2011;19:45-57 
41. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, 
Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. 
Selective brafv600e inhibition enhances t-cell recognition of melanoma 
65 
 
without affecting lymphocyte function. Cancer research. 2010;70:5213-
5219 
42. Kono M, Dunn IS, Durda PJ, Butera D, Rose LB, Haggerty TJ, Benson 
EM, Kurnick JT. Role of the mitogen-activated protein kinase signaling 
pathway in the regulation of human melanocytic antigen expression. 
Molecular cancer research : MCR. 2006;4:779-792 
43. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The braf-mapk 
signaling pathway is essential for cancer-immune evasion in human 
melanoma cells. The Journal of experimental medicine. 2006;203:1651-
1656 
44. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, 
Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, 
Hodi FS, Overwijk WW, Lizee G, Murphy GF, Hwu P, Flaherty KT, 
Fisher DE, Wargo JA. Braf inhibition is associated with enhanced 
melanoma antigen expression and a more favorable tumor 
microenvironment in patients with metastatic melanoma. Clinical cancer 
research : an official journal of the American Association for Cancer 
Research. 2013 
45. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, 
Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A. Braf inhibitor 
vemurafenib improves the antitumor activity of adoptive cell 
immunotherapy. Cancer research. 2012;72:3928-3937 
46. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, 
Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, 
Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, 
Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. Bay 43-9006 
exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk 
pathway and receptor tyrosine kinases involved in tumor progression and 
angiogenesis. Cancer research. 2004;64:7099-7109 
47. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, 
Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, 
Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, 
Keilholz U. Results of a phase iii, randomized, placebo-controlled study of 
sorafenib in combination with carboplatin and paclitaxel as second-line 
treatment in patients with unresectable stage iii or stage iv melanoma. 
Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2009;27:2823-2830 
48. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, 
Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, 
Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu 
C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang 
66 
 
KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis 
DR, Herlyn M, Bollag G. Discovery of a selective inhibitor of oncogenic 
b-raf kinase with potent antimelanoma activity. Proceedings of the 
National Academy of Sciences of the United States of America. 
2008;105:3041-3046 
49. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang 
C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, 
Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger 
J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee 
RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, 
Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. Clinical 
efficacy of a raf inhibitor needs broad target blockade in braf-mutant 
melanoma. Nature. 2010;467:596-599 
50. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao 
S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, 
Su F. Rg7204 (plx4032), a selective brafv600e inhibitor, displays potent 
antitumor activity in preclinical melanoma models. Cancer research. 
2010;70:5518-5527 
51. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, 
Kluger HM, Narayan D, Halaban R. Incidence of the v600k mutation 
among melanoma patients with braf mutations, and potential therapeutic 
response to the specific braf inhibitor plx4032. Journal of translational 
medicine. 2010;8:67 
52. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, 
Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, 
Solit DB, Rosen N. The raf inhibitor plx4032 inhibits erk signaling and 
tumor cell proliferation in a v600e braf-selective manner. Proceedings of 
the National Academy of Sciences of the United States of America. 
2010;107:14903-14908 
53. Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, 
Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M. Plx4032, a potent 
inhibitor of the b-raf v600e oncogene, selectively inhibits v600e-positive 
melanomas. Pigment cell & melanoma research. 2010;23:820-827 
54. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, 
O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of 
mutated, activated braf in metastatic melanoma. The New England journal 
of medicine. 2010;363:809-819 
55. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, 
Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, 
Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in 
67 
 
patients with melanoma, untreated brain metastases, and other solid 
tumours: A phase 1 dose-escalation trial. Lancet. 2012;379:1893-1901 
56. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. Raf inhibitors 
transactivate raf dimers and erk signalling in cells with wild-type braf. 
Nature. 2010;464:427-430 
57. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, 
Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. 
Kinase-dead braf and oncogenic ras cooperate to drive tumor progression 
through craf. Cell. 2010;140:209-221 
58. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, 
Krauthammer M, McCusker JP, Kluger Y, Sznol M. Plx4032, a selective 
braf(v600e) kinase inhibitor, activates the erk pathway and enhances cell 
migration and proliferation of braf melanoma cells. Pigment cell & 
melanoma research. 2010;23:190-200 
59. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of mek-
erk1/2 signaling and resistance to apoptosis induced by the oncogenic b-raf 
inhibitor, plx4720, in mutant n-ras melanoma cells. Oncogene. 
2011;30:366-371 
60. Ribas A, Flaherty KT. Braf targeted therapy changes the treatment 
paradigm in melanoma. Nature reviews. Clinical oncology. 2011;8:426-
433 
61. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, 
Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, 
Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA. Ras 
mutations are associated with the development of cutaneous squamous cell 
tumors in patients treated with raf inhibitors. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology. 
2012;30:316-321 
62. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, 
Pavlick AC, Darvishian F, Christos P, Mazumdar M, Osman I, Polsky D. 
Intra- and inter-tumor heterogeneity of braf(v600e))mutations in primary 
and metastatic melanoma. PloS one. 2012;7:e29336 
63. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular 
classification of melanoma. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology. 2007;25:1606-1620 
64. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, 
Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A. Mutually 
exclusive nrasq61r and brafv600e mutations at the single-cell level in the 
same human melanoma. Oncogene. 2006;25:3357-3364 
65. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, 
Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas 
68 
 
A, Lo RS. Melanomas acquire resistance to b-raf(v600e) inhibition by rtk 
or n-ras upregulation. Nature. 2010;468:973-977 
66. Paraiso KH, Smalley KS. Making sense of mek1 mutations in intrinsic and 
acquired braf inhibitor resistance. Cancer discovery. 2012;2:390-392 
67. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, 
Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ. Pharmacodynamic 
characterization of the efficacy signals due to selective braf inhibition with 
plx4032 in malignant melanoma. Neoplasia. 2010;12:637-649 
68. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar 
H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, 
Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, 
Lo RS, Ribas A. Differential sensitivity of melanoma cell lines with 
brafv600e mutation to the specific raf inhibitor plx4032. Journal of 
translational medicine. 2010;8:39 
69. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, 
Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn 
M, Nathanson KL. Increased cyclin d1 expression can mediate braf 
inhibitor resistance in braf v600e-mutated melanomas. Molecular cancer 
therapeutics. 2008;7:2876-2883 
70. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, 
Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, 
Tragni G, Parmiani G, Pierotti MA, Rodolfo M. Braf alterations are 
associated with complex mutational profiles in malignant melanoma. 
Oncogene. 2004;23:5968-5977 
71. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, 
Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, 
De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit DB. 
Concurrent loss of the pten and rb1 tumor suppressors attenuates raf 
dependence in melanomas harboring (v600e)braf. Oncogene. 2012;31:446-
457 
72. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies 
MA. Basal and treatment-induced activation of akt mediates resistance to 
cell death by azd6244 (arry-142886) in braf-mutant human cutaneous 
melanoma cells. Cancer research. 2010;70:8736-8747 
73. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, 
Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, 
Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. 
Tumour micro-environment elicits innate resistance to raf inhibitors 
through hgf secretion. Nature. 2012;487:500-504 
74. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, 
Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R. 
69 
 
Gatekeeper mutations mediate resistance to braf-targeted therapies. Science 
translational medicine. 2010;2:35ra41 
75. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, 
Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker 
AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, 
Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M. 
Acquired resistance to braf inhibitors mediated by a raf kinase switch in 
melanoma can be overcome by cotargeting mek and igf-1r/pi3k. Cancer 
cell. 2010;18:683-695 
76. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson 
LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, 
Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, 
Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root 
DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers 
WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. Cot drives 
resistance to raf inhibition through map kinase pathway reactivation. 
Nature. 2010;468:968-972 
77. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, 
Engelman JA. Braf gene amplification can promote acquired resistance to 
mek inhibitors in cancer cells harboring the braf v600e mutation. Science 
signaling. 2010;3:ra84 
78. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, 
Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, 
Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, 
Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. Raf inhibitor resistance 
is mediated by dimerization of aberrantly spliced braf(v600e). Nature. 
2011;480:387-390 
79. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, 
Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, 
Settleman J. Elevated craf as a potential mechanism of acquired resistance 
to braf inhibition in melanoma. Cancer research. 2008;68:4853-4861 
80. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe 
SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway 
LA. Dissecting therapeutic resistance to raf inhibition in melanoma by 
tumor genomic profiling. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 2011;29:3085-3096 
81. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky 
WE, Jr., You MJ, DePinho RA, McMahon M, Bosenberg M. Braf(v600e) 
cooperates with pten loss to induce metastatic melanoma. Nature genetics. 
2009;41:544-552 
70 
 
82. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. 
Multiple signaling pathways must be targeted to overcome drug resistance 
in cell lines derived from melanoma metastases. Molecular cancer 
therapeutics. 2006;5:1136-1144 
83. Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD. Mek-
independent survival of b-rafv600e melanoma cells selected for resistance 
to apoptosis induced by the raf inhibitor plx4720. Clinical cancer research 
: an official journal of the American Association for Cancer Research. 
2011;17:721-730 
84. Smalley KS, Aplin AE, Flaherty KT, Hoeller C, Bosserhoff AK, Haass 
NK, Bosenberg M, Ribas A, Barnhill R, Kudchadkar R, Messina JL. 
Meeting report from the 2011 international melanoma congress, tampa, 
florida. Pigment cell & melanoma research. 2012;25:E1-11 
85. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, 
Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, 
3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, 
Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. 
Combined braf and mek inhibition in melanoma with braf v600 mutations. 
The New England journal of medicine. 2012;367:1694-1703 
86. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome 
pdgfrbeta-driven resistance of melanoma cells to v600eb-raf inhibition. 
Cancer research. 2011;71:5067-5074 
87. Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, 
Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen 
JM, Smalley KS. The hsp90 inhibitor xl888 overcomes braf inhibitor 
resistance mediated through diverse mechanisms. Clinical cancer research 
: an official journal of the American Association for Cancer Research. 
2012;18:2502-2514 
88. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. 
Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow 
cytometry and immunohistochemical staining. Tissue antigens. 
2003;62:385-393 
89. Tang JB, Goellner EM, Wang XH, Trivedi RN, St Croix CM, Jelezcova E, 
Svilar D, Brown AR, Sobol RW. Bioenergetic metabolites regulate base 
excision repair-dependent cell death in response to DNA damage. 
Molecular cancer research : MCR. 2010;8:67-79 
90. Chow LQ, Eckhardt SG. Sunitinib: From rational design to clinical 
efficacy. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2007;25:884-896 
91. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, 
Lydon NB. Inhibition of the abl protein-tyrosine kinase in vitro and in vivo 
71 
 
by a 2-phenylaminopyrimidine derivative. Cancer research. 1996;56:100-
104 
92. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, 
Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, 
Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. 
Braf and ras mutations in human lung cancer and melanoma. Cancer 
research. 2002;62:6997-7000 
93. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in 
physiology and medicine. Genes & development. 2008;22:1276-1312 
94. Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, Besmer 
P, Antonescu CR. Novel v600e braf mutations in imatinib-naive and 
imatinib-resistant gastrointestinal stromal tumors. Genes, chromosomes & 
cancer. 2008;47:853-859 
95. Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, 
Hartmann A, Bihl MP. V600e braf mutations are alternative early 
molecular events in a subset of kit/pdgfra wild-type gastrointestinal stromal 
tumours. Journal of clinical pathology. 2009;62:613-616 
96. Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, Bringuier PP, 
Scoazec JY, Coindre JM. Braf mutation status in gastrointestinal stromal 
tumors. American journal of clinical pathology. 2010;133:141-148 
97. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, 
Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, 
Frattini M. Kras and braf mutations predict primary resistance to imatinib 
in gastrointestinal stromal tumors. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 2012;18:1769-
1776 
98. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and 
mutant v600e b-raf cooperate to promote early melanoma development. 
Cancer research. 2008;68:3429-3439 
99. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin 
RA, Basecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino 
MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, 
Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, 
Cocco L, Martelli AM, McCubrey JA. Ras/raf/mek/erk and 
pi3k/pten/akt/mtor inhibitors: Rationale and importance to inhibiting these 
pathways in human health. Oncotarget. 2011;2:135-164 
100. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, 
Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas 
A. Reversing melanoma cross-resistance to braf and mek inhibitors by co-
targeting the akt/mtor pathway. PloS one. 2011;6:e28973 
72 
 
101. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman 
KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM. Combinations of 
braf, mek, and pi3k/mtor inhibitors overcome acquired resistance to the 
braf inhibitor gsk2118436 dabrafenib, mediated by nras or mek mutations. 
Molecular cancer therapeutics. 2012;11:909-920 
102. Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, 
Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, 
Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, 
Bollag G. Resistance to selective braf inhibition can be mediated by 
modest upstream pathway activation. Cancer research. 2012;72:969-978 
103. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role 
and therapeutic potential of pi3k-mtor signaling in de novo resistance to 
braf inhibition. Pigment cell & melanoma research. 2012;25:248-258 
104. Sanchez-Hernandez I, Baquero P, Calleros L, Chiloeches A. Dual 
inhibition of (v600e)braf and the pi3k/akt/mtor pathway cooperates to 
induce apoptosis in melanoma cells through a mek-independent 
mechanism. Cancer letters. 2012;314:244-255 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
7. TABLE 
 
Table 1 
 
 
 
 
1 
 
Title: p53 modulates the enhanced cytotoxicity induced by Poly(ADP-
Ribose) Polymerase-1 inhibition to Topoisomerase-I inhibitor and 
radiotherapy in human glioblastoma cell lines. 
Running title: p53, PARP inhibitor, topotecan, radiotherapy in glioblastoma cells   
Authors: 
Francesco Sabbatino1,4, Celeste Fusciello 1, Antonio Leonardi 2, Roberto Pacelli3, 
Ravin Poudel3, David Pepin4, Soldano Ferrone4, Chiara Carlomagno1, Stefano 
Pepe5 
 
University of Naples “Federico II”, 1Department of Clinical and Molecular 
Oncology and Endocrinology, 2Department of Cellular and Molecular Biology and 
Pathology, 3Department of Diagnostic Imaging and Radiation Oncology, Federico 
II University School of Medicine, Via Sergio Pansini 5, Naples, Italy 80131.  
4Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, 
Boston, MA 02114.  
5Department of Medicine, University of Salerno and Division of Oncology, San 
Giovanni di Dio e Ruggi d’ Aragona Hospital, Salerno, Italy 84131. 
 
Correspondence should be addressed to Stefano Pepe (spepe@unisa.it) 
 
There are no conflicts of interest to disclose. 
Keywords: p53, glioblastoma, PARP inhibitor, radiotherapy, topotecan 
 
2 
 
Abstract 
Purpose. Chemo-radiotherapy still represents the standard of care for 
glioblastoma (GBM) patients. This combination, although leads to increased 
overall survival, is effective for limited time and GBM patients continues to carry a 
poor overall survival. Inhibition of Poly (ADP-Ribose) polymerase-1 (PARP-1) is 
shown to offer great promise for the treatment of GBM by sensitizing GBM cells 
to DNA- damaging agents such as radiotherapy or Topoisomerase-1 inhibitors.  
Nevertheless, there is the need to identify molecular biomarkers which can 
predict use of PARP inhibitors in combination with TPT and/or RT.  Methods and 
Materials. Here, we investigated and compared the cytotoxic effects of combined 
treatment with the DNA-topoisomerase- 1-inhibitor topotecan (TPT), PARP-1 
inhibitor NU1025 and radiotherapy in GBM cells. Results and Conclusions. Our 
results demonstrate that although PARP inhibition enhances the cytotoxicity of 
TPT and radiotherapy, the extent of this enhanced inhibition is modulated by the 
activity of p53. Specifically, utilizing cells carrying a different status of p53 and 
evaluating the growth inhibitory effects, the cell cycle perturbations and the DNA 
damage induced by the different combinatorial strategies of TPT, NU1025 and 
RT we demonstrated that in GBM cells carrying a p53 wild type the combination 
of PARP inhibitor and radiotherapy represents the most effective therapeutic 
strategy. On the other hand in GBM cells carrying a p53 mutated or silenced the 
combination of PARP inhibitor and TPT is the most effective therapeutic strategy. 
Our results can be clinical relevant since they expand the potential application of 
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PARP inhibitors in combination with TPT or RT for the treatment of GBM based 
on their p53 status. 
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Introduction 
Gliomas represent the most common solid tumors of the Central Nervous 
System (CNS). Around 30% of Gliomas are Astrocitomas, which are further 
divided into four subgroups in relation to their grading: III and IV are named 
Glioblastomas (GBM). Chemotherapy (temozolomide) given concurrently or after 
radiation therapy (RT) is the standard of care for patients with newly diagnosed 
GBM [33]. This combination has been  shown to significantly increase the overall 
survival of newly diagnosed GBM patients when compared with RT alone (12.1 
vs 14.6 months). However, despite these successes, GBMs continue to carry a 
dismal two year survival rate of 3.3%[22] .  
Disruption of p53, which is widely prevalent in GBM cells, has been shown 
to sensitize them to chemotherapeutic agents such as inhibitors of DNA 
topoisomerase I (TOPO I)[39].Topotecan (TPT), an inhibitor of TOPO I, is 
approved for GBM treatment in the refractory and relapsed setting[31]. In vitro 
and in vivo [2,9,12,17,26]evidence demonstrates that TPT exhibits 
radiosensitization and cell growth inhibition effects on human GBM cells. 
However, concurrent administration of TPT and radiotherapy in phase II trials 
demonstrated an increased toxicity with only small benefits in terms of 
progression-free survival (PFS) for GBM patients [10,18].  
Recently, the use of Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors 
has shown great promise in the treatment of several cancers, including GBMs 
[29]. PARP-1, as well as p53, is involved in the DNA repair system. Specifically, it 
is a nuclear protein involved in sensing and signaling the presence of DNA 
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damage. Its activation causes the addition of poly (ADP-ribose) branched chains 
from nicotinamide adenine dinucleotide donors onto several proteins of DNA 
repair machinery. In this way PARP-1 leads the recruitment of proteins of the 
base excision repair system [28], single or double stranded break repair pathway 
[6,7,23], and nuclear proteins such as p53 [40] and TOPO I/II [32].  
Different chemical inhibitors of PARP-1 have been shown in vitro and in vivo to 
potentiate the cytotoxic effects induced by RT and by chemotherapeutic agents 
such as temozolomide or TOPO I inhibitors in GBMs [3,5,11,35,36]. Nevertheless 
the lack of predictive factors of response to different emerging strategies 
emphasizes the need to identify biomarkers which indicate the most effective 
strategy to achieve the maximum cytotoxic effect without an increase of the side 
effects. 8-idrossi-2-metiquinazoline-4-one (NU1025) is a PARP-1 inhibitor that 
has been shown in vitro to inhibit PARP-1 activity without cytotoxicity [5,30].  
In this study, using human GBM cell lines with an active or inactive p53, 
we compared in vitro treatments utilizing TPT and/or RT and/or PARP-1 
inhibition. Our aim is to define the role of p53 in modulating the potentiated 
cytotoxicity of TPT and/or RT induced by PARP-1 inhibition and simultaneously 
to define the most effective strategy for the treatment of GBM. Our data confirm 
the clear potential of PARP-1 inhibition in potentiating the cytotoxicity of TPT and 
RT in GBM cells. Furthermore, they demonstrate that p53 activity influences and 
predicts the response to the enhanced cytotoxicity induced by PARP-1 inhibition. 
Specifically our data provide a rational basis for treating subgroups of patients 
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carrying a functional or non-functional p53 with a PARP inhibitor in combination 
with RT and TPT, respectively.  
 
Materials and Methods 
Cell cultures 
The human GBM cell line D54, carrying an active p53 (D54p53wt), and the 
human GBM cell line U251, carrying a mutated (codon 273) and inactive p53 
(U251p53mut), were obtained from American Type Culture Collection. Cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s nutrient 
mixtures F-12 (Ham’s) 1:1 (GIBCO/Invitrogen, CA, USA), supplemented with 
10% foetal calf serum (FCS, Lonza, CA, USA), 20 mM HEPES, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 5 mM L-glutamine (complete medium). Cells 
were cultured at 37°C in a 5% CO2 atmosphere. 
 
Chemical reagents and antibodies  
Topotecan (TPT) was purchased from Glaxo Smith-Kline (Brentford, United 
Kingdom). 8-hydroxy-2 methylquinazolinone-4one (NU1025) was purchased from 
Alexis Biochemicals (San Diego, CA, USA). 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) Propidium iodide (PI) and RNAse were 
purchased from Sigma Chemicals Co (St Louis, MO, USA). 5-bromo-2'-
deoxyuridine (BrdU) and Alexa Fluor 488 goat anti-mouse were purchased from 
Invitrogen (Portland, OR, USA). Anti-BrdU Pure mouse monoclonal antibody was 
purchased from BD Biosciences (San Giose, CA, USA). Anti-phospho-Histone 
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γH2AX (Ser139) Fluorescein isothiocyanate (FITC)-conjugate and anti-Poly 
(ADP-Ribose) mouse monoclonal antibodies were purchased from Millipore 
(Billerica, MA, USA). FITC-conjugated secondary antibody goat anti-mouse was 
purchased from Dako (Milan, Italy). p53-, p21- and β-actin-specific monoclonal 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). Secondary antibody horseradish peroxidase-conjugated was purchased 
from Amersham-Pharmacia (Buckinghamshire, UK).  
 
Cell proliferation and MTT assay 
Cells were plated in triplicate in 96-well microtiter plates at a density of 2.5 x 103 
per well in 100 ul of complete medium. Following a 24 h incubation at 37°C in a 
5% CO2 cells were treated with TPT, NU1025 and RT. Adherent cells were 
irradiated in medium with 250 kVp X-rays (dose rate 0.5 Gy/min). For the 
combined treatments NU1025 was administrated at 10µM. This dose has been 
shown to inhibit PARP activity in D54p53wt and U251p53mut tumor cells by 
>90% [5]. For each experiment an untreated control was included. Cell 
proliferation was evaluated by MTT assay at indicated time points. MTT assay 
was carried out as reported elsewhere [20]. Absorbance was measured using a 
spectrophotometric microplate reader (MTX Lab System, Inc, Vienna, VA) at 540 
nm. Cells in randomly selected fields per well were photographed at different 
time points using a Zeiss Inverted Fluorescence Microscope (AxioVision 
Software, Carl Zeiss Micro-Imaging GmbH, Germany). Data were expressed as 
8 
 
percent inhibition of treated cells compared with the untreated control cells. All 
experiments were performed three independent times in triplicates. 
 
Cell cycle analysis and BrdU incorporation 
Cells were seeded in triplicate in 6-well plates at a density of 3 x 105 cells. 
Following a 24 h incubation at 37°C in a 5% CO2 cells were treated with TPT, 
NU1025 and RT. Untreated control cells were included. Cell-cycle analysis was 
determined by PI staining at indicated time points. Briefly, cells were trypsinized, 
counted, washed with PBS and stained with PI (50µg/ml; 60 min at RT). Possible 
double-stranded RNA was removed by incubation with RNAse (0.1 mg/ml). Cell 
proliferation with possible freezing or block phase in cell cycle was determined by 
BrdU incorporation and PI staining. After treatment cells were labelled with BrdU 
(20µM) for 30 min, immediately the medium was removed and fresh medium was 
added. Cells were then trypsinized at 0, 6 and 12 h and washed with PBS. After 
centrifugation cell were resuspended in 70% ice-cold ethanol and stored at -20°C 
until cell cycle analysis. Preparation of samples for FACS analysis was 
performed as described elsewhere [15]. Cells were analyzed by flow cytometry 
(FACScan, Becton Dickinson, San Josè, CA, USA) using the CyCLOPS Summit 
(Cytomation, Fort Collins, CO, USA). Distribution of the cells in the different cell 
cycle phases was evaluated by Mod Fit 2.0 (Verity Software HOUSe INC., 
Ranger, ME, USA). For analysis of the BrdU-DNA bivariate graphs, cells were 
split into the following four categories according to their DNA content and 
fluorescence intensity level: (1) BrdU-positive cells (BrdU+); (2) G1 phase / BrdU-
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positive cells (G1+); (3) S phase / BrdU positive (S+); (4) G2/M phase / BrdU-
positive cells (G2/M+).  
 
DNA damage 
Cells were seeded and were treated with TPT, NU1025 and RT as described 
above. Untreated control cells were included. DNA damage was assessed by 
flow cytometric characterization of DNA Strand Breaks using phosphorylated 
Histone γH2AX on Ser-139 and DNA content detection [14]. Following 1 and 4 h 
of treatment cell media was aspirated and cells were trypsinized, washed with 
TBS, fixed with 70% ice-cold ethanol and stored at -20°C until flow-cytometric 
analysis. During preparation for FACS analysis cells were permeabilized with 1% 
paraformaldehyde and 0.25% Triton-X-100 in TBS for 5 min. After centrifugation, 
cells were suspended in TBS and 3% BSA for 30 min. Then the cells were 
stained with anti-phosho-Histone H2AX (Ser139)-FITC conjugate antibody with 
3% BSA and incubated for 1 hr at room temperature. To correlate DNA damage 
with cell position in the cell cycle after three washes with TBS, cells were stained 
with PI 20µg/ml and RNAse 0.1 mg/ml for 60 min at RT. Cells with their 
distribution in the different cell cycle phases with or without γH2AX expression 
were analysed by FACScan. Cells were plotted with bivariate distributions (DNA 
content versus γH2AX expression). To evaluate cell analysis distribution 
untreated and treated cells were split in the following different gates: (1) H2AX-
positive cells (H2AX+); (2) H2AX-negative cells (H2AX-). Mathematic difference 
(∆) between percentage of levels of γH2AX expression (H2AX+) of treated cells 
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(tr) and untreated cells (untr) was calculated to compare the effects (∆ % = 
H2AX+tr – H2AX
+
untr).  
 
Immunofluorescent staining  
Cells were seeded at a density of 1 x 105 cells and were grown as monolayers on 
cover slips placed in cell culture dishes. Following a 24 h of incubation at 37°C in 
a 5% CO2 cells were treated with TPT, NU1025 and RT. Untreated control cells 
were included. PARP-1 activity was determined by immunofluorescent detection 
of poly-ADP-ribosylation of DNA as described by Bürkle et al. [4]. Following 4 h 
of treatment cover slips were gently removed and cells were fixed with 3% 
paraformaldehyde pH 7 in PBS at room temperature. Cells on cover slips were 
then washed three times with PBS and were permeabilized with 0.2% Triton-X-
100 for 5 min on ice. After washing with PBS and 1% BSA, cells were incubated 
with anti-Poly (ADP-Ribose) monoclonal antibody at dilution of 1:200 in 1% BSA 
for 1 h at room temperature. Then cells were washed again with PBS and 1% 
BSA and stained with FITC-conjugated goat anti-mouse IgG antibody (1:100 in 
PBS and 1% BSA) for 1 h at room temperature. Lastly cells were stained with PI 
(5µg/ml) for 30 min as an indicator of nuclear compartment and cover slips were 
mounted on slides. Slides were examined by Leica DMRXA fluorescent 
microscope. Images were captured by a QImaging CCD camera and exported in 
Microsoft PowerPoint.  
 
Cell transfection 
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D54p53wt cells were seeded at the density of 6 x104 per well in a 6-well plate 
and incubated in culture medium for 24 h at 37ºC in a 5% CO2 atmosphere prior 
to viral infection. Cells were transfected with vector encoding for p53-RNAi using 
Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. Two 
synthetic oliginucleotides were designed using the following sequences: 5’-
CCGGAATTCCCGACTCCAGTGGTAATCTACttcaagagaGTAGATTACCA-
CTGGAGTCTTTTTGGAACTCGAGCGG-3’ and 5’-
CCGCTCGAGTTCCAAAAAGACTCC-
AGTGGTAATCTACtctcttgaaGTAGATTACCACTGGAGTCGGGAATTCCGG-3’ 
[13]. The resulting double stranded oligonucleotides were then cloned into the 
pcRNAi vector encoding resistance for geneticin (G-418), and derived from the 
pcDNA3.1 vector (Invitrogen) replacing the viral promoter-cassette with the H1 
promoter that is specifically recognized by RNA polymerase III (kindly provided 
by Prof. Antonio Leonardi). Two days after transfection, geneticin G-418 (GIBCO) 
was added to cell culture medium (200 µg/ml) and maintained to enrich resistant-
transfected clones (D54p53-) (clones named P1 and P2).  
 
Western blot analysis 
D54p53wt and D54p53- (P1 and P2) GBM cells were seeded at a density of 1 x 
105 cells and treated with doxorubicin 2.5 µg/ml at 37 °C in a 5% CO2 
atmosphere for 1 h. Untreated control cells were included. After treatment cells 
were collected and lysed in lysis buffer [10 mM Tris–HCl (pH 8.2), 1% NP40, 1 
mM EDTA, 0.1% BSA, 150 mM NaCl) containing 1/50 (vol/vol) of protease 
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inhibitor cocktail (Sigma). Protein concentrations were determined with the 
Protein Assay Kit (Bio-Rad). Equal amounts of proteins were subjected to SDS-
page and transferred to PVDF membranes (Millipore). Nonspecific binding was 
blocked by incubation with TBST (20mM Tris-HCl pH 7.4, 150mM NaCl and 0.1% 
Tween-20) plus 5% of non fat dry milk. Membranes were incubated with p53-, 
p21- and β-actin-specific monoclonal antibodies for 1 h at room temperature. 
After TBST washing, blots were incubated for 1 h at room temperature with 
secondary antibody horseradish peroxidase-conjugated and the signals detected 
diluted 1:5000 in TBST buffer, and then revealed by ECL (Amersham 
Biosciences). 
 
Statistical methods  
Averages, standard deviations, and unpaired t-test were calculated using Excel 
software (Microsoft). Data showed the mean ± SD of the results obtained in at 
least three independent experiments. Differences between groups were 
considered significant when the P value was < 0.05. The asterisk (*) indicates P 
< 0.05. 
 
Results 
Effect of NU1025 in Combination with TPT and RT on Tumor Cell Growth  
 The ability of NU1025 to enhance the growth-inhibitory effects of TPT and/or RT 
was evaluated using human GBM cell lines D54p53wt and U251p53mut. In order 
to establish the dose of TPT and RT to be used in the combinatorial treatments 
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and to confirm the lack of cytotoxicity induced by NU1025, a dose titration 
experiment was performed in all cell lines utilizing different doses of TPT (0.024-
800 nM), RT (1; 2; 4 Gy) and NU1025 (0.170-160µM) (Fig 1A-C). U251p53mut 
cells were found to be more radioresistant than D54p53wt. The doses of 5nM 
and 10nM for TPT and those of 2Gy for RT were chosen for further testing in the 
combinatorial treatments. The dose of 10µM for NU1025 was chosen to combine 
with TPT and RT based on the data available in the literature that demonstrated 
90% inhibition of PARP-1 activity [5]. Analysis of the cell growth inhibition by MTT 
assay demonstrated that  (Fig. 2): 
1.  in the D54p53wt  cell line, the inhibition of PARP-1 with NU1025 10µM 
synergized (P<0.05) with TPT (5nM / 10nM) or 2Gy in inhibiting tumor cell 
growth. However the combination of 2Gy and NU1025 inhibited the 
proliferation of D54p53wt cells to a significantly (P<0.05) greater extent 
than the combinations of TPT (5nM / 10nM) and NU1025. In addition no 
statistically significant differences were detected between the combination 
of 2Gy and NU1025, and the combinations of TPT (5nM / 10nM) and 2Gy;  
2. in the U251p53mut cell line, although it is more radioresistant than 
D54p53wt, the inhibition of PARP-1 with NU1025 10µM synergized 
(P<0.05) with TPT (5nM / 10nM) or 2Gy in inhibiting tumor cell growth. 
However the combination of TPT 10nM and NU1025 caused the 
maximum inhibitory effect inhibiting the proliferation of U251p53mut cells 
to a significantly (P<0.05) greater extent than the combination of NU1025 
and 2Gy, and TPT (5nM / 10nM) and 2Gy; 
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3. in both cell lines, use of triple treatments did not increase the cytotoxicity 
when compared with the more effective double combinations. 
These data confirmed the clear potential of the inhibition of Poly (ADP-
ribosyl)ation in enhancing the cytotoxicity of TPT and RT in GBM cell lines 
although its inhibition did not cause direct cytotoxic effects. However in the 
D54p53wt cell line the combination of RT and NU1025 showed greater activity 
than the combination of TPT and NU1025, and comparable activity than the 
potential toxic combination of TPT and RT. On the other hand, in the 
U251p53mut cell line, which are more radioresistant than D54p53wt cells, the 
combination of TPT 10nM and NU1025 demonstrated more cytotoxicity than the 
combination of RT and NU1025, and the combination of TPT and RT. 
 
Effects of PARP-1 Inhibition, TPT and RT on the cell cycle distribution 
To evaluate the effects of NU1025, RT and TPT on cell cycle, PI staining was 
performed in D54p53wt and U251p53mut GBM cell lines. Cell cycle analysis 
following a 96 h incubation demonstrated no alteration in cell cycle distribution in 
both cell lines after treatment with NU1025 (10 µM). In D54p53wt cells treatment 
with 2Gy or TPT 5nM or TPT 10nM alone did not alter cell cycle distribution as 
compared with untreated cells (Fig 3A, B). Treatment with TPT (5nM or 10nM), 
2Gy and NU1025 used as double or triple combinatorial treatment significantly 
(p<0.05) increased the percentage of cells in S-phase. However a significant 
(p<0.05) difference in the percentage of S-phase was found between the cells 
treated with 2Gy and NU1025 and those treated with TPT (5nM or 10nM) and 
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NU1025. Furthermore no difference was found between cells treated with 2Gy 
and NU1025, and those treated with TPT (5nM or 10nM) and 2Gy. In the 
U251p53mut cell line (Fig 3C, D) cell cycle analysis demonstrated that treatment 
with 2Gy, and 2Gy in combination with NU1025 did not alter cell cycle 
distribution. Treatment with TPT (5nM and 10nM) alone or in combination with 
2Gy significantly (p<0.05) increased the percentage of cell death and of cells in 
S- and G2/M-phase. However the combination of TPT and NU1025 more 
markedly (p<0.05) increased the cell death and accumulation of cells in S- and 
G2/M-phase when compared to TPT and RT (p<0.05) or to NU1025 and RT 
(p<0.05) combinations.  
To validate the S-phase block or delay in cell cycle progression, BrdU 
incorporation and PI staining were performed after treatment with TPT, 2Gy and 
NU1025 in D54p53wt and in U251p53mut GBM cells.  Following a 96 h 
incubation, flow cytometric analysis demonstrated that in the D54p53wt cells 
treatment with 2Gy and NU1025 decreased the percentage of cells labeled with 
BrdU (BrdU+) when compared to untreated cells (Fig 4A). Analysis of cell cycle 
at different time points defined a delay of cell cycle progression. The cells 
principally reached G1-phase, but 12 h after BrdU incorporation they were still 
arrested in G1. Similar results were obtained with the combination of TPT and 
2Gy (data not shown). 
 In U251p53mut BrdU incorporation and PI staining confirmed a strong 
accumulation in S-phase and block in G2/M-phase following 96 h incubation 
treatment with TPT 10nM and NU1025 (Fig 4B). This effect was more evident 
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gating BrdU-positive cells: at 0 h the cells were in G1-phase and entered in S-
phase, but at 6 hrs and at 12 hrs from BrdU incorporation all cells were arrested 
in G2/M-phase.  
These data demonstrate that the inhibition of poly(ADP-ribosyl)ation enhanced 
cell cycle perturbations caused by TPT or RT, but did not cause alterations when 
used alone. However in D54p53wt cells the combination of RT and NU1025, 
which showed comparable activity to RT and TPT combination and greater 
activity than TPT and NU1025 combination, caused a delay of cell cycle 
progression consistent with a G1-phase block. In U251p53mut cells the 
combination of TPT and NU1025, which altered cell cycle progression to a 
greater extent than the RT and NU1025 combination or the TPT and RT 
combination, caused complete  block in G2/M phase and cell death.    
 
Effects of PARP-1 Inhibition, TPT and RT on DNA Damage 
To evaluate the mechanisms underlying the enhanced cytotoxic effects of TPT 
and RT by PARP-1 inhibition, we determined DSB presence by γH2AX detection 
and PI staining in the cells treated with TPT, 2Gy and NU1025. Flow cytometric 
analysis demonstrated that: 
1. in D54p53wt cells (Fig 5A-C ), following a 1 h incubation,  treatment of 
TPT, 2Gy and NU1025 alone or in combination did not increase γH2AX 
expression in treated cells when compared to untreated cells (∆).  An 
increase of γH2AX expression was found after 4 h of treatment with TPT 
or RT. These effects were markedly enhanced (p<0.05) by the treatment 
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with NU1025, which did not increase γH2AX expression when used alone. 
However, the combination of RT and NU1025 increased γH2AX 
expression to a greater extent (p<0.05) than the combination of TPT and 
NU1025 and demonstrated comparable effect to the combination of TPT 
(10nM) and RT, which also strongly increased γH2AX expression in 
treated cells; 
2. in U251p53mut cells (Fig 5D-E) following a 1 h and 4 h treatment of TPT 
or RT increased γH2AX expression in the treated cells when compared to 
untreated cells. The inhibition of PARP-1 by NU1025, as seen in D54 
p54wt, enhanced the DNA damage induced by TPT or RT. Nonetheless in 
U251p53mut cells the combination of TPT (10nM) and NU1025 increased 
γH2AX expression to a greater extent than the combination of RT and 
NU1025 (p<0.05) or the combination of TPT (10nM) and RT.   
These data are in line with the growth inhibitory effects and with cell cycle 
perturbations obtained by the treatment with TPT, NU1025 and RT in human 
GBM cells D54p53wt and U251p53mut.  The Inhibition of poly(ADP-
ribosyl)ation enhances the cytotoxic effect caused by TPT and RT in both cell 
lines through an increase of DNA damage. However in D54p53wt cells the 
combination of RT and NU1025 demonstrate a comparable effect than the 
combination of TPT and RT but a greater effects than the combination of TPT 
and NU1025. In U251p53mut cells the combination of TPT and NU1025 
demonstrated more cytotoxicity than the combination of RT and NU1025, and 
the combination of TPT and RT. 
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Fluorescent microscopy expression of PARP activity in D54p53wt and 
U251p53mut cells and its inhibition by NU1025  
To demonstrate the activation of PARP-1 by TPT or RT treatment and its 
inhibition by NU1025, we evaluated the poly(ADP-ribosyl)ation expression of 
DNA damaged sites in D54p53wt and U251p53mut  cells. D54p53wt and 
U251p53mut GBM cell lines were treated with TPT 10nM, 2Gy, NU1025 10µM 
and stained after 4 h of treatment. Immunofluorescent staining demonstrated 
that: 
1. In D54p53wt (Fig 6A) treatment with TPT 10nM or 2Gy increased nuclear 
activation of PARP-1 when compared to untreated cells. However its 
activation was strongly decreased by the treatment with NU1025 10µM.  
2. In U251p53mut cells (Fig 6B) a higher nuclear activity of PARP-1was 
found compared to D54p53wt in basal conditions. This ‘‘stand alone’’ 
phenomenon was most likely caused by the lack of functional active p53 
as reported in other tumors [21]. Nonetheless treatment with 2Gy and 
even more with TPT strongly increased PARP-1 activation. This effect was 
strongly decreased by the treatment with NU1025, as in D54p53wt cells. 
These data demonstrated the ability of NU1025 to inhibit PARP-1 activation at 
10µM in both GBM cell lines.  
 
p53 activity as a predictive marker of PARP-1 dependent enhancement of 
RT and TPT inhibition.   
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Our studies indicated that inhibition of poly(ADP-ribosyl)ation by NU1025 
enhances the cytotoxic effects of TPT or RT in both D54p53wt and U251p53mut 
human GBM cell lines. However these two cell lines showed different sensitivity 
to the enhanced cytotoxicity of TPT and RT induced by PARP-1 inhibition. To 
test whether p53 activity may modulate the enhanced cytotoxicity of TPT and RT 
induced by PARP-1, p53 was knocked down in D54p53wt cells using two specific 
p53-siRNAs, and the effects of TPT, RT, and NU1025 were studied by cell 
proliferation assay and cell cycle analysis.  Western blot analysis demonstrated 
that p53 expression was strongly inhibited in both transfected clone (P1 and P2 
cells) cells (D54p53-) under basal conditions and after treatment with doxorubicin 
(Fig. 7). p53 as well as its downstream protein p21 were both down regulated. 
Irradiation of both GBM cell lines D54p53wt and D54p53- with different doses of 
RT demonstrated that D54p53- cells were more radioresistant than D54p53wt 
cells (Fig 8A). Furthermore analysis of cells growth inhibition after treatment with 
TPT 10nM, 2Gy and NU1025 in both cell lines demonstrated that PARP-1 
inhibition enhanced the cytotoxicity of TPT and RT also in D54p53- (Fig. 8B). 
However in D54p53- cells the combination of TPT and NU1025 inhibited cell 
growth to a greater extent than the combination of TPT and RT, and the 
combination of RT and NU1025. Lastly, cell cycle analysis of D54p53- cells 
treated with TPT, RT and NU1025 demonstrated an accumulation in S- and 
G2/M-phase of treated cells (Fig 8C) when compared to untreated cells.  
However this effect was more pronounced with the combination of TPT and 
20 
 
NU1025 than the combination of 2Gy and NU1025 or TPT and 2Gy.  These 
results were in line with the data obtained with U251p53mut cells.  
 
Discussion 
In the Era of the targeted therapy current treatment for GBMs still involves a 
combination of chemotherapy and radiotherapy.  So far, the combination of 
temozolomide and radiotherapy still represents the standard of care for GBM 
treatment. This combination, although leads to increased overall survival, is 
effective for limited time and GBM patients continues to carry a poor overall 
survival. There is evidence that the combination of Topoisomerase-I inhibitors 
and radiotherapy may be an alternative strategy for the treatment of GBMs. 
However its use seems to lead to an increased toxicity [10,12,27]. 
Radioresistance and chemoresistance are the most significant causes for 
treatment failure and toxicity. Therefore there is a need to identify novel agents 
that will sensitize resistant cancer cells to traditional cytotoxic therapies. PARP 
inhibitors have been shown to sensitize tumor cells including GBM cells to 
radiotherapy (RT) and to different classes of chemotherapeutic agents such as 
temozolomide and topotecan (TPT). Furthermore use of PARP inhibitors has 
been demonstrated to not affect the toxicities induced by the treatment and to 
improve both the therapeutic index and the potential success rate of established 
cancer therapies [8,16,24,37,38]. Thus PARP inhibition might serve as a target 
for the development of chemo and radiation modifiers in GBMs. Nevertheless, no 
evidence identifies molecular biomarkers which can predict use of PARP 
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inhibitors in combination with TPT or RT and no data compare different strategies 
which utilize TPT, RT and PARP inhibitors in GBM.  
To date many PARP inhibitors have been developed for cancer therapy [24]. In 
this study we show in vitro that NU1025, a PARP-1 inhibitor, selectively inhibits 
an enhanced PARP activity induced by TPT or RT but its administration, as 
expected, not induced any cytotoxic effects in GBM cell lines.  Furthermore we 
confirmed the role of PARP inhibitor in potentiating the cytotoxic effects of TPT 
and RT in GBM cell lines. The increase cytotoxicity induced by PARP inhibitor in 
combination with TPT or RT is likely to reflect an increase cell growth inhibition, 
an increase perturbation of the cell cycle and an enhanced induction of DNA 
damage of GBM cells induced by TPT and RT. It is known that a critical event in 
determining sensitivity to RT or to TPT is the repair of DNA DSBs. In the data 
presented here, we demonstrate that inhibition of poly(ADP)ribosilation leads to 
an increase of DNA DSBs induced by TPT and RT. γH2AX expression a marker 
of DNA DSBs induced by RT or TPT [1,19,25] is found to be elevated in cells 
treated with RT or TPT in combination with NU1025 as compared with the cells 
treated with agents alone. Therefore these findings in line with data available in 
literature confirm that the effects of NU1025 are related to an inhibition of DNA 
repair.  
p53 is one of the major protein involved in DNA repair and most of the GBM carry 
a mutated and inactive p53 [34]. The enhanced cell growth inhibition and the 
increased DNA DSBs by PARP inhibition in combination with TPT or RT is 
shown to be independent by the integrity of p53. PARP inhibition enhances the 
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cytotoxicity of TPT and RT in GBM cell lines carrying a p53 wild type (D54p53wt) 
and in cells carrying a p53 mutated and inactive (U251p53mut and D54p53-). 
However our data demonstrate that p53 activity modulates the extent of the 
enhanced cytotoxicity of TPT or RT induced by PARP inhibition and may 
represent a useful marker to predict the most effective strategies utilizing TPT, 
RT and PARP inhibition for the treatment of GBM cells. Specifically the loss of 
p53 appears to be correlated with an increased radioresistance of GBM cells. 
Therefore, although PARP inhibition synergizes with RT in GBM cells with p53 
loss (U251p53mut and D54p53-), the extent of GBM growth inhibition as well as 
cell cycle perturbations and induction of DNA damage are demonstrated to be 
less than the combination of PARP inhibition and TPT. Furthermore in these cells 
the combination of PARP inhibition and TPT demonstrates not only to be better 
than the combination of PARP inhibition and RT but also to be the most effective 
strategy, been more cytotoxic than the supposed toxic combination of TPT and 
RT. On the other hand in cells carrying an active p53 (D54p53wt), although both 
the combinations of PARP inhibition and RT or TPT appears to be reasonable 
strategies, PARP inhibition and RT combination demonstrates to be more 
effective that the combination of PARP inhibition and TPT and shows 
comparable efficacy than the supposed toxic combination of TPT and RT.           
These in vitro results although need to be validated in vivo are clinical relevant 
since they expand the potential application of PARP inhibitors in combination 
with TPT or RT for the treatment of GBM based on their p53 status. Furthermore 
they might suggest selective treatments for GBM cell lines based on status of 
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activity of p53 but with a potential more favourable therapeutic index as 
compared with the more toxic combination of chemotherapy and radiotherapy. 
Indeed radio- and chemo-sensitizing agents that do not carry side effects such as 
PARP inhibitors have the great potential to achieve selective modulation of 
cytotoxic drug action in tumors by increasing their efficacy and dose tolerance.  
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Figure Legend 
Figure 1. Dose dependent effect of TPT, RT and NU1025 on the in vitro 
proliferation of human GBM cell lines D54p53wt and U251p53mut. 
D54p53wt and U251p53mut cells were treated with the indicated concentrations 
of TPT (A), RT (B) and NU1025 (C). Cell growth inhibition was determined by 
MTT assay following a five day incubation at 37°C. Percentage of cell growth 
inhibition was calculated as the ratio of treated to untreated cells at each 
concentration point. Data are expressed as mean ± SD of the results obtained in 
three independent experiments. (C) A representative experiment with D54p53wt 
and U251p53mut cells treated with NU1025 (10µM) is shown.  
 
Figure 2. Enhancement by PARP-1 inhibition with NU1025 of the in vitro 
anti-proliferative activity of TPT or RT in human GBM cell lines D54p53wt 
and U251p53mut. 
D54p53wt and U251p53mut cells were treated with the indicated concentrations 
of TPT and/or RT and/or NU1025 (10µM). Cell growth inhibition was determined 
by MTT assay following a five days of treatment. Percentage of cell growth 
inhibition was calculated as ratio of treated to untreated cells at each treatment. 
Data are expressed as mean ± SD of the results obtained in three independent 
experiments.  
 
Figure 3. Enhancement by PARP-1 inhibition with NU1025 of the cell cycle 
perturbations induced by TPT or RT in human GBM cell lines D54p53wt and 
U251p53mut.  
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D54p53wt (A, B) and U251p53mut (C, D) cells were treated with the indicated 
concentrations of TPT and/or RT and/or NU1025 (10µM). Cell cycle perturbations 
were detected by PI staining following a five days of treatment. The percentage 
of D54p53wt and U251p53mut cells in the different phases of cell cycle is shown. 
Data presented are representative of three indipendent experiments.   
 
Figure 4. Enhancement by PARP-1 inhibition with NU1025 of the cell cycle 
block and delay induced by TPT or RT in human GBM cell lines D54p53wt 
and U251p53mut.  
D54p53wt (A) and U251p53mut (B) cells were treated with the indicated 
concentrations of TPT and/or RT and/or NU1025 (10µM). Cell cycle perturbations 
were detected by BrdU incorporation (at the indicated time points) and PI staining 
following a five days of treatment. The percentage of D54p53wt and U251p53mut 
BrdU positive cells in the different phases of cell cycle (G1+, S+ and G2/M+) is 
shown. Data refer to one of two experiments giving similar results. 
 
Figure 5. Enhancement by PARP-1 inhibition with NU1025 of the DNA 
damage  induced by TPT or RT in human GBM cell lines D54p53wt and 
U251p53mut.  
D54p53wt (A-C) and U251p53mut (D-F) cells were treated with the indicated 
concentrations of TPT and/or RT and/or NU1025 (10µM). DNA damage was 
determined by flow cytometric γH2AX expression following the indicated time 
points of treatment. Relative γH2AX expression was calculated as the 
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mathematic difference (∆) between percentage of levels of (H2AX+) of treated 
cells and untreated cells (∆ % = H2AX+tr – H2AX
+
untr).  A representative 
experiment of γH2AX expression in D54p53wt (A, B) and in U251p53mut (D, E) 
with or without treatment with TPT, RT and NU1025 is shown. Data are 
expressed as mean ± SD of the results obtained in three independent 
experiments (C, F).  
 
Figure 6. Inhibtion by NU1025 of PARP-1 activation induced by TPT or RT in 
human GBM cell lines D54p53wt and U251p53mut. 
D54p53wt (A) and U251p53mut (B) cells were treated with the indicated 
concentrations of TPT and/or RT and/or NU1025 (10µM). PARP-1 activity was 
determined by immunofluorescent staining of poly-ADP-ribosylation of DNA 
following a 4h of treatment. PI staining was used  as an indicator of nuclear 
compartment.  
 
Figure 7. p53 downregulation in human GBM cell line D54p53wt.  
D54p53wt were transduced with transfected with vector encoding for p53-RNAi. 
Resistant-transfected clones (D54p53-) were named P1 and P2. D54p53wt and 
transduced cells were treated with doxorubicin (2.5 µg/ml). Untreated cells were 
used as a control group. Following a 12h incubation at 37°C cells were harvested 
and lysed. Cell lysates were analyzed by western blot with the indicated mAbs. β-
actin was used as a loading control. The results presented are representative of 
the results obtained in three independent experiments.  
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Figure 8. Modulation by p53 of the enhanced cytotoxicity of TPT or RT 
induced by PARP-1 inhibition in human GBM cell lines. 
A. D54p53wt and D54p53- P1 cells were irradiated with the indicated doses of 
RT. Cell growth inhibition was determined by MTT assay following a five day 
incubation at 37°C. B. D54p53wt and D54p53- P1 cells were treated with the 
indicated concentrations of TPT and/or RT and/or NU1025 (10µM). Cell growth 
inhibition was determined by MTT assay following a three day incubation at 
37°C. Percentage of cell growth inhibition was calculated as the ratio of treated to 
untreated cells at each concentration point. Data are expressed as mean ± SD of 
the results obtained in three independent experiments. C. Cell cycle 
perturbations were detected by PI staining following a three days of treatment. 
The percentage of D54p53wt and D54p53- cells in the different phases of cell 
cycle is shown. Data presented are representative of three indipendent 
experiments.   
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Abstract: The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, 
with a median survival of 8–9 months and a 3-year overall survival (OS) rate less than 15% [1,2]. 
A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of 
excision margins still remain [4]. 
Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative 
patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness 
to enforce the execution of the SLNB [5]. 
To date, Interferon-? (IFN-?)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication 
remains still controversial [2,6]. 
Keywords:  chemotherapy Inibithors, B-RAF immunotherapy, melanoma,    
INTRODUCTION 
 Dacarbazine (DTIC) has been the standard first-line therapy for 
patients with metastatic disease for a long time with a reported 
response rate less than 15% [7]. Recently, two drugs have been 
approved for treating patients with metastatic melanoma. The 
first one, ipilimumab, is a monoclonal antibody which targets the 
cytotoxic T-lymphocyte Antigen 4 (CTLA4). Two phase III clinical 
trials comparing ipilimumab with DTIC demonstrated an improved 
OS for patients treated with ipilimumab. Nevertheless, this agent 
resulted to be effective only in a subset of patients and the related 
toxicities were considerable. 
 Vemurafenib is the second drug that has been approved for the 
treatment of metastatic melanoma. It is an agent that selectively 
targets BRAF, a component of the MAPK pathway. Approximately 
60% of all melanomas harbor activating mutations in BRAF 
oncogene. Treatment with vemurafenib has shown to improve OS 
and to induce tumor regression in approximately 50% of treated 
patients with metastatic melanoma carrying a BRAF V600E 
mutation that implies the substitution of glutamic acid instead of 
valine at amino acid 600. However, the responses are rarely 
complete and the median time to disease progression is less than 7 
months due the onset of specific drug resistance. Several 
mechanisms of resistance have been described and clinical trials are 
testing new strategies to overcome the intrinsic or acquired BRAF-
inhibitors resistance.  
DIAGNOSIS 
 Early detection of cutaneous melanoma and its early removal is 
the only therapeutic strategy able to increase the percentage of 
cures. Therefore identification and treatment of suspected skin 
lesions play the major role in the treatment of melanoma.  
 Dermoscopy is a non-invasive skin imaging technique which 
can help in this aim. The technique consists of a magnifier  
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(typically x10), a non-polarized light source, a transparent plate and 
a liquid medium between the instrument and the skin, and allows 
inspection of skin lesions unobstructed by skin surface reflections. 
Modern dermatoscopes avoid the liquid medium and employ 
instead polarized light to cancel skin surface reflections [8]. 
 Argenziano et al. showed that the introduction of dermoscopy 
leads to a reduction of excised nevi and to an increased number of 
early diagnosed melanomas [9].  
 Timing of dermoscopy is an issue of outstanding difficulty and 
several randomized clinical studies have faced the argument 
comparing different follow-up schedules [10-12]. 
 Results of these studies suggest two follow-up plan: (a) short-
term follow-up of 3 months for patients with familial atypical mole 
and melanoma syndrome and (b) long-term follow-up of 6-12 
months for those with atypical mole syndrome. Patients with 
multiple common nevi and no additional risk factors were found to 
have low benefit from sequential digital dermoscopy. 
 It’s now clear that dermoscopy imaging is a useful strategy to 
avoid missing melanomas while minimizing unnecessary excision 
of benign lesions.  
 The informations to be taken early during diagnostic work-up 
are detailed in Table 1. 
LIMITATED DISEASE 
Surgical Treatment 
 Surgical excision remains the mainstay of treatment for primary 
cutaneous melanoma. Controversy exists concerning the extension 
of excision margin for cutaneous melanoma with Breslow ? 2 mm. 
 In the first prospective randomized trial, 584 melanoma patients 
with tumors thinner than 2.0 mm were included. Results 
demonstrated that 1 cm of radial margin was a safe strategy for thin 
melanoma <1.0 mm thick, but not for melanomas >1.1 mm thick. In 
fact, melanomas with a thickness > 1.1 mm surgically treated with a 
free margin of 1 cm, recorded a recurrence rate of 4% [13]. Results 
of other trials have not provided clear features both regarding thin 
(<1 mm) and deeper (> 1mm) lesions [14-19]. 
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 At present, the scientific community agrees on the following 
recommendations:  
a) for melanoma ? 1 mm, wide excision with 1.0 cm margin 
(Category 1);  
b) for melanomas with thickness > 1mm, wide excision with 2 cm 
(category 1 for tumors 4 mm or less in thickness; category 2A 
for melanomas more than 4 mm) [20]. 
 Sentinel lymph node biopsy (SLNB) is a minimally invasive 
staging method to identify patients with subclinical nodal 
involvement [21].Vital blue-dye and radio-colloid are used to map 
the lymphatic drainage from primary cutaneous melanoma to the 
first tumor-draining regional lymph node (or nodes). Radical 
limphoadenectomy is avoided in absence of metastasis in sentinel 
node (nodes). On the other hand, when metastases are detected, 
regional limphoadenectomy is required since other nodes in the 
basin might be involved. 
 Multicenter Selective Lymphadenectomy Trial (MSLT-I) was 
the most important study designed to evaluate the contribution of 
SLNB to the outcomes of patients with newly diagnosed melanoma. 
This randomized study enrolled 1,269 patients with intermediate 
thickness (1.2 to 3.5 mm) melanomas. Patients were randomized to 
receive: i) wide excision of primary tumor associated with a 
postoperative observation and complete lymph node dissection 
(CLND) only if nodal metastases were clinically detected or, ii) 
wide excision and SLNB with CLND if metastasis in sentinel 
lymph node (SLN) was detected. The results of the study did not 
demonstrate statistically significant differences in OS between 
patients treated with SNLB and those treated without SNLB. 
However, a significant improvement in 5-year disease free survival 
(DFS) in the SLNB group was found [22]. 
 The value of SLNB for thin (< 1mm) and thick (> 4mm) 
melanomas was not addressed specifically in MSLT-I study. The 
incidence of occult regional nodal metastasis in patients with thin 
melanoma (?1.0 mm) is low and the necessity to perform SLNB in 
these patients remains controversial. Andtbacka and Gershenwald 
reviewed literature with the aim to identify sentinel node positivity 
predictors in patients with thin melanomas [23]. The authors 
concluded that SLNB can be considered for Breslow ?0.75mm, in 
patients with T1b melanomas (i.e. Clark level IV/V and/or 
ulcerated) or with thin melanomas characterized by high mitotic 
activity (?1 mitosis/mm2). The young age (? 40 years) could be an 
additional parameter to be considered, particularly if the primary 
tumor is characterized by a high tumor mitotic rate. Tumor 
regression does not seem to be associated with an increased risk for 
SLN metastasis.  
 In conclusion, in the scientific community there is broad 
agreement in recommending SLNB only for patients with 
melanoma 1 mm. SLNB should be considered for patients with 
melanoma thickness ? 0.75 mm in presence of adverse features, 
such as ulceration, mitotic rate ? 1/mm2, positive deep margins, 
lymphovascular invasion or young patient age [20]. 
 The value of the SNLB is still controversial in patients with 
melanomas Breslow thickness ?4 mm. A number of clinical trials 
have faced this issue, but there are no strong recommendations to 
perform SNLB in this category of patients and the choice is 
committed to the clinicians experience and discretion.  
 Some pathologic melanoma characteristics are prognostics and 
they should be detailed in the pathology report. The NCCN 
melanoma panel recommends the inclusion in pathology report of 
Breslow thickness, ulceration, mitotic rate, margin status (positive 
or negative), presence of satellitosis, and Clark’s levels for non-
ulcerated and T1 melanomas [20]. In patients with localized 
melanoma, Breslow thickness, ulceration and mitotic rate are the 
most important predictive factors for outcome [24]. Recent studies 
suggested that mitotic rate is an independent prognostic variable in 
patients with thin and non ulcerated melanomas [25]. Controversy 
exists about the prognostic value of the tumor regression in patients 
with cutaneous melanoma. Tumor regression might be associated 
with an underestimation of the true Breslow thickness. On the other 
hand it can indicate recognition of the primary tumor by the 
immune system. Authors who have faced this argument have 
discovered that tumors regression cannot be considered a 
prognostic factor for patients with cutaneous melanoma and it 
should not be used to guide clinical decision-making for such 
patients [26]. 
 Several markers have been studied as predictors of SLN 
involvement in melanoma. Results of clinical trials highlighted that 
the site of primary melanoma (extremities vs. axial locations) and 
T-lymphocytes infiltrating tumor (TILs) were predictive for lower 
probability of SLN involvement, while thickness (>4mm vs. 0-
1mm) was predictive for higher risk of SLN involvement [27].  
Adjuvant Therapy 
 The immune system plays a key role in the onset of tumors, in 
the regulation of tumor growth and even in response to therapy, 
mainly by the immunosurveillance mediated by CD8+T and NK 
cells [28]. Melanoma, as well as other tumors like renal cell 
carcinoma, is strongly immunogenic. This hypothesis stems from 
data demonstrating the presence of infiltrating tumor specific  
CD8+ T lymphocytes in patients with spontaneous regression of 
Table 1. Pathological  Melanoma of Characteristics Main 
Diagnosis of Melanoma Important Features to Determinate 
Hystotype in situ melanoma; superficial spreading melanoma; nodular melanoma; malignant lentigo and melanoma developed from malignant 
lentigo; acral melanoma; desmoplasic melanoma; malignant blu nevus; melanoma developed fromcongenital nevus; metastatic 
melanoma  
Cellular tipology epithelioid; fusate; nevoid 
Growth phase radial; vertical 
Invasion depth according to Breslow mm 
Number of mitosis per mm?  Particularly important for thick lesions (<)1 mm 
Ulceration yes or not 
Distance from resection margins Necessary for staging completion and re-resection performing 
Tumor Infiltrating Lymphocytes  present or absent 
Microsatellytosis Necessary for staging completion and indication to perform also radiotherapy (discussed) 
Regression parzial or total; It may indicate a poor prognosis for invasive lesions 
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melanoma. The elusion of immunosurveillance has been proposed 
in 2004 by Schreiber et al. as the seventh hallmark of cancer [38] 
and avoidance of immunosurveillance is a mechanism put in place 
by the majority of tumors through different mechanisms. Several 
data support the ability of melanoma cells to suppress the immune 
system by a specific immunoediting to select non-immunogenic 
tumor cell clones or by an in situ immune suppression driven by  
the tumor and /or specific cytokines [29]. Advanced melanoma is 
often associated with an immunosuppressive status driven by the 
increase of negative regulatory specific T cells (Treg) [30, 31] and 
the induction of immunosuppressive chemokynes, such as IL-10 
[32-36]. 
 Three main immuno therapies have been used in melanoma:  
i pleiotropic immunomodulators, such as IL-2 and IFN-?2b. 
ii monoclonal antibodies (mAbs) targeting the specific negative 
immunoregulator receptors CTLA4 and PD1. 
iii cancer vaccines (protein-, peptide- and cell based vaccines) and 
adoptive cell transfer (ACT) therapy. 
 In the last two decades, several observations led to the evidence 
that IFN-?, a molecule belonging to the type I IFN family, had 
antitumor activity towards several cancers, like renal cancer, 
lymphoma and melanoma [37, 38, 39]. 
 Many trials have been conducted over the last 3 decades and 
several trials are still ongoing to establish the real benefits deriving 
from IFN-?2b as adjuvant therapy of melanoma. 
 Three main clinical trials need to be mentioned: 1) the ECOG 
Trial E1684 comparing High Dose Interferon (HDI) (IFN-?2b 20 
million UI/m
2
/day i.v. x 4 weeks followed by 10 million 
UI/m
2
/3times a week s.c. x 48 weeks) versus Observation; 2) 
Intergroup Trial E1690 comparing HDI and Low Dose Interferon 
(LDI) versus Observation; 3) Intergroup E1694 comparing GMK 
vaccine versus HDI. 
 All these trials showed significant and durable effects of IFN-
?2b on recurrence free survival (RFS) and overall survival OS. A 
meta-analyses pooled data from these three trials and confirmed the 
benefits deriving from IFN-?2 therapy as adjuvant treatment for 
patients with highrisk of recurrence [40-42]. On the basis of these 
data, HDI emerged to be the only effective regimen to be 
administered.  
 In 2011 the pegylated preparation of IFN-?2 (Peg-IFN-?2) has 
been approved by Federal Drug Administration (FDA) as adjuvant 
treatment of stage III melanoma. Peg-IFN-?2 is administered 
subcutaneously for up to five years. The approval is justified by 
data deriving from a randomized phase III trial, the EORTC 
18991[43].  
 However, updated analysis of this trial raised some 
controversies since its benefits in terms of RFS and OS appeared to 
be not statistically significant at 7.6 years follow up [44]. 
 Unfortunately, predictive factors of response to IFN are still 
unknown and, at present, it is not possible to identify those patients 
who will respond to this specific immunotherapy. 
 Yurkovetsky et al. [45] showed that a multiplexed analysis of 
pre-treatment serum concentrations of pro-inflammatory cytokines 
(IL-1?, IL-1?, IL-6, TNF-?, and chemokines MIP-1? and MIP-1?) 
were significantly higher in patients obtaining longer RFS 
following an IFN-?2 treatment than patients with low levels of 
cytokines. Eggermont et al. [46] conducted a retrospective analysis 
of two phase III adjuvant trials (EORTC 18952 and EORTC 18991) 
and demonstrated that only the subset of melanoma patients 
characterized by ulcerated primary tumors and/or regional lymph 
node involvement (stage IIB and III-N1/N2) obtained a significant 
improvement of RFS and OS by IFN-a treatment. Moreover, Gogas 
et al. demonstrated that the development of clinical and 
immunological manifestations of autoimmunity during IFN-?2 
treatment appeared to correlate with a better clinical outcome in 
terms of RFS and OS [47]. 
 Different adjuvant treatments for high risk melanoma patient 
have been explored, such as treatment with antitumor vaccines 
(CancerVax or GMK), but with negative results. Data from ongoing 
trials evaluating the role of anti-CTLA-4 mAbs, BRAF and MEK 
inhibitors in the adjuvant setting are awaited for the next years. 
 Anticancer vaccine and adoptive cell transfer approaches 
represent an attractive research topic since both strategies try to  
kill tumor cells by the engagement of the immune system. 
Unfortunately, to date only modest clinical benefits have been 
demonstrated with these approaches in melanoma patients. This is 
probabily due to the huge complexity of the mechanisms underlying 
an immune response against tumor cells and to the immuno- 
suppressive state caused by the tumor cells and even associated 
with advanced-stage cancer patients. Anticancer vaccine use finds 
its roots on the identification of Tumor Antigens (TAs) which are 
expressed by tumor cells but not by normal cells. Thus, TAs might 
be recognized by T cells by their presentation in the context of 
MHC class I molecules and stimulate a cellular/humoral response 
able to target cancer cells by the activation of cytotoxic T 
lymphocytes (CD8+ T cells). 
 Five classes of TAs can be distinguished: differentiation 
antigens, mutated antigens, cancer-testis or cancer-germline antigens, 
overexpressed antigens and viral antigens [48].  
 Among TAs, several different melanoma-associated antigens 
(MAGE) have been identified since 1991, when Van der Bruggen et 
al. isolated the first one (MAGE-A1) and discovered that it antigen 
was recognized by cytotoxic T lymphocytes. Two main classes of 
MAGEs (MAGE I and MAGE II) have been distinguished 
according to their structure and expression profile [49]. 
 The first class of MAGEs is widely expressed among various 
types of malignant tissues, but not in adult normal cells, except for 
the germ-line cells lacking HLA expression; it appears to be more 
interesting as immunotherapy target, showing promising results in 
preliminary trials [50].  
 In order to enhance the efficacy of a vaccine approach utilizing 
TAs they can be synthetically engineered (i.e., GP100 melanoma-
associated antigen and MELAN-1 peptides) [51] or be associated to 
adjuvant chemical components (like water-in-oil emulsion, 
Montanide). 
 The introduction of toll-like receptor ligands (TLR9L, TLR3L, 
and TLR4L) to activate NK and APCs [52] also showed promising 
results.  
 Adoptive cell transfer is the passive transfer of cells, most 
commonly immune-derived cells, into a new recipient host with the 
goal of transferring the immunologic functionality and characteristics 
into the new host. Clinically, this approach has been exploited to 
transfer either immune-promoting or tollerogenic cells (often 
lymphocytes) to patients to either enhance immunity against viruses 
and cancer or to promote tolerance in the setting of autoimmune 
disease. Tumor Infiltrating Lymphocytes (TIL) therapy represent a 
milestone in ACT, although it is an expensive, difficult and time-
consuming approach. Autologous TIL are selected from tumor, 
grown under conditioning presence of stimulating T lymphocyte 
cytokines, such as IL-2, and re-injected in patients. The adoptive 
transfer of autologous TILs or genetically re-directed peripheral 
blood mononuclear cells has been used to successfully treat patients 
with advanced solid tumors, including melanoma and colorectal 
carcinoma, as well as patients with CD19-expressing hematologic 
malignancies. During the last decades several strategies have been 
proposed and tested to overcome technical difficulties of production 
and handling of ACT. 
 Pre-conditioning regimens utilizing non mieloablative 
chemotherapy or total body irradiation have been successfully 
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introduced to induce patient lymph depletion before TILs 
administration in patients with melanoma. It avoids endogenous 
Treg and myeloid derived suppressor cells (MDSCs) suppression of 
immune antitumor response [53]. 
 Faster TIL production techniques which utilize the so called 
‘young TILs’ appear to warrantee, combined with patients’ lymph 
depletion, improved persistence and antitumor response in vivo 
[54]. 
 TILs derived from autologous T cells carrying genetically 
engineered TCRs showed promising preliminary results [55]. These 
TCRs are directed to some TAs, such as the cancer/testis antigen 
NY-ESO-1, and allowed to administer ACT therapy even to 
patients in whose a TIL isolation and sampling might be not 
performed due to difficult access to the metastatic site. 
 Dendritic cells (DCs) are professional antigen presenting cells 
(APCs) which are involved in inducing primary T-cell response. 
This feature makes them optimal candidates to be used as 
anticancer immunotherapy [56]. The administration of tumor-
antigen loaded DCs showed encouraging results in the treatment of 
advanced solid tumors, but, unfortunately, these results were often 
transient. These poor results are probably due to: i) tumor-induced 
immune suppressive state which prevents a strong and durable 
immunoresponse by down-regulation of MHC class I antigen; ii) 
secretion of soluble immunosuppressive cytokines converting DCs 
into tolerogenic status; iii) induction of Treg cells [57]. 
 Many devices have been studied to improve response to DCs 
based therapy. Additional activation of DCs by toll-like-receptors 
ligands (TLRLs) seems to neutralize the immunosuppressive effects 
induced by Tregs and enhances T cells proliferation [58]. 
 Other approaches to induce stronger and more durable 
responses to DCs have been proposed. One of them includes DCs 
maturation under conditioning cytokines cocktails containing IL-
1?, TNF-?, IL-6 and PGE2 [59]. The other one is based on adding 
to the classical type1 polarizing cocktail administration of IFN-? 
(alpha-type-1-polarized dendritic cells). This approach guarantees a 
satisfying population of efficient DCs which display high ability in 
chemotaxis, interleukin12, p70 secretion and the expression of 
several co-stimulatory molecules. The clinical activity of alpha-1 
polarized DCs in melanoma, as well as in other malignancies, is on 
evaluation [60]. 
METASTATIC DISEASE 
Immunotherapy 
 The use of immunotherapy in metastatic melanoma has 
undergone profound changes in the last decade and remains one of 
the most promising therapeutic strategies in this setting. 
Historically, the first immunotherapeutic agent registered for the 
treatment of metastatic melanoma has been the IL-2, a T cell 
growth factor, which plays a crucial role in immune regulating 
process and T cell proliferation [61], demonstrated a potent 
antitumor activity in murine models [62]. 
 In 1992, the FDA approved high dose IL-2 (HD-IL2) for the 
treatment of patients with metastatic renal cell carcinoma [63] and, 
in 1998, for the treatment of metastatic melanoma. In metastatic 
melanoma patients, HD-IL2 treatment induced an interesting 
overall response rate, around 10-15%, and, in a small proportion of 
patients (3-5%) a durable complete response (> 5 years). 
 Predictive factors of response to IL-2 therapy include 
development of autoimmunity (hypothyroidism), low LDH levels, 
good ECOG performance status, a low number of metastases in 
specific sites (lung, lymph-nodes and soft-tissues) and high pre-
treatment neutrophil count [64]. 
 Biochemotherapy regimen associating chemokines, such as IL-
2 or IFN-?, with chemotherapeutic demonstrated no improvement 
of OS, a slightly increase of response rates and RFS with a 
significative increase of toxicity [65]. 
 However, there have been important advances in the 
understanding of crucial immunoregulatory pathways underlying 
the regulation of the immune response against tumors which have 
led to develop novel therapeutic strategies for the treatment of 
metastatic melanoma. One of the most promising approaches to 
overcome cancer immune tolerance is the promotion of T cell 
activation by blocking inhibitory signals arising from receptors like 
the cytotoxic T lymphocytes-associated antigen-4 (CTLA-4) and 
Programmed Death-1 (PD-1) receptor [66]. 
 CTLA-4 receptor represents a key molecule able to decrease T-
cell activation; its activation is physiologically required to induce 
tolerance to self antigens avoiding autoimmunity reactions and can 
be figured as a natural brake of the immune system [67, 68]. 
CTLA-4 receptor is up regulated on activated T-cells and competes 
with CD28 for binding to the ligand B7; the binding of CTLA-4 
with B7 leads the block of co-stimulatory signals needed for T-cell 
activation [68]. Specific mAbs blockade of CTLA-4 receptor 
activity allows CD28 to bind B7. 
 Two fully human anti-CTLA-4 mAbs are currently in clinical 
setting: ipilimumab and tremelimumab. 
 Ipilimumab is a fully human mAb IgG1 which demonstrated 
activity in several phase II trials on metastatic melanoma and, more 
recently, in two phase III trials. In the first one, published in 2010, 
pre-treated melanoma patients were randomized to receive gp100 
peptide vaccine and ipilimumab in combination or gp100 vaccine or 
ipilimumab alone. Data analysis demonstrated a significant OS 
improvement in ipilimumab arms compared with gp100 vaccine 
arm (10 vs. 6.4 months; HR 0.68 and P<0.001). No statistically 
significant different in OS was found between ipilimumab and 
ipilimumab plus gp100 peptide vaccine [69]. The OS among 
subgroups of patients showed a benefit for all subgroups in 
ipilimumab and ipilimumab plus gp100 versus gp100 alone. In the 
second phase III trial (MDX-024), published in 2011, untreated 
metastatic melanoma patients were randomized to receive DTIC 
with or without ipilimumab. The study confirmed a significant 
survival benefit in the ipilimumab/DTIC arm (median OS 11.2vs. 
9.1 months). There was no difference in disease control rate and in 
ORR (15%vs. 10%), but the duration of response was longer for 
ipilimumab/DTIC combination (19.3 vs. 8.1 months). Interestingly, 
several patients obtained long-lasting benefit from ipilimumab 
despite they did not meet the standard RECIST criteria for 
evaluation of objective response. The toxicity of the 
ipilimumab/DTIC combination was considerable and 56% of 
patients experienced grade 3 or 4 adverse events. Toxicity profile 
resulted to be different from that seen with ipilimumab alone or in 
combination with gp100 in the first clinical trials. Patients in the 
ipilimumab/DTIC arm experienced more hepatic toxicity and 
slightly less gastrointestinal toxicity mainly caused by the 
concomitant administration of the chemotherapeutic agents [70]. 
The FDA has approved ipilimumab for the treatment of metastatic 
melanoma, although the iindividuation of predictive biomarkers of 
response for ipilimumab is lacking. The study of tumour 
microenvironment led to the observation that a pro-inflammatory 
gene expression profile appears to correlate with favourable clinical 
outcome in patients treated with ipilimumab [71]. 
 Tremelimumab is the second anti-CTLA-4 mAb which has 
been tested in melanoma patients, but the single phase III trial, with 
tremelimumab vs. DTIC or temozolomide in naïve metastatic 
melanoma, failed to demonstrate a significant increase of OS in 
patients treated with tremelimumab [72]. 
 PD-1 is a receptor belonging to the CD28 family. It plays a role 
in tumor associated mechanisms of immune-escape [73]. PD-1 has 
two ligands: PD-L1 and PD-L2, which act as down-regulators of 
immune response. PD-L1 and PD-L2 are widely expressed on cell 
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membrane of macrophages, B lymphocytes, T resting lymphocytes, 
dendritic cells and cancer cells [74]. Several evidences demonstrate 
a predominant role of PD-1 in melanoma immune tolerance. It has 
been shown that engaged of PD-1 receptor by his natural ligands 
and the up-regulation of Tim-3 is associated with tumor antigen 
CD8
+
cell dysfunction in advanced melanomas [75]. Furthermore, 
an increase of PD-1 expression on a subset of Melan-A-reactive T 
cells has been shown in metastatic melanoma patients in 
comparison with those in stage I-II (67). Lastly, PD-1 appears to be 
a negative regulator of CD8+ T cells by the specific tumor antigen 
NY-ESO-1 which activity was restored by PD-1/PD-L1 pathway 
blockade [76]. 
 Taken together all these evidences support the idea that 
targeting of PD-1 may represent a promising tool to enhance tumor 
specific Tcell activity. The MDX 1106 mAb, a fully human mAb 
againstPD-1 receptor, has been recently tested in advanced 
melanoma patients and preliminary data have been presented at the 
ASCO 2012. MDX 1106 activity and safety were encouraging, 
showing durable clinical benefits in patients with advanced melanoma. 
However, these remarkable results require further evaluations [77, 78]. 
Target Therapy 
 Around 60% of patients with advanced melanoma have 
mutations affecting BRAF, with nearly all of those affecting a 
single-amino-acid residue within the kinase domain. The most 
common mutation of BRAF gene is the valine to glutamate 
substitution at 600 position of kinase domain (V600E). This altered 
amino acid sequence results in a protein that remains constitutively 
in the active conformation and has an 800-fold increased kinase 
activity compared with its wild-type counterpart. Less frequent 
mutations, between 10 and 30%, have been discovered, such as the 
variant V600K, which represents 5% to 20% of BRAF mutation 
[79, 80]. 
 BRAF (V600E) leads to the sustained activation of the 
MEK1/2?ERK1/2 MAP kinase pathway. This pathway plays a 
critical role in regulating gene expression, cell proliferation and 
survival, thereby contributing to the initiation and progression of 
melanomas [81, 82]. Knockdown of BRAF (V600E) leads to 
inhibition of cell proliferation in vitro by the lack of MEK and ERK 
activation. Beyond proliferation and apoptosis, knockdown of 
BRAF (V600E) increased the expression of melanocyte-associated 
antigens and suppressed the expression of pro-angiogenic cytokines 
[83]. 
 Several inhibitors have been developed to target BRAF 
(V600E). The first attempt with a small-molecule inhibitor, 
sorafenib, a multi-targeted receptor tyrosine kinase (RTK) utilized 
for its properties to inhibit mutated and wild-type BRAF, produced 
disappointing results [84]. 
 In contrast, selective BRAF inhibitors (BRAF-I), such as 
vemurafenib (formerly known as a PLX4032) and dabrafenib (also 
known as GSK2118436), have been showed to largely mimic the 
effects of selective BRAF (V600E)-specific siRNA knockdown 
[85]. In fact, inhibition of proliferation and induction of apoptosis is 
limited to BRAF mutant cancer cells and these effects are mediated 
by inhibition of MEK and ERK phosphorylation.  
 Vemurafenib and dabrafenib are orally available drugs and have 
been both validated in clinical setting. Phase I, II and III trials all 
have shown that both BRAF-I can induce ORR in approximately 
60% of patients with metastatic melanoma harboring the BRAF 
(V600E) oncogene [86]. 
 The IC50 of vemurafenib for mutated BRAF (V600E) is 31 nM 
while for wild-type BRAF is about 100 nM. Other kinases, such as 
CRAF, ACK1, KHS1, and SRMS appear to be inhibited at 
concentrations less than 100 nM [87]. 
 Recommended dose of vemurafenib was determined to be  
960 mg twice daily. The common toxicities observed at this dose 
are rash, photosensitivity, arthralgia, and the appearance of  
well-differentiated cutaneous squamous cell carcinomas or 
keratoacanthomas during the first 3 months of therapy. Rash, 
photosensitivity and arthralgia are typically mild to moderate and 
do not require dose modification. However, approximately 30% of 
patients require at least a temporary dose reduction to 720 mg twice 
daily because of these toxicities [86]. In the context of clinical trials 
cutaneous squamous cell carcinomas and keratoacanthomas have 
been successfully excised and patients have been permitted to 
continue the treatment without interruption. To date, no other type 
of malignancy beyond these cutaneous tumors has been observed 
[88]. 
 In phase III clinical trial, 675 patients with previously untreated 
metastatic melanoma with BRAF mutations (V600E or V600K) 
were randomly assigned to receive vemurafenib (960 mg orally 
twice daily) or DTIC (1000 mg/m
2
 intravenously every 3 weeks). In 
the interim analysis for OS after 6 months, the hazard ratio for 
death in the vemurafenib group was 0.37 (P < .001). Thus the trial 
was modified so that patients assigned to DTIC could immediately 
switch to vemurafenib. Data analysis showed that OS was 84% in 
the vemurafenib group and 64% in the DTIC group. PFS was 5.3 
months in the vemurafenib group versus only 1.6 months in the 
DTIC arm. The ORR for patients receiving vemurafenib was 48% 
versus only 5% in the DTIC group (P< .001). Interestingly, tumor 
response occurred early in the vemurafenib group, approximately 6 
weeks. Anyway, a 15% of patients appeared to have primary 
refractory disease and, although the likelihood of initial response 
was high, there was a high degree of variability in the duration of 
responses. vemurafenib have been approved by FDA in 2011 for 
the treatment of patients affected by advanced melanoma harboring 
BRAF V600E mutation [89]. 
 Dabrafenib (GSK2118436) is a highly potent and selective ATP 
competitive BRAF (V600E) inhibitor. The phase I trial identified 
the dose of 150 mg twice daily for further studies. The most 
common toxicities observed were pyrexia, fatigue, rash, and 
headache. Arthralgia was observed, as it had been with 
vemurafenib, but photosensitivity was not described. Cutaneous 
squamous cell carcinomas and keratoacanthomas were observed in 
fewer than 10% of patients treated at the highest dose level. Among 
the V600E BRAF mutant patients enrolled at the highest dose of 
dabrafenib (150 mg twice daily), 25 of 26 patients demonstrated 
evidence of tumor regression, with an ORR in 77% of cases. 
Results of a multicenter phase III trial have been recently published. 
Briefly, 250 BRAF (V600E)-mutated metastatic melanoma patients 
were randomly assigned to receive either dabrafenib or DTIC. Data 
analyses showed a significant improvement of PFS (5.1 months  
for dabrafenib arm vs. 2.7 months for DTIC; p<0.0001; HR 0.30) 
[90]. 
 However, complete response is infrequently seen and these 
drugs are effective for a short time before the occurrence of 
resistance to BRAF kinase inhibitors. 
 The mechanisms of resistance to BRAF-I can be divided in two 
groups: a) those mediated by ERK signaling reactivation, which can 
be caused by point mutation in MEK1 [91, 92], amplification of 
mutated BRAF [93], elevated CRAF activity [94], activating NRAS 
mutation [95], increased levels of COT/Tpl2 [96], FGFR3 [97] 
and/or aberrantly spliced BRAF (V600E) [98]; b) those mediated 
by an increase of receptor tyrosine kinase (RTK) driven signaling 
via PDGFR? over expression [99], IGF1R activation [100, 101], 
AXL [102], ERBB4 [103], stromal cell secretion of HGF [104], and 
PTEN loss with possibly elevated activation of PI3K/AKT [105], 
which is a major pro-survival signaling of RTKs.  
 From a therapeutic perspective, a recent phase 1/2 study 
combined the oral MEK1/2 inhibitor GSK1120212 (trametinib) 
with the BRAF inhibitor GSK2118436 (dabrafenib). One hundred 
and sixty-two metastatic melanoma patients with BRAF (V600) 
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mutations were randomized to receive combination treatment with 
dabrafenib plus trametinib or dabrafenib alone. The study 
demonstrated a significant median PFS increase for combination 
arm (9.4 vs 5.8 months; p<0.001; HR 0.39) and a significant 
improvement of ORR [106]. 
Chemotherapy 
 Chemotherapy is an accepted palliative therapy for stage IV 
metastatic disease and DTIC is the most widely used single 
chemotherapeutic agent for the treatment of metastatic melanoma. 
For symptomatic patients, or patients who are not eligible for 
investigational trials, chemotherapy remains a reasonable palliative 
option; for novel agents being tested in clinical trials, DTIC based 
chemotherapy is the accepted comparator. DTIC originally reported 
objective responses in up to 25% of patients in older phase II trials, 
but current trials have shown response rates of 5% –12%. 
Unfortunately, most responses to DTIC are transient; in fact, only 
1%–2% of patients achieve a durable long-term response. 
Temozolomide (TMZ), an oral prodrug with the same active 
intermediate (3-methyl-[triazen-1-yl]imidazole-4-carboxamide) as 
DTIC, has been demonstrated to be as effective as DTIC in phase 
III studies. EORTC Melanoma Group randomized a total of 859 
patients to receive oral TMZ at 150 mg/m(2)/day for seven 
consecutive days every 2 weeks or DTIC, administered as 
intravenous infusion, 1000 mg/m(2)/day on day 1, every 3 weeks. 
The primary endpoint was OS. Only ORR was higher in the TMZ 
arm, but there were no differences between TMZ and DTIC arms in 
PFS and OS. Moreover, the median duration of response was longer 
for DTIC [107]. 
 Fotemustine, a chloroethyl nitrosourea, have shown to be 
effective as single agent against metastatic melanoma with an ORR 
of 24% in a large phase II trial including 153 patients [108]. The 
efficacy of fotemustine was confirmed in international phase II 
studies with an ORR ranging from 12% to 47% and median 
duration of responses ranging from 18 to 26 weeks [109-111]. In a 
phase III study was evaluated ORR, as primary end-point, and OS, 
duration of responses, time to progression, time to occurrence of 
brain metastases (BM), safety and quality of life in patients with 
metastatic cutaneous melanoma, treated with fotemustine compared 
to DTIC. ORR was higher in the fotemustine arm compared to the 
DTIC arm. A trend in favor of fotemustine in terms of OS and time 
to development of BM was seen [112]. 
 In a French dermato-oncology retrospective study, the outcome 
of patients with metastatic melanoma who received two lines or 
more of cytotoxic treatments has been analyzed. Most of these 
patients received DTIC for the first line of chemotherapy and 
fotemustine for the second line of chemotherapy. A clinical benefit 
was observed in 24.1 % of the patients and OS was 4.1 months after 
the second-line treatment. The presence of more than two sites of 
metastasis and an M1c staging represented negative predictive 
factors of clinical benefit. This study shows a modest benefit of a 
second line of cytotoxic chemotherapy in a non-selected population 
[113]. 
 The efficacy and tolerability of fotemustine, cisplatin, IFN? and 
IL-2 biochemotherapy was evaluated in advanced melanoma 
patients. The schedule consisted of fotemustine (100 mg/m) and 
cisplatin (75 mg/m) intravenous on day 1, followed by 
subcutaneous IL-2 (4.5 MUI) on days 3-5 and 8-12 and IFN? (3 
MUI) three times/week, every 3 weeks for six cycles. Sixty patients 
were evaluated for tumor response, 12 of whom had brain 
metastases. One patient with BM showed a complete response and 
partial responses were observed in 10 patients. Disease control 
(ORR and stable disease) was 58.4% in all patients and 75% in 
patients with BM. Median time to progression was 3.2 months (4.2 
months in BM patients). Median OS was 8.9 months (7.6 months in 
BM patients). This combination was well tolerated and showed 
acceptable clinical activity, especially in BM patients [114]. 
 In another phase II trial, patients with advanced melanoma were 
enrolled to receive induction treatment of 10 mg/kg intravenous 
ipilimumab every 3 weeks to a total of four doses, and 100 mg/m
2 
intravenous fotemustine weekly for 3 weeks and then every 3 
weeks from week 9 to week 24. Patients with a confirmed clinical 
response received maintenance treatment from week 24, with 
ipilimumab every 12 weeks and fotemustine every 3 weeks. This 
combination was clinically active. It was reported a significantly 
disease control also in patients with brain metastases [115]. 
 In a retrospective analysis, 36 consecutive patients with hepatic 
metastases from ocular or cutaneous melanoma were assigned for 
surgical hepatic port-catheter implantation. Fotemustine was 
delivered weekly for a 4-week period, followed by a 5-week rest 
and a maintenance period every 3 weeks until progression. OS, 
ORR and toxicity were analyzed and compared. After port-catheter 
implantation 30/36 patients were finally treated. Nine out of 30 
patients achieved partial remission, 10/30 stable disease; 11/30 
patients were progressive. Median OS was 14 months. Serum LDH 
was a significant predictor of both response and survival. Treatment 
was well tolerated [116]. Similarly, Meldola et al conducted a 
retrospective study on patients with hepatic melanoma metastases 
(from both cutaneous and uveal melanoma) which had been treated 
with intra-hepatic arterial chemotherapy with fotemustine or 
carboplatin. Treatment was well tolerated. The ORR and disease 
control rate was 16.7% and 38.9% in patients with uveal melanoma. 
Median time to progression was 6.2 months and median OS was 21 
months. The authors concluded that intra-hepatic arterial chemo- 
therapy was a valid choice for patients with hepatic metastases 
[117]. 
 Polychemotherapy regimen was tested in a phase III trials 
(Dartmouth regimen: cisplatin/vinblastine/dacarbazine/tamoxifen). 
However the trial failed to demonstrate a benefit in OS compared 
with a monochemotherapy with DTIC alone [118]. 
 Several investigators have attempted to combine different 
strategies with the aim to improve treatment response and patients 
survival. Immunotherapy regimens with IFN-? and/or IL-2 in 
combination with chemotherapeutic agents have been explored too. 
Combinations of IL-2–based immunotherapy and cisplatin- and 
DTIC-based chemotherapy in patients with metastatic melanoma 
have been reported to induce 50% of response rate. The median 
survival has been reported between 11 and 12 months [119-124]. 
Two meta-analyses performed suggested that this approach induced 
higher response rate and a potentially longer median survival than 
chemotherapy or IL-2 alone [125,126].  
 Two systematic reviews of the literature including 18 trials and 
more than 2,600 patients compared administration of immuno- 
therapy with IFN-?, IL-2, or IL-2 plus IFN-? in combination with 
chemotherapeutic agents was compared with chemotherapy alone. 
They reported higher response rates for combined strategy but no 
significant difference in OS [127,128]. This data were further 
confirmed by Atkins et al., in a phase III trial. In consideration of 
the severe toxicity reported in the combination, the authors 
concluded that concurrent administration of immunotherapy and 
chemotherapy regimen cannot be recommended for patients with 
metastatic melanoma [129]. 
FUTURE PERSPECTIVES 
 Some investigators have attempted to evaluate the efficacy and 
safety of concurrent administration of sorafenib and DTIC in 
patients with advanced melanoma. Sorafenib is an orally available 
multi-kinase inhibitor that inhibits tumor proliferation by targeting 
multiple kinases including the vascular endothelial growth factor 
receptors VEGFR1, VEGFR2, VEGFR3, the platelet-derived 
growth factor receptor PDGFR, and targets tumor progression by 
inhibiting FLT3, C-Kit and BRAF. A randomized multicenter study 
enrolled chemo-naıve patients with advanced melanoma to receive 
placebo plus DTIC (n 50) or sorafenib plus DTIC (n 51). The 
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primary end point was progression PFS by independent assessment. 
Secondary and tertiary end points included time to progression 
(TTP), ORR, and OS. Median PFS in the sorafenib plus DTIC arm 
was 21.1 weeks versus 11.7 weeks in the placebo plus DTIC arm. 
There were statistically significant improvements in PFS rates and 
in TTP at 6 and 9 months in sorafenib and DTIC arm. However no 
difference in OS was observed [130]. 
 In a phase II trial investigation, conducted in chemotherapy-
naive patients with advanced melanoma, 93 patients were 
randomized to receive TMZ plus bevacizumab or nab-paclitaxel 
plus bevacizumab and carboplatin. The addition of bevacizumab to 
nab-paclitaxel and carboplatin shows promising activity despite 
tolerability issues, with a significant improvement of median PFS 
[131]. Bevacizumab was tested also in association with fotemustine 
[132], as first line treatment, in a multicenter, single-arm, open-
label, phase II study, in which serum cytokines, angiogenesis, and 
lymphangiogenesis factors were monitored by multiplex arrays and 
by in vitro angiogenesis assays. The study demonstrated a clinical 
activity of this association and found that this combination 
promoted suppression of some soluble factors involved in 
angiogenesis and lymphangiogenesis. Aflibercept is a soluble decoy 
VEGF receptor and angiogenesis inhibitor with potent preclinical 
antitumor activity in melanoma. Tarhini et al. conducted a 
multicenter phase II study in chemotherapy-naïve patients with 
advanced skin and uveal melanoma. Aflibercept was intravenously 
administered at 4 mg/kg every 2 weeks. Response rate and 
progression-free survival rate was evaluated after 4 months. These 
results were promising and a significant association between 
severity of hypertension following aflibercept treatment and survival 
improvement was found [133]. C-kit, also known as CD117, is a 
receptor tyrosine kinase that is mutated in approximately 20% of 
acral, mucosal, and chronically sun-damaged skin melanomas. The 
ligand for c-kit is the stem cell factor (SCF) and binding of SCF to 
c-kit induces activation of downstream signaling pathways that are 
involved in mediating growth and survival signals within the cell, 
including the P13K-AKT-mTOR pathway and the RAS-RAF-
MEK-ERK pathway. Melanomas c-kit mutations are usually point 
activating mutations in the juxta-membrane domain at exon 11 and 
exon 13, or in the kinase domain at exon 17. Imatinib, an oral 
multi-tyrosine kinase inhibitor, which inhibits c-kit activation, has 
been evaluated in a phase II trial in metastatic melanoma patients 
expressing at least one of the target protein of imatininb (c-kit, 
platelet-derived growth factor receptors, c-abl, or abl-related gene). 
Imatinib induced a dramatic response after 6 weeks of treatment 
and a partial response lasting 12.8 months was reported [134]. 
Another phase II trial tested imatinib [135] in 33 patients with 
metastatic melanoma harboring mutations and/or gene copy number 
amplification of c-Kit. The study demonstrated a significant 
antitumor activity of imatinib with an ORR of 23.3%. Escalation of 
imatinib to 800 mg have been tested to restore disease control after 
tumor progression, as seen in treatment of gastro-intestinal stromal 
tumors carrying c-kit mutation, but the result was disappointing. 
Nilotinib, a new tyrosine kinase inhibitor which inhibits c-Kit more 
than imatinib, was also tested in several clinical studies [136]. It has 
demonstrated to be a promising agent in the treatment of metastatic 
melanoma harboring the c-Kit mutation. A multicenter randomized 
phase III trial (Tasigna Efficacy in Advanced Melanoma) enrolling 
patients with locally advanced or metastatic mucosal melanoma, 
acral melanoma or solar melanoma is ongoing and results are still 
pending. 
Palliative Treatments 
 It is of paramount importance to manage patients with multi 
metastatic disease, especially in presence of metastatic sites which 
may result difficult to treat. Nineteen percent of metastatic 
melanoma patients developed skin metastases. Skin metastasis can 
seriously affect the quality of life of melanoma patients. During 
tumor progression skin lesions increase in number and size, are 
often ulcerated and associated with bleeding and severe pain.  
 Electro-chemotherapy (ECT) is a therapeutic approach based on 
the local application of short and intense electric pulses that 
transiently permeabilize cell membrane, thus allowing transport of 
molecules otherwise not permitted by a cellular membrane. 
Applications for treatment of cutaneous and subcutaneous tumors 
have reached clinical use (antitumor electro-chemotherapy using 
bleomycin or cisplatin). A typical protocol for ECT of solid tumors 
consists of an intratumoral injection of the chemotherapeutic drug 
(bleomycin or cisplatin) or systemic intravenous administration of 
bleomycin, followed by delivery of a sequence of (typically eight) 
square monopolar electric pulses to the tumor. Electric pulses can 
be delivered either noninvasively, using a pair of parallel plate 
electrodes, or invasively, using several needle-shaped electrodes 
arranged in various configurations with predefined distances 
between the electrodes. Electric pulses are delivered at the time 
when the maximum extracellular concentration of the chemo- 
therapeutic drug is expected. Typically, the optimum effect is 
obtained 3 min after systemic intravenous injection or immediately 
after intratumoral injection. Since drugs are adminstred at lower 
dose than systemic treatment, ECT treatment of skin lesions does 
not induce systemic side effects [137]. Several studies had 
demonstrated the efficacy of ECT in improving the local disease 
control and the quality of life of melanoma patients. [138-142].  
 Isolated limb perfusion is a therapeutic approach employed for 
treating cutaneous isolated melanoma metastases of the extremities. 
In this procedure, the major vascular structures are isolated, 
cannulated, and then attached to a bypass device so that therapeutic 
agents can be given to the extremity at high doses [143]. Several 
retrospective studies demonstrated that isolated limb perfusion 
using IFN-?, melphalan and TNF-? as single agent or in 
combination, can induce complete response rates ranging from 26% 
to 69% and additional partial responses from 25% to 43% [144,145]. 
Unfortunately, objective responses appear to be transient and PFS 
ranges from 9 to 12.4 months [146]. Furthermore, long-term 
toxicities such as lymphedema, abnormal limb function, muscle 
atrophy or fibrosis, neuropathy, persistent pain, and recurrent 
infection are associated with isolated limb perfusion [147]. 
 The role of radiotherapy in the management of melanoma is 
still controversial. This reflects the extreme radioresistance of 
melanoma. Several clinical studies have shown no benefits from 
radiotherapy in melanoma patients either as adjuvant treatment after 
surgical resection or definitive treatment [148]. However recent 
results suggest a role of the radiotherapy in adjuvant setting for 
patients with high risk of local and regional recurrence. Specifically 
radiotherapy can be useful to reduce local recurrence rate in 
patients with desmoplastic histology, positive margins, recurrent 
disease, Breslow > 4.0 mm, ulceration and satellitosis. Similarly, 
patients with ?4 lymph nodes involvement, extracapsular node 
extension, lymph node size ? 3 cm, cervical lymph node 
involvement, SLN involvement without complete lymph node 
dissection, and node recurrent disease may also benefit from 
radiotherapy [149]. In a phase II study of adjuvant radiation 
therapy, an impressive regional control rate was shown. The study 
enrolled 234 patients from 3 nodal basins (head and neck, axilla/ 
supraclavicular, and ilio-inguinal). The authors observed a low 
local recurrence rate (7%), a low adjacent relapse rate (14%), and 
an impressive 5 year regional control rate (91%) [150].  
 In a multicenter phase III trial, which included post-
lymphadenectomy patients with isolated regional recurrence who 
were at high risk for further regional recurrence (?1 parotid lymph 
node, ?2 cervical or axillary lymph node, ? 3 groin nodes, any extra 
nodal spread of melanoma, or maximum metastatic node diameter ? 
3 cm in neck or axilla, or ? 4 cm node in the groin), 250 patients 
were randomly assigned to observation versus regional radiation 
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therapy. Total dose performed was 48 Gy in 20 fractions delivered 
at 2.4 Gy per fraction. As result, postoperative radiation significantly 
improved DFS (HR 1.77, p=0.041) [151]. These results were 
further confirmed by other two clinical trials [152,153]. Therefore, 
adjuvant radiotherapy after therapeutic lymphadenectomy for 
lymph node-metastatic melanoma can be an appropriate treatment 
in selected patients.  
 Radiotherapy is still one of the available treatments to control 
brain metastases in melanoma patients. Brain is one of most 
common site of melanoma metastases, contributing to 20%–54% of 
all deaths for melanoma. Patients with brain metastases have 
generally a poor prognosis and systemic treatments are almost 
ineffective. Surgical resection, usually followed by radiotherapy, 
can be used to treat brain metastases in selected patients. Patients 
which undergo to surgical resection have usually solitary and 
superficial lesion. In surgically unresectable metastasis, whole brain 
radiotherapy (WBRT, generally 3000 cGy in 10 fractions) has been 
employed as palliative treatment. Median OS of patients with 
melanoma brain metastases treated with WBRT has been reported 
to range from 3.6 to 4.8 months. Fife et al recently showed a 
survival benefits from WBRT compared with supportive care (OS, 
3.4 vs. 2.1 months) [154]. Recent reports have suggested high local 
control rates for patients with 1 to 3 brain metastases by stereotactic 
radio surgery (SRS). SRS can be performed by linear accelerator 
(Linac) or Gamma-Knife-based approaches. Samlowski et al. 
reported their clinical experience utilizing SRS in patients with up 
to 5 brain metastases. SRS was followed by planned systemic 
therapy. Results suggest that an aggressive approach, including 
SRS and systemic treatment, prolong overall survival (11.1 months, 
95% CI: 8.2–14.9 from diagnosis). SRS demonstrated a high local 
control rate and the median duration of response in treated lesions 
was 10.2 months. Based on their results, they propose a new 
treatment algorithm for patients with brain metastases. Treatment 
includes SRS when metastasis are up to 5 and re-irradiation with 
SRS or WBRT when less or more than 5 metastasis are respectively 
detected [155]. 
 Fig. (1) illustrates a possible approach to the patients with 
metastatic melanoma on the basis of the disease localization, 
hystopatologic and biomolecular findings. 
CONCLUSION 
 The treatment of melanoma has been for decades a source of 
frustration for clinical oncologists. In fact, surgery was the 
cornerstone of treatment, not only as a primary treatment, but also 
to treat metastatic lesions if that were possible. Over the past five 
years, we have seen the advent of new therapeutic strategies that 
have sparked new hope in the treatment of this deadly disease. In 
the area of immunotherapy, the introduction into clinical practice of 
specific monoclonal antibodies able to overcome cancer immune 
tolerance by blocking inhibitory signals arising from receptors like 
the cytotoxic T lymphocytes-associated antigen (CTLA) -4 and 
Programmed Death-1 (PD-1) receptor have been shown to prolong 
significantly the survival of patients with advanced melanoma. 
Furthermore, specific inhibitors of BRAF(V600) have shown 
 
Fig. (1). Therapeutic   alghorytm   proposal for treating metastatic disease. 
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extraordinary activity against melanoma characterized by this 
specific mutation. It is possible that the combination of treatments 
to target specific molecular and immunotherapy may lead, in the 
near future, to a significant survival increase of patients with this 
disease. 
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Can the "Right" EGFR-Speciﬁc mAb Dramatically Improve
EGFR-Targeted Therapy?
Francesco Sabbatino and Soldano Ferrone
EGF receptor (EGFR)–specific monoclonal antibodies (mAb) display limited therapeutic efficacy in
EGFR-positive solid tumors. To overcome this limitation, the significant improvement of the antibody-
dependent cell-mediated cytotoxicity–mediated antitumor activity of a novel EGFR-specific mAb
is described. Its potential impact on the efficacy of immunotherapy for EGFR-positive solid tumors is
discussed. Clin Cancer Res; 19(5); 958–60. 2013 AACR.
In this issue of Clinical Cancer Research, Gerdes and
colleagues (1) describe the development and characteriza-
tion of the functional properties of the novel EGF receptor
(EGFR)–specific monoclonal antibody (mAb) GA201. The
latter immunoglobulin G (IgG)1 mAb was generated by
humanization of the EGFR-specific rat mAb ICR62 and
glycoengineering of its Fc portion to enhance its binding
to FcgRIIIA expressed on effector cells.
EGFR has been shown to be expressed and activated in
several epithelial malignancies, including colorectal cancer
(CRC), squamous cell carcinoma of the head and neck
(HNSCC), and carcinoma of the pancreas, lung, cervix,
renal cell, prostate, bladder, and breast (2). Like other
growth factor receptors, EGFR can mediate oncogenic sig-
nals involved in proliferation and survival of tumor cells.
This background information has provided the rationale to
develop EGFR-targeted therapies, with small-molecule
EGFR tyrosine kinase inhibitors (TKI) and with EGFR-spe-
cific mAbs (3).
Several lines of evidence have convincingly shown that
both TKIs and mAbs can blockade proliferative and/or
antiapoptotic pathways in tumor cells and that these
mechanisms play a major role in their therapeutic activity.
However, the EGFR-TKIs and theEGFR-specificmAbs inhib-
it EGFR activation through different mechanisms; the latter
block the EGF binding to EGFR (4), whereas the former
inhibit its autophosphorylation (5).
In addition to inhibiting EGFR-activated signaling, IgG1
EGFR-specificmAbsmay display antitumor activity through
an antibody-dependent cell-mediated cytotoxicity (ADCC)
mechanism, that is, by mediating the lysis of target cells by
effector cells such as monocytes, macrophages, and natural
killer (NK) cells. This effect is influenced by the binding
affinity of the mAb to the Fcg receptors (FcgR) expressed by
effector cells, as indicated by the association between poly-
morphism of FcgRIIIA and extent of lysis of target cells in
ADCC (ref. 6; Fig. 1).
Some EGFR-TKIs (erlotinib and gefitinib) and EGFR-
specific mAbs (chimeric IgG1 cetuximab and humanized
IgG2 panitumumab) have received U.S. Food and Drug
Administration (FDA) approval for treatment of various
types of cancer either as single agents or in combination
with chemotherapy or radiotherapy. In general, EGFR-TKIs
have been poorly effective in the treatment of malignancies
with an EGFR pathogenesis, except for those which selec-
tively target EGFR abnormalities responsible for the onco-
genic signal. This is exemplified by the significant thera-
peutic efficacy of erlotinib and gefitinib in patients with
lung adenocarcinomaharboring activatingmutations in the
EGFR tyrosine kinase domain (7). Modest clinical efficacy
has also been reported for the FDA-approved EGFR-specific
mAbs cetuximab and panitumumab (8).
The antitumor activity mediated by EGFR-TKIs can be
bypassed by mutations in molecules, which activate onco-
genic signals downstream EGFR blockade. These mutations
seem to counteract also the immune-mediated antitumor
activity of the available EGFR-specific mAbs. This is exem-
plified by the poor therapeutic efficacy of the EGFR-specific
mAbs, cetuximab and panitumumab, in patients with
KRAS-mutated CRC (8). These findings are surprising as
no mechanism is readily available to explain why signaling
activation downstream EGFR blockade can be associated, if
not cause the resistance of CRC cells harboring KRAS
mutations to the immune attack mediated by the IgG1
EGFR-specific mAbs used.
In this issue of Clinical Cancer Research, Gerdes and
colleagues (1) postulate that these surprising findings reflect
the poor ADCC activity of the presently FDA-approved
EGFR-specific mAbs. This possibility is supported by the
results Gerdes and colleagues (1) have obtained with their
own newly developed mAb GA201. Comparison of the
binding characteristics and of the functional properties of
the lattermAbwith themAb cetuximab in in vitro assays and
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in animalmodel systems has shown that these 2 IgG1mAbs
recognize distinct and spatially distant EGFR epitopes.
Furthermore,mAbGA201displays a lower affinity for EGFR
than cetuximab. Nevertheless, the 2 mAbs do not differ in
their ability to inhibit tumor cell proliferation and to induce
apoptosis in vitro. Both mAbs exert these effects by inhibit-
ing EGFR/HER2 heterodimerization and downstream sig-
naling. However, mAb GA201 displays a significantly
higher activity than cetuximab in ADCC assays conducted
with several types of effector cells and with target cells
expressing different EGFR levels. Whether this difference
reflects at least in part the distinct characteristics of the
EGFR epitopes recognized by the 2 mAbs remains to
be determined. Furthermore, at variance with cetuximab,
the ADCC activity of mAb GA201 is not influenced by its
affinity for FcgRIIA and FcgRIIIA as the extent of lysis of
target cells mediated by mAb GA201 is similar when
FcgRIIIA high- and low-affinity human NK cells are used
as effectors. It is noteworthy that differences in affinity of
FcgRIIIA, which reflect its polymorphism, seem to have
clinical significance, as an association between FcgRIIIA
polymorphism and clinical response to cetuximab in
patients with CRC has been reported (9). This association
is not unique of cetuximab as it has been described also in
patients with follicular lymphoma and in patients with
breast cancer treated with the CD20-specific mAb rituxi-
mab (10) and with the HER2-specific mAb trastuzumab
(11), respectively. Finally, at variance with cetuximab, mAb
GA201 is not affected in its ADCC activity by the presence
of KRASmutation in target cells. mAbGA201mediates lysis
of target cells even when they express low EGFR level and
the human NK cells used as effectors express a low-affinity
FcgRIIIA.
The conclusions derived from the described in vitro
experiments have been corroborated by those derived from
in vivo experiments. Using various types of human tumor
cell lines grafted in immunodeficient mice, Gerdes and
colleagues (1) have convincingly shown that mAb GA201
is significantly more effective than cetuximab in controlling
tumor growth, both as a single agent and in combination
with chemotherapy. More importantly, the in vivo antitu-
mor activity of mAb GA201 does not seem to be affected by
variables such as level of EGFR expression and/or presence
of KRAS mutations, which abrogate the cetuximab antitu-
mor activity.
In view of the potential clinical relevance of Gerdes and
colleagues’ results (1), it is noteworthy that themAbGA201
broadens the patient population who may be treated with
EGFR-targeted immunotherapy. Specifically, the patients to
be treated with mAb GA201 will include also those with
low-affinity FcgRIIIA as well as those with KRAS-mutated
tumors.
The comparison of the properties of mAb GA201 and
cetuximab would have benefited from the identification of
the normal tissue(s) with an EGFR expression level suffi-
cient to trigger an ADCC bymAb GA201. Are the likely side
effects caused by this mechanism a major obstacle to the
clinical use of mAb GA201? Furthermore, does mAb
GA201, like other tumor antigen–specific mAbs (12), trig-
ger a tumor antigen–specific T-cell response? Finally, in view
of the postulated role of cancer-initiating cells in disease
recurrence and metastatic spread, does mAb GA201 either
Figure 1. EGFR-speciﬁc mAb
can mediate antitumor effect by
inhibiting EGFR activation and
mediating cell-dependent lysis of
tumor cells in ADCC.
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as a single agent or in combination with chemotherapeutic
agent(s) and/or inhibitor(s) of core stem cell pathways
(Notch, Sonic Hedgehog, Wnt) target cancer-initiating
cells? Nevertheless, Gerdes and colleagues’ compelling
results emphasize the urgency to translate to a clinical
setting the strategies developed with mAb GA201, once its
potential toxicity has been better defined.
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